[
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the treatment of atrial fibrillation and atrial flutter. The diseases are represented by their names and corresponding ICD-10 codes. The drugs being studied are dronedarone (sr33589) and a placebo. \n\nThe eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include patients aged 75 years or older (or 70 years or older before a protocol amendment), or patients aged at least 70 years with specific risk factors. Other criteria include the availability of recent electrocardiograms (ECGs) showing the patient's condition in atrial fibrillation or sinus rhythm.\n\nExclusion criteria include general criteria such as refusal or inability to give informed consent, non-cardiovascular illnesses or disorders that could limit survival, pregnancy or breastfeeding, previous or current participation in other clinical trials, and previous participation in this specific trial. \n\nCriteria related to a cardiac condition include patients in permanent atrial fibrillation, patients in unstable hemodynamic condition, patients with certain cardiac surgeries or procedures planned, and patients with specific cardiac conditions or abnormalities.\n\nCriteria related to concomitant medications include the need for prohibited medications that would interfere with the study drug.\n\nCriteria related to laboratory abnormalities include low plasma potassium levels and a calculated Glomerular Filtration Rate (GFR) below a certain threshold.\n\nOverall, this sample provides a snapshot of the trial's phase, diseases being studied, drugs being tested, and the eligibility criteria for participants.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease being studied is liver transplantation. The ICDCodes associated with this disease are Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, and K70.0. The drugs being used in the trial are sirolimus (rapamune) and either cyclosporine or tacrolimus. The eligibility criteria for participants include being over 13 years old (or 18 years old depending on local regulations), currently receiving immunosuppressive therapy with calcineurin inhibitors, being 6 to 144 months post-orthotopic liver transplantation, and having Cockcroft-Gault GFR values between 40 mL/min and 90 mL/min at screening. Exclusion criteria include a history of nonhepatic transplantation, evidence of systemic infection, and a known or suspected malignancy within the past 5 years.",
    "The sample provided is for a phase 3 clinical trial for Alzheimer's Disease. The trial is testing the efficacy and safety of two different transdermal patches containing rivastigmine, a medication commonly used to treat Alzheimer's Disease. \n\nThe inclusion criteria for participants in this trial are as follows:\n- Participants must be at least 50 years of age.\n- Participants must have a diagnosis of probable Alzheimer's Disease.\n- Participants must have a Mini-Mental State Examination (MMSE) score between 10 and 24.\n- Participants must have a caregiver who can attend all study visits.\n- Participants must have been receiving continuous treatment with donepezil (another medication for Alzheimer's Disease) for at least 6 months prior to screening, and have been on a stable dose of either 5 mg/day or 10 mg/day for the last 3 months of those 6 months.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants with advanced, severe, progressive, or unstable diseases that may interfere with efficacy and safety assessments or put the patient at special risk.\n- Participants with a history of malignancy (cancer) of any organ system within the past 5 years, whether treated or untreated.\n- Participants with a history within the past year or current diagnosis of cerebrovascular disease (disease affecting blood vessels in the brain).\n- Participants with a current diagnosis of severe or unstable cardiovascular disease, or a history of myocardial infarction (heart attack) within the last six months.\n- Participants with severe or unstable respiratory conditions (e.g., severe asthma, severe lung disease).\n- Participants with digestive problems related to peptic ulcer.\n- Participants with urinary obstruction or a current severe urinary tract infection.\n- Participants with abnormal thyroid function tests.\n- Participants with low folate or Vitamin B12 levels.\n- Participants with a disability that may prevent them from completing all study requirements.\n- Participants with a current diagnosis of an active skin lesion or disorder that would prevent the adhesion of a patch.\n\nIt is also mentioned that there may be other inclusion/exclusion criteria defined by the protocol of the trial.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is phase 3. The diseases being studied are bipolar mania and bipolar disorder. The corresponding ICD-10 codes for these diseases are F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, and F31.32. The drugs being tested in the trial are placebo and ziprasidone oral capsule. The eligibility criteria for the trial include meeting the DSM-IV criteria for Bipolar I Disorder with manic or mixed symptoms. However, individuals who are ultra rapid cyclers or have significant cardiovascular disease, including a history of QT prolongation and/or congenital long QT syndrome, are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on the disease \"congestive heart failure.\" The trial is associated with specific ICD-10 codes related to the disease. The drugs being studied in this trial are \"dronedarone (sr33589)\" and a placebo. The record also includes the eligibility criteria for the trial, including both inclusion and exclusion criteria. The inclusion criteria specify that patients must be hospitalized with symptomatic CHF and have certain symptoms and measurements related to their condition. The exclusion criteria list various conditions and circumstances that would disqualify a patient from participating in the trial. The record concludes with a note stating that the information provided is not exhaustive and there may be additional considerations for potential participants.",
    "The sample is a phase 3 clinical trial for the treatment of acute myelogenous leukemia (AML). The trial is evaluating the effectiveness of the drugs clofarabine (iv formulation), placebo, and cytarabine. The eligibility criteria for participants include having a diagnosis of AML according to the World Health Organization (WHO) classification, having relapsed after receiving up to 2 prior induction regimens or being refractory to not more than one prior combination chemotherapy induction regimen, being at least 55 years of age, having an Eastern Cooperative Oncology Group (ECOG) score of 0-2, being able to comply with study procedures and follow-up examinations, being nonfertile or agreeing to use birth control during the study and for at least 90 days after the last dose of study drug, and having adequate liver and renal function. Exclusion criteria include previous treatment with clofarabine, receiving certain types of cytarabine induction therapy, having received a hematopoietic stem cell transplant (HSCT) within the previous 3 months, having moderate or severe graft versus host disease (GVHD), receiving any other chemotherapy or investigational therapy, having a psychiatric disorder that would interfere with study participation, having an active, uncontrolled infection, having any other severe concurrent disease or history of serious organ dysfunction, having been diagnosed with another malignancy unless disease-free for at least 5 years, having clinical evidence suggestive of central nervous system (CNS) involvement with leukemia unless confirmed otherwise, being HIV positive, and being pregnant or lactating.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and focuses on prostate cancer. The associated ICD-10 codes for the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drug being tested in this trial is chemotherapy, specifically docetaxel and prednisone. The eligibility criteria for participants in this trial include having a confirmed diagnosis or clinical history consistent with adenocarcinoma of the prostate, having metastatic prostate cancer that is unresponsive or refractory to hormone therapy, having detectable metastases, having an ECOG performance status of 2 or lower (3 if due to bone pain), having any Gleason score, having only received one prior treatment with systemic chemotherapy, not having received gene therapy or immunotherapy for prostate cancer in the past, being taxane na\u00efve, and experiencing cancer-related pain.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"type 2 diabetes mellitus.\" The associated ICD-10 codes for this disease are listed as \"E11.65,\" \"E11.9,\" \"E11.21,\" \"E11.36,\" \"E11.41,\" \"E11.42,\" and \"E11.44.\" The drugs involved in the trial are \"lixisenatide (ave0010),\" \"placebo,\" \"metformin,\" and \"sulfonylurea.\" \n\nThe eligibility criteria for this trial are provided, including both inclusion and exclusion criteria. Inclusion criteria state that participants must have been diagnosed with type 2 diabetes mellitus for at least 1 year before the screening visit and have insufficient control with metformin alone or metformin with sulfonylurea at the time of screening. \n\nExclusion criteria include factors such as having an HbA1c level below 7% or above 10% at screening, being below the legal age of majority, being pregnant or breastfeeding without effective contraception, having type 1 diabetes mellitus, and not having a stable dose of metformin or sulfonylurea for at least 3 months prior to screening. \n\nThere are additional exclusion criteria related to various medical conditions, such as uncontrolled hypertension, history of myocardial infarction or stroke within the last 6 months, history of drug or alcohol abuse within 6 months, and presence of certain diseases or conditions that may interfere with the study or pose risks to the participant. \n\nThe record also mentions specific medications and substances that participants should not have used within a certain timeframe prior to screening, such as other antidiabetic or hypoglycemic agents, systemic glucocorticoids, and investigational drugs. \n\nLastly, there are criteria for exclusion based on renal impairment, gastrointestinal diseases associated with prolonged nausea and vomiting, allergic reactions to certain medications, and additional factors such as withdrawal of informed consent, lack of compliance during the placebo run-in phase, and adverse events that would preclude inclusion in the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 3 and focuses on ovarian cancer, peritoneal cancer, and cancer of the fallopian tube. The associated ICD-10 codes for these diseases are provided as well. The trial involves the use of tamoxifen and chemotherapy as potential treatments. The eligibility criteria for participants are listed, including requirements such as having resistant cancer, clinical progression, stable disease, specific age and performance status, and giving informed consent. The exclusion criteria are also mentioned, which include conditions such as brain metastasis, abnormal blood counts, active infections, pregnancy or lactation without adequate contraception, and previous treatment with tamoxifen.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is evaluating the effectiveness of a combination of drugs including epirubicin, cyclophosphamide, paclitaxel, carboplatin, and g-csf. The eligibility criteria for the trial include patients who have accepted modified radical mastectomy, have histologically confirmed ER(-) PR(-) and HER-2(-) breast cancer, have positive axillary lymph nodes or negative axillary lymph nodes with certain characteristics, are between 18 and 65 years old, able to give informed consent, have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, are not pregnant and using appropriate birth control if of child-bearing potential, have adequate bone marrow reserve, renal function, and hepatic reserve, and do not have any major medical or psychosocial problems that could be complicated by study participation. The exclusion criteria include patients who have received neo-adjuvant therapy, have cardiac dysfunction, have uncontrolled medical problems, have evidence of active infection, are pregnant or breastfeeding, or have hepatic, renal, or bone marrow dysfunction.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied include recurrent non-small cell lung carcinoma, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, and stage IV non-small cell lung cancer. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are erlotinib hydrochloride and pemetrexed disodium. The eligibility criteria for participants in the trial are listed, including requirements such as documented recurrence or disease progression of NSCLC, measurable disease, specific blood counts and liver function, performance status, availability of tissue for pathology review, previous treatment history, and other factors. Exclusion criteria are also listed, including factors such as pregnancy, certain infections, prior therapies, and other medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on studying the effects of a drug called milnacipran on patients with fibromyalgia and neurocognition issues. The trial has specific inclusion and exclusion criteria that participants must meet.\n\nThe inclusion criteria for the trial include being between the ages of 18 and 65, having a specific diagnosis of fibromyalgia confirmed by a rheumatologist or physician, meeting the diagnostic criteria set by the American College of Rheumatology, being able to give informed consent, not being pregnant or lactating if female, and using adequate contraception if sexually active and of reproductive potential.\n\nThe exclusion criteria for the trial include having bipolar disorders or any psychotic disorder, having concomitant rheumatological disorders such as rheumatoid arthritis or lupus, having substance dependence (except nicotine) in the previous 3 months, being currently suicidal or at high suicide risk, having serious or unstable medical disorders, receiving psychotropic drug treatment in the previous 2 weeks before screening, having a positive urine pregnancy test, having screening laboratory values three times the limits of normal or clinically significant as determined by the investigator, having a history of hypersensitivity to milnacipran, having seizure disorder or traumatic brain injury, having any CNS disorder that affects cognitive status, being on concomitant medications such as analgesics, antidepressants, fibromyalgia-specific medication, or supplements within specific timeframes, and having narrow-angle glaucoma.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is schizophrenia. The ICD-10 codes associated with this disease are F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, and F20.9. The drugs being tested in this trial are asenapine, placebo, and olanzapine. The eligibility criteria for inclusion in the trial are currently suffering from an acute exacerbation of schizophrenia. The exclusion criteria include having an uncontrolled, unstable medical condition and having any other psychiatric disorder other than schizophrenia as a primary diagnosis.",
    "The sample is a phase 3 clinical trial for the treatment of acquired immunodeficiency syndrome (AIDS) and HIV infections. The trial is evaluating the effectiveness of the drugs cobi, drv, and nrtis. The eligibility criteria for participants include being adults aged 18 or older, having the ability to understand and sign a consent form, having a general medical condition that does not interfere with the trial, and being either treatment naive or treatment experienced. Other criteria include having specific HIV-1 RNA levels, genotype report results, normal electrocardiogram, specific liver function levels, adequate hematologic and renal function, and utilizing contraception methods for females of childbearing potential. Exclusion criteria include previous or current use of darunavir, recent AIDS-defining condition diagnosis, breastfeeding, positive pregnancy test, acute hepatitis, ongoing liver disease, implanted defibrillator or pacemaker, current alcohol or substance use, history of malignancy, active serious infections, participation in other clinical trials, and any other condition or therapy that would make the subject unsuitable for the study. Additionally, subjects receiving ongoing therapy with certain medications or having allergies or contraindications to specific drugs are excluded.",
    "The sample from the table is for a phase 3 clinical trial for the treatment of pediatric bipolar disorder. The diseases listed are bipolar disorder. The icd-10 codes associated with the disease are R63.31, R63.32, G47.33, Z68.51, Z68.54, Z68.52, and Z68.53. The drugs being tested in the trial are asenapine, placebo to match asenapine, and rescue medication. The eligibility criteria for participants include being able to provide written informed consent, being between the ages of 10 and 17, having a diagnosis of bipolar I disorder, not being pregnant or lactating, and having a caregiver or responsible person living with them. The exclusion criteria include having a diagnosis of bipolar II disorder or other forms of bipolar or psychotic disorder, having known or suspected mental retardation, recent substance abuse or dependence, risk of self-harm or harm to others, history of tardive dyskinesia or dystonia, pregnancy or lactation, history of seizure disorder, participation in another clinical trial, having a family member involved in the study, and having other medical conditions that may interfere with the study evaluations.",
    "The sample is a phase 3 trial for asthma. The diseases being studied are asthma. The icd-10 codes associated with the diseases are 'J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40'. The drugs being tested are 'flutiform 250/10', 'skp-fluticasone', and 'flovent fluticasone hfa'. The eligibility criteria for the trial include being at least 12 years old, having a history of asthma for 12 months, and documented use of an inhaled corticosteroid for at least 4 weeks prior to the screening visit. Patients must also have an FEV1 of 40% to 80% of predicted normal values and documented reversibility within 12 months of the screening visit. The exclusion criteria include having life-threatening asthma in the past year, recent use of systemic corticosteroid medication, recent respiratory infection, significant non-reversible pulmonary disease, a smoking history equivalent to \"10 pack years\", current smoking history within 12 months, and previous exposure to FlutiForm.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is hypertension. The ICDCodes associated with this disease are ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']. The drug being tested is telmisartan/amlodipine. \n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". Inclusion criteria include the ability to provide written informed consent, being 18 years or older, and having uncontrolled hypertension as defined by specific blood pressure measurements. Exclusion criteria include being a pre-menopausal woman who is not surgically sterile, having known or suspected secondary hypertension, having certain blood pressure measurements, having renal dysfunction or renal artery stenosis, having certain electrolyte imbalances or other medical conditions, and having a history of drug or alcohol dependency, among others.\n\nOverall, this sample provides information about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on hypertension.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is gastroesophageal reflux. The corresponding ICD-10 codes for this disease are 'K21.9', 'K21.00', and 'K21.01'. The drug being tested is pantoprazole sodium enteric-coated spheroid. The eligibility criteria for this trial include the ability to undergo endoscopy with required biopsy, being between the ages of 1 and 5 years, and having endoscopically confirmed GERD. The exclusion criteria include a history or presence of upper gastrointestinal anatomic or motor disorders, known current or active cow's milk allergy, malignancy, and other exclusions that may apply.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is bladder cancer. The ICDCodes associated with this disease are 'D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', and 'D41.4'. The drugs being used in the trial are apaziquone and placebo. \n\nThe eligibility criteria for this trial are divided into inclusion and exclusion criteria. The inclusion criteria include requirements such as the patient giving written informed consent, being at least 18 years old, having transitional cell carcinoma of the bladder with clinically apparent tumor Ta, grade G1-G2, and using an acceptable/effective method of contraception for females of childbearing potential. Additionally, a negative serum pregnancy test within the past 14 days and willingness to abide by the protocol are also required.\n\nThe exclusion criteria include factors that would disqualify a patient from participating in the study. These factors include having more than 5 bladder tumors, having a single bladder tumor exceeding 3.5 cm in diameter, having a single primary bladder tumor <0.5 cm without a previous diagnosis of bladder cancer, having received EOquin(r) treatment in the past, having bladder tumors other than tumor Ta or grade G1 or G2, having bladder tumors with histology other than transitional cell carcinoma, having carcinoma in situ (CIS), having an active urinary tract infection, having a bleeding disorder or low platelet count, having unstable medical conditions that would make it unsafe for the patient to undergo TURBT (transurethral resection of bladder tumor) under general or spinal anesthesia, having low hemoglobin or absolute neutrophil count, having a known immunodeficiency disorder, having received any investigational treatment within the past 30 days, currently breastfeeding, having a history of interstitial cystitis, having a history of allergy to red color food dye, or having had transitional cell carcinoma of the bladder within the past 4 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 3. The diseases being studied are schizophrenia and psychotic disorders. The corresponding ICDCodes for these diseases are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9'] for schizophrenia and ['F23', 'F24', 'F12.159', 'F12.259', 'F12.150', 'F12.151', 'F12.250'] for psychotic disorders.\n\nThe drugs being investigated in this trial are aripiprazole, risperidone long-acting injectable (LAI), and quetiapine. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Patients must have a diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV).\n- Patients must currently be treated with oral risperidone, olanzapine, or a conventional neuroleptic monotherapy at doses not exceeding 6 mg risperdal, 20 mg olanzapine, or a conversion dose of 10 mg haloperidol for oral conventional agents.\n- Patients must be clinically stable and on a stable dose of medication for 4 weeks or longer, but not optimally treated in terms of symptoms or adverse events.\n\nExclusion Criteria:\n- Patients must not have a diagnosis other than schizophrenia or schizoaffective disorder according to DSM-IV Axis I criteria.\n- Patients must not be treated with antipsychotic agents other than oral risperidone, olanzapine, or conventional oral neuroleptic agents.\n- Patients must not have known hypersensitivity to oral risperidone, quetiapine, aripiprazole, or be known non-responders to these medications or previous treatment with at least 2 antipsychotic agents.\n- Patients must not be treated with mood stabilizers or antidepressants unless on a stable dose for at least 3 months before the study initiation.\n- Pregnant or nursing females, or those lacking adequate contraception, are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 3. The diseases being studied are embolism and thrombosis. The corresponding ICDCodes for these diseases are provided as well. The drugs being tested in this trial include idrabiotaparinux sodium, warfarin, placebo (for idrabiotaparinux sodium), avidin, placebo (for warfarin), and enoxaparin. \n\nThe eligibility criteria for this trial are also listed. The inclusion criteria state that individuals with symptomatic pulmonary embolism, with or without symptomatic deep vein thrombosis, are eligible to participate. The exclusion criteria include conditions such as end-stage renal failure, hepatic failure, uncontrolled hypertension, active bleeding or high risk for bleeding, pregnancy or childbearing potential without proper contraceptive measures, breastfeeding, known allergies to certain medications, hypersensitivity to certain drugs, indication of prolonged anticoagulation therapy for reasons other than pulmonary embolism, and a life expectancy of less than 6 months.",
    "The sample is a phase 3 trial for the treatment of bipolar disorder. The trial is looking at the effectiveness of drugs such as olanzapine, placebo, and risperidone long acting injectable (lai). The eligibility criteria for participants include a diagnosis of bipolar I disorder, currently experiencing a manic or mixed episode, and having had at least 2 bipolar mood episodes in the past year. Participants who are not currently in an acute episode must have had a manic episode within 4 months of enrollment. Exclusion criteria include a history of rapid cycling, ADHD, anxiety disorder, or panic disorder as the primary diagnosis, and not meeting criteria for other comorbid or active Axis I disorders. Participants should also not have antisocial or borderline personality disorder, and should not have any chronic or serious general medical illnesses.",
    "The sample is a phase 3 trial for breast cancer. The trial is specifically targeting patients with metastatic or unresectable locally advanced/recurrent breast cancer who have HER2-positive disease. The eligibility criteria include being an adult participant over 18 years old, having histologically or cytologically documented breast cancer, and having disease progression on the last regimen received. Prior treatment with trastuzumab, a taxane, and lapatinib is also required. Adequate organ function and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 are necessary. Additionally, the left ventricular ejection fraction (LVEF) must be at least 50% by echocardiogram or multi gated acquisition scan. \n\nThere are also exclusion criteria, such as recent chemotherapy, trastuzumab, or lapatinib treatment, and prior enrollment in a trastuzumab emtansine containing study. Patients with untreated or symptomatic brain metastases that require treatment within 1 month of randomization are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The disease being studied is diabetes mellitus, type 2. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are placebo and empagliflozin. The eligibility criteria for participants in this trial include a diagnosis of type 2 diabetes prior to informed consent, being on a diet and exercise regimen for 12 weeks prior to informed consent, and being either drug-na\u00efve or pre-treated with one oral antidiabetic drug. The glycosylated hemoglobin (HbA1c) levels for inclusion vary depending on the patient's antidiabetic therapy. There are also exclusion criteria, such as uncontrolled hyperglycemia, impaired renal function, recent acute coronary syndrome, stroke or transient ischemic attack, and indication of liver disease.",
    "The sample provided is for a phase 3 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). The trial is testing the effectiveness of the drugs ambrisentan and placebo. The eligibility criteria for participants include being between 40 and 80 years old, having a diagnosis of IPF, having less than or equal to 5% fibrosis in the lung, being willing to undergo certain medical tests and monitoring, being able to perform a 6-minute walk test, meeting lung function requirements, having normal liver function, and using reliable contraception methods. Exclusion criteria include not having any restrictive or obstructive lung disease other than IPF, no recent or active respiratory exacerbations or hospitalizations for IPF, no recent history of alcohol abuse, no chronic use of certain medications for pulmonary hypertension, and no other serious medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the treatment of chronic lymphocytic leukemia. The trial is investigating the use of drugs such as rituximab, fludarabine phosphate, and cyclophosphamide. The eligibility criteria for participants include being at least 18 years old, having a confirmed diagnosis of B-cell CLL, having received no more than one previous line of chemotherapy, and having an expected survival of more than 6 months. Other criteria include acceptable hematologic, liver, renal, and pulmonary function, negative pregnancy test for women, and written informed consent. The exclusion criteria include prior treatment with certain medications, previous bone marrow or stem cell transplants, fertility without adequate contraception, severe toxicity or cytopenia from previous treatments, history of certain malignancies, long-term use of corticosteroids, active infections, severe cardiac disease, seizure disorders, severe chronic obstructive pulmonary disease, uncontrolled diabetes or hypertension, transformation to aggressive B-cell malignancy, known infections with HIV, HCV, or hepatitis B, recent participation in other clinical trials, known hypersensitivity to certain antibodies or proteins, and any other medical or psychological condition that would prevent participation or compromise informed consent.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The disease being studied is obesity, and its corresponding ICD-10 codes are ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drugs being tested in the trial are lorcaserin 10 mg once daily (qd), lorcaserin 10 mg twice a day (bid), and a matching placebo. The eligibility criteria for participants in the trial include being overweight or obese individuals with type 2 diabetes managed with oral anti-hyperglycemic agents, having a body mass index (BMI) between 27 and 45 kg/m2, and being able to complete a 1-year study. Exclusion criteria include pregnancy, recent use of insulin, exenatide (Byetta), or pramlintide (Symlin), history of symptomatic heart valve disease, and serious or unstable medical conditions.",
    "The sample is a phase 3 trial for the treatment of type 2 diabetes mellitus. The trial is testing the effectiveness of several drugs, including ly2189265, exenatide, placebo, metformin, and pioglitazone. The eligibility criteria for participants include having poorly controlled type 2 diabetes on one, two, or three oral antidiabetic medications, being able to tolerate a minimum dose of metformin and pioglitazone, being willing to inject subcutaneous medication up to two times per day, having a stable weight for three months prior to screening, having a body mass index (BMI) between 23 and 45 kg/m^2, and females of childbearing potential must test negative for pregnancy and use reliable birth control during the study. Exclusion criteria include having type 1 diabetes, having a low HbA1c level, chronic insulin use, taking weight loss drugs, history of certain medical conditions such as heart failure or pancreatitis, and various other medical conditions and medications. Participants must not have enrolled in another clinical trial within the last 30 days and must not have previously participated in a study involving LY2189265 or taken a GLP-1 receptor agonist within the last 3 months.",
    "The sample is a phase 3 trial for the treatment of rheumatoid arthritis. The trial is evaluating the effectiveness of golimumab and methotrexate compared to a placebo. The eligibility criteria for participants include having a diagnosis of rheumatoid arthritis for at least 3 months, being treated with and tolerating methotrexate, having active rheumatoid arthritis with specific symptoms, and meeting certain tuberculosis screening criteria. Participants must not have other inflammatory diseases, have received other disease-modifying drugs or biologic anti-tumor necrosis factor drugs, or have a history of serious or chronic infections.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial is evaluating the effectiveness of the drug leuprolide acetate in treating males who are 18 years or older and have histologically proven carcinoma of the prostate. The trial requires participants to have a life expectancy of at least 1 year and a World Health Organization/Eastern Cooperative Oncology Group performance status of 0, 1, or 2. Adequate renal and hepatic function is also required.\n\nThe inclusion criteria include the ability to comprehend the study's nature and purpose, willingness to cooperate with the investigator, and signing a written informed consent. \n\nThe exclusion criteria include evidence of brain metastases or spinal cord compression, severe urinary tract obstruction, or excruciating pain from extensive osseous deposits. Other exclusion criteria include low testosterone levels, previous cancer systemic therapy within 3 months, previous hormonal therapy for prostate cancer, previous treatment with androgen receptor blockers, previous orchiectomy, adrenalectomy or hypophysectomy, previous prostatic surgery within 2 weeks, previous local therapy to the primary tumor within 2 weeks, recent use of investigational drugs, administration of 5-alpha-reductase inhibitors within 3 months, use of over-the-counter or alternative medical therapies with estrogenic or anti-androgenic effects within 3 months, abnormal hematological parameters, co-existent malignancy, uncontrolled congestive heart failure or significant cardiovascular disease, recent venous thrombosis, insulin-dependent diabetes mellitus, history of drug and/or alcohol abuse, serious concomitant illnesses or diseases, use of anticoagulants or antiplatelet medications, recent blood donations/losses, known hypersensitivity to certain substances, and history of certain medical conditions or treatments.\n\nThe sample also mentions the exclusion of patients who have had immunization or flu shots within specific timeframes, experienced anaphylaxis, have skin disease that would interfere with injection site evaluation, or have dermatographism.",
    "The sample from the table is for a clinical trial in phase 2/phase 3 for Huntington's disease. The trial is testing the effectiveness of three different doses of a drug called ACR16 (10 mg, 22.5 mg, and 45 mg). The eligibility criteria for participants include being able to provide written informed consent, having clinical features of Huntington's disease with a positive family history or the presence of a certain genetic marker, being at least 30 years old, able to take oral medication, and able to travel to the assessment center. Participants must also have a caregiver or family member available for two visits and score at least 10 points on a screening assessment. Exclusion criteria include recent use of certain medications, previous participation in the study, certain medical conditions, history of epilepsy or seizures, severe illness, alcohol or drug abuse, pregnancy or lactation, and known allergies to the trial medication or placebo.",
    "The sample from the table is for a phase 3 clinical trial focused on osteoporosis in postmenopausal women. The diseases being studied are osteoporosis, specifically in postmenopausal women. The icd-10 codes associated with these diseases are \"N95.0\" and \"N95.2\". The drugs being tested in the trial are teriparatide, placebo, calcium supplement, and vitamin D supplement. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- The participant must be an ambulatory, postmenopausal woman.\n- They must have at least one moderate or two mild atraumatic vertebral fractures, and a minimum of seven evaluable nonfractured vertebrae.\n- Their hip or lumbar spine bone mineral density (BMD) measurement must be at least 1.0 standard deviation below the average bone mass for young, healthy women (T-score), but only if they have fewer than two moderate fractures or have previously been treated with therapeutic doses of bisphosphonates or fluorides.\n- Their laboratory values, including serum calcium, PTH(1-84), and urine calcium, must be within normal limits at baseline. Their 25-hydroxyvitamin D levels must be between the lower limit of normal and three times the upper limit of normal at baseline.\n\nThe exclusion criteria for the trial are as follows:\n- Fractures in areas of bone affected by diseases other than osteoporosis, such as cancer or Paget's disease.\n- Inability to obtain satisfactory baseline thoracic and lumbar spinal x-ray views, as determined by the centralized x-ray quality assurance center, due to severe scoliosis or kyphosis.\n- Current or recent metabolic bone disorders other than postmenopausal osteoporosis, such as Paget's disease, renal osteodystrophy, osteomalacia, or any secondary causes of osteoporosis.\n- Current or recent diseases that affect bone metabolism, such as hypoparathyroidism, hyperparathyroidism, or hyperthyroidism.\n- Currently suspected carcinoma or a history of carcinoma in the 5 years prior to randomization.\n- Nephrolithiasis or urolithiasis in the 2 years prior to randomization.\n- Current or recent sprue, inflammatory bowel disease, or malabsorption syndrome, or any indication of poor intestinal absorption of calcium.\n- Poor medical or psychiatric risk for treatment with an investigational drug, as determined by the investigator.\n- Treatment with androgens or other anabolic steroids in the 6 months prior to randomization.\n- Treatment with calcitonins in the 2 months prior to randomization.\n- Treatment with estrogen.\n- Treatment with progestins in the 3 calendar months prior to randomization, or for more than 2 months in the 12 calendar months prior to randomization.\n- Treatment with corticosteroids.\n- Treatment with fluorides in the 6 months prior to randomization or for more than 60 days in the 24 months prior to randomization.\n- Treatment with oral bisphosphonates in the 3 months prior to randomization or for more than 60 days in the 24 months prior to randomization; treatment with intravenous bisphosphonates in the 24 months prior to randomization.\n- Treatment with vitamin D >50,000 IU/week, or with any dose of calcitriol, analogs, or agonists in the 6 months prior to randomization. The 25-hydroxyvitamin D laboratory value at randomization must be between the lower limit of normal and three times the upper limit of normal.\n- Treatment with coumarins and indandione derivatives in the 3 months prior to randomization; treatment with heparins >10,000 U/day for more than 30 days in the 6 months prior to randomization.\n- Treatment with calcium- or aluminum-containing antacids.\n- Treatment with any other drug known to affect bone metabolism in the 6 months prior to randomization.\n- Treatment with any investigational drug during the month prior to the calcium and vitamin D run-in phase. Treatment with investigational drugs in certain therapeutic classes during the month prior to the calcium & vitamin D run-in phase.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied are \"esophagitis, reflux\" and \"esophagitis, peptic\". The corresponding ICDCodes for these diseases are \"K21.9\", \"K21.00\", \"K21.01\" for the first disease, and \"B37.81\", \"K20.0\", \"K20.80\", \"K20.81\", \"K20.90\", \"K20.91\", \"K21.9\" for the second disease. The drugs being used in the trial are \"dexlansoprazole mr\", \"dexlansoprazole mr\", and \"lansoprazole\". The eligibility criteria for this trial include various inclusion and exclusion criteria, such as having endoscopically confirmed erosive esophagitis, not having a positive test for Helicobacter pylori, not using certain medications, not having certain medical conditions or surgical history, and not experiencing acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease of low back pain. The corresponding ICD-10 codes for the disease are 'M54.50', 'M54.51', and 'M54.59'. The trial involves two drugs, namely 'buprenorphine transdermal system' and 'placebo'. The eligibility criteria for participants are listed, including requirements such as having moderate to severe chronic low back pain for at least 3 months, being treated with nonopioid therapy or low-dose opioids, and not having adequate pain control with non-opioid medication. There are also exclusion criteria, such as recent back surgery, allergies to buprenorphine or other opioids, and contraindications to transdermal delivery systems or patch adhesives. The sample concludes by mentioning that there may be additional inclusion/exclusion criteria specific to the trial protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is hyperlipidemia. The ICDCodes associated with this disease are E78.2, E78.49, and E78.5. The drugs being tested in this trial are fenofibrate/simvastatin and pravastatin. The eligibility criteria for this trial include inclusion criteria such as mixed dyslipidemia, and exclusion criteria such as known hypersensitivity to the drugs, pregnancy or lactation, contra-indication to the drugs, and unstable or severe cardiac disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease being studied is psoriatic arthritis. The ICDCodes associated with this disease are 'L40.52'. The drug being tested is adalimumab. The sample also includes the eligibility criteria for participants in the trial, including inclusion and exclusion criteria. Inclusion criteria include having active psoriatic arthritis with a certain number of tender and swollen joints, as well as having an unsatisfactory response or intolerance to previous treatments. Exclusion criteria include a history of certain cancers, other inflammatory joint diseases, unstable diseases, and a history of tuberculosis or other infections.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is schizophrenia. The ICDCodes associated with schizophrenia are listed as ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are cariprazine and placebo. The eligibility criteria for this trial include various conditions such as patients providing informed consent, meeting the DSM-IV-TR criteria for schizophrenia, having a specific score on the SCIPANSS scale, having a minimum diagnosis duration of 1 year, and having normal physical examination, laboratory, vital signs, and/or ECG results. The exclusion criteria include patients with other psychotic disorders, patients in their first episode of psychosis, pregnant or breastfeeding individuals, individuals with certain cognitive disorders or personality disorders, and those with substance abuse or dependence within the past 3 months.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 3 and is focused on the disease called fibromyalgia. The corresponding ICD-10 code for fibromyalgia is \"M79.7\". The drug being studied in this trial is milnacipran hydrochloride. \n\nThe record also includes eligibility criteria for participants in the trial. The inclusion criteria state that participants must have a diagnosis of fibromyalgia based on the 1990 American College of Rheumatology (ACR) criteria. \n\nOn the other hand, the exclusion criteria list various conditions that would disqualify someone from participating in the trial. These conditions include psychiatric illness, depression, suicidal risk, substance abuse, pulmonary dysfunction, renal impairment, active cardiac disease, liver disease, autoimmune disease, cancer, sleep apnea, and inflammatory bowel disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 3. The diseases being studied are osteoarthritis of the hip, osteoarthritis of the knee, lower back pain, and general pain. The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being investigated in this trial are oxycodone cr and tapentadol (cg5503) er. \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must have a clinical diagnosis of knee or hip osteoarthritis with a history of pain at the reference joint for at least 3 months, or a clinical diagnosis of low back pain of benign origin for at least 3 months.\n- Participants must be dissatisfied with their current analgesic therapy, such as non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, opioids, or paracetamol/acetaminophen.\n- Participants must have a pain intensity rating of greater than 4 on the Numerical Rating Scale.\n\nThere are also exclusion criteria that would disqualify participants from the trial, including a lifelong history of seizure disorder or epilepsy, certain brain injuries or neoplasms within the past year, severe traumatic brain injury within the past 15 years, history of malignancy within the past 2 years (with the exception of successfully treated basal cell carcinoma), and the presence of significant pain associated with conditions other than osteoarthritis or low back pain that could affect the assessment or self-evaluation of pain.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The disease being studied is chronic obstructive pulmonary disease (COPD), and the corresponding ICD-10 codes for COPD are J44.9, J44.1, and J44.0. The drugs being tested in this trial are formoterol turbuhaler\u00ae 4.5mg, formoterol turbuhaler\u00ae 9 mg, and turbuhaler\u00ae placebo. The eligibility criteria for participants in this trial include being above the age of 40, having a clinical diagnosis of COPD with current symptoms, being a current or previous smoker with a smoking history of 10 or more pack years, and having specific lung function parameters. There are also exclusion criteria, such as a history or current diagnosis of asthma or atopic diseases, recent use of inhaled glucocorticosteroids, and any relevant cardiovascular or respiratory disorders other than COPD.",
    "The sample from the table is for a phase 3 trial focused on sexual dysfunction. The diseases being studied are listed as \"sexual dysfunction\" and the corresponding ICD-10 codes are provided as ['R37', 'N53.8', 'N53.9', 'F10.181', 'F10.281', 'F11.181', 'F11.281']. The drugs being tested in the trial are 'tibolone' and 'estradiol-norethisterone'. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Physically and mentally healthy postmenopausal women, aged between 48 and 68, with an intact uterus.\n- Women who experience decreased satisfactory sexual activity compared to younger age and whose sexual problems are not caused by relationship/partner issues. The decreased sexual functioning should result in sexually related personal distress as confirmed by the FSDS (score =15).\n- Affirmative answers to the following questions: (a) In previous years, did you find sexual activity satisfying? (b) Has there been a decline in your satisfaction with sexual activity? (c) Are you satisfied with your partner as a friend?\n- All subjects should have an established sexual relationship of at least 6 months duration prior to screening.\n- Women should be sexually active.\n- Normal mammography within 6 months prior to randomization.\n- Body mass index (BMI) should be greater than 18 and less than or equal to 32 kg/m2.\n- Voluntary written informed consent.\n\nThe exclusion criteria for the trial are as follows:\n- Any unexplained abnormal uterine bleeding.\n- Double layer endometrial thickness greater than 4 mm.\n- Use of tibolone or transdermal E2/NETA within 3 months prior to screening.\n- Use of progestogen implants or injections and estrogen/progestogen injectable therapy within 6 months prior to screening.\n- Use of intra-uterine progestogen.\n- Unsuccessful previous treatment with androgens or compounds known to enhance androgenic activity.\n- Current successful treatment with androgens, without applying the applicable washout period of 3 months prior to screening.\n- Any previous or current unopposed estrogen administration, prior use of estrogen pellets or tamoxifen citrate (previous low dose vaginal estrogen-only applications are allowed).\n- Use of anti-androgens within the preceding 5 years prior to screening.\n- Women with significant organic disorder of sexual dysfunction or a partner with sexual dysfunction.\n- Women who had early onset sexual dysfunction (>15 years prior to menopause).\n- Women suffering from androgenic alopecia, acne, or hirsutism.\n- Women suffering from illnesses influencing sexuality.\n- Women using medication influencing sexuality.\n- Moderate to severe depression.\n- Current or prior use of antidepressant within 8 weeks prior to screening.\n- Major gynecological surgery in the preceding 3 months.\n- Any serious disease or disorder; or any endocrine disorder with systemic disease which would have impaired overall health and well-being (controlled hypo/hyperthyroidism and diabetes mellitus Type II was allowed).\n- History or presence of severe psychiatric illness and/or any addictions to drugs, medication, or alcohol in the past 3 years.\n- Diseases for which exogenous hormonal steroids were contraindicated.\n- History or presence of any malignancy, except successfully treated non-melanoma skin cancers.\n- History or presence of cardiovascular or cerebrovascular conditions, thrombosis or thromboembolic disorders.\n- History or presence of liver, gallbladder, or renal disease, epilepsy, or classical migraine headaches.\n- Uncontrolled hypertension.\n- Women with abnormal cervical smear results.\n- History or presence of breast cancer, suspicious breast lump, or mammographic abnormality.\n- Known hypersensitivity to any of the ingredients of the trial medication.\n- Non-compliance with the screening diary.\n- Current use of raloxifene, clonidine, veralipride, phytoestrogen extracts.\n- Drugs known to interfere with the pharmacokinetics of the steroids.\n- Use of investigational drugs within the past 60 days.\n- Any disease or condition that was clinically relevant and which, in the opinion of the investigator, would have jeopardized the subject's well-being during the course of the trial.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is non-small-cell lung carcinoma. The corresponding ICD-10 codes for the disease are D02.20, D02.21, and D02.22. The drugs being tested in the trial are pf-3512676 + paclitaxel + carboplatin and paclitaxel + carboplatin. The eligibility criteria for inclusion in the trial are having advanced non-small-cell lung cancer (stage IIIB with pleural effusion or stage IV), no prior systemic treatment for non-small-cell lung cancer, and an Eastern Cooperative Oncology Performance Status (ECOG PS) of 0 or 1. The exclusion criteria include having small cell or carcinoid lung cancer, known central nervous system metastasis, and pre-existing autoimmune or antibody-mediated diseases.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is restless legs syndrome. The corresponding ICD-10 code for this disease is G25.81. The drugs being tested in the trial are xp13512 600mg, xp13512 1200mg, and a placebo. The eligibility criteria for the trial include patients with primary RLS based on the International RLS Study Diagnostic Criteria. Exclusion criteria include having a sleep disorder that may significantly affect the assessment of RLS, having a neurologic disease or movement disorder, abnormal laboratory results, being pregnant or lactating, and being a woman of childbearing potential who is not practicing an acceptable method of birth control.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2/phase 3, and the disease being studied is macular edema associated with diabetes mellitus. The ICD-10 codes associated with this disease are J95.851, D76.2, E87.71, J65, M04.2, A80.0, and G44.82. The drugs being used in the trial are \"standard of care\" and \"macugen\". The eligibility criteria for participants include having macular edema associated with diabetes and a visual acuity between 20/50 and 20/200. The exclusion criteria include recent laser therapy in the eye, recent signs of uncontrolled diabetes, blood pressure worse than 160/100, and severe cardiac disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease being studied is hypertension. The ICDCodes associated with this disease are \"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", and \"I10\". The drug being tested is nifedipine, which is also known as adalat and baya1040. The eligibility criteria for this trial include inclusion criteria, such as patients who have completed the 8-week double-blind treatment phase of Study 13176 and for whom the test drug is tolerable. The exclusion criteria include patients who are expected to have difficulties with the continuous 1-year follow-up.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and is focused on prostate cancer. The ICD-10 codes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drug being studied is triptorelin (decapeptyl\u00ae), and the treatment duration is 8 months for the pivotal study, followed by an 8-month extension study. \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that the patient must provide written informed consent, be 18 years or older, have a confirmed diagnosis of locally advanced or metastatic prostate cancer, and have an estimated survival time of more than 8 months. The exclusion criteria include patients at risk of serious complications, those who have undergone previous surgical castration, those who have received prostate cancer therapy within 2 months of the baseline visit, and patients with testosterone levels below 150 ng/dL at screening.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease \"thromboembolism.\" The associated ICD-10 codes for this disease are \"O88.22,\" \"O88.23,\" \"O88.211,\" \"O88.212,\" \"O88.213,\" and \"O88.219.\" The drugs being studied in this trial are \"certoparin\" and \"unfractionated heparin.\" \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria are as follows: \n1. Hospitalized medical patients who are 70 years of age or older.\n2. Patients with an acute medical illness that is expected to significantly decrease mobility for at least 4 days (bedridden or only able to walk short distances).\n3. Patients who have provided written informed consent.\n\nThe exclusion criteria for the trial are as follows:\n1. Patients who have been immobilized for longer than 3 days prior to randomization.\n2. Patients who have undergone major surgery, trauma, or invasive procedures within the last 4 weeks, including any injuries or operations on the central nervous system.\n3. Patients who are expected to undergo major surgical or invasive procedures within the next 3 weeks after randomization.\n4. Patients who have received LMWH/heparin administration for longer than 48 hours in the 5 days prior to randomization.\n5. Patients who are immobilized due to a cast or fracture.\n6. Patients who have an indication for anticoagulatory or thrombolytic therapy.\n7. Patients with acute symptomatic DVT/PE (deep vein thrombosis/pulmonary embolism).\n8. Patients with known hypersensitivity to any of the study drugs or drugs with similar chemical structures.\n9. Patients with acute or a history of heparin-induced thrombocytopenia type II (HIT II).\n\nIt is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply to the trial.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is relapsing-remitting multiple sclerosis. The corresponding ICD-10 codes for this disease are 'G35', 'G93.81', 'K74.1', 'Q85.1', 'G12.21', 'G12.23', and 'M34.0'. The drugs being tested in this trial are fingolimod 1.25 mg, fingolimod 0.5 mg, and a placebo. The eligibility criteria for inclusion in the trial are as follows: patients must be between the ages of 18-55, have a diagnosis of multiple sclerosis with a relapsing-remitting disease course, and have an EDSS score of 0-5.5. Exclusion criteria include having other chronic diseases of the immune system, malignancies, acute pulmonary disease, cardiac failure, and being pregnant or nursing. Additionally, there may be other protocol-defined inclusion/exclusion criteria specific to this study.",
    "The sample from the table represents a phase 3 clinical trial for the treatment of pharyngitis. The trial involves the use of the drug celecoxib and a placebo. The eligibility criteria for inclusion in the trial include having a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis and being willing to abstain from consuming anything by mouth, except for the trial medication, for two hours while at the trial site. After the two-hour assessment, patients are allowed to consume food and drink. Exclusion criteria include recent use of any analgesic/antipyretic medication and anticipation of using any inhaled therapy, including beta-agonists, during the 24-hour trial period.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is low back pain, which is associated with the icd-10 codes M54.50, M54.51, and M54.59. The drugs being tested are oxycodone/naloxone controlled-release and a placebo. \n\nThe eligibility criteria for participants include being at least 18 years old, having moderate to severe chronic low back pain for at least 3 months, and the pain must be related to nonmalignant and nonneuropathic conditions without radiation or with only proximal radiation. Participants must also be on opioid analgesic therapy for low back pain for at least 4 weeks prior to screening, with a stable opioid regimen at a specific dose range. They must require continuation of opioid analgesic treatment and have a certain level of pain score on a numerical rating scale. Participants must also be willing and able to comply with the study protocol, understand questionnaires, use a diary, and provide informed consent in English.\n\nExclusion criteria include being pregnant or lactating, having contraindications or hypersensitivity to the drugs being tested, having certain medical conditions such as acute spinal cord compression or fibromyalgia, having a history of substance abuse or addiction, and having received any investigational medication within 30 days prior to the study.\n\nIt is important to note that there may be additional inclusion/exclusion criteria specific to the protocol.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is plaque-type psoriasis. The ICD-10 codes associated with the disease are L40.0, L40.4, L40.8, L40.9, L40.1, and L40.50. The drugs being tested in the trial are secukinumab 150mg and secukinumab 10mg/kg i.v. regimen. The eligibility criteria for participants are listed, including requirements for written informed consent, ability to understand and communicate with the investigator, and previous participation in a specific study with a partial response. There are also exclusion criteria, such as being pregnant or lactating, having forms of psoriasis other than chronic plaque-type, and ongoing use of prohibited treatments.",
    "The sample from the table represents a phase 3 clinical trial for the treatment of psoriatic arthritis. The trial is evaluating the effectiveness of two drugs, infliximab + methotrexate (ifx + mtx) and methotrexate (mtx). The eligibility criteria for participants include being 18 years or older, having a diagnosis of psoriatic arthritis with peripheral polyarticular involvement, and having active disease with specific symptoms such as swollen and tender joints. Female participants of childbearing potential must use contraception during the study. Exclusion criteria include pregnancy, previous treatment with infliximab or methotrexate, and certain medical conditions or infections. The sample provides detailed inclusion and exclusion criteria to ensure the safety and effectiveness of the trial.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is asthma. The ICD-10 codes associated with the disease are 'J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', and 'J45.40'. The drug being tested is budesonide/formoterol. The eligibility criteria for inclusion in the trial are being between 18 and 65 years of age and presenting at a study emergency department with an asthma exacerbation. The exclusion criteria are admission to the hospital and patients receiving more than 2000 \u00b5g/day of beclomethasone equivalent inhaled corticosteroids (1000 \u00b5g/day fluticasone or 1600 \u00b5g/day budesonide).",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the disease asthma. The ICD-10 codes associated with asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being studied in the trial are ciclesonide, placebo, and salbutamol. The eligibility criteria for participants in the trial include having a history of asthma for at least 6 months, demonstrating optimal use of a metered-dose inhaler (MDI), and meeting specific lung function and reversibility requirements. There are also exclusion criteria, such as having severe concomitant diseases, contraindications for inhaled steroids, recent hospitalizations for asthma, recent respiratory tract infections or asthma exacerbations, recent use of systemic steroids, recent immunotherapy, and inability to follow the study procedures.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is restless legs syndrome. The corresponding ICD-10 code for this disease is G25.81. The drugs being tested in the trial are \"gen (xp13512)\", \"gen (xp13512)\", and \"placebo\". The eligibility criteria for inclusion in the trial are having primary RLS based on the International RLS Study Group Diagnostic Criteria. The exclusion criteria include having a sleep disorder that may significantly affect the assessment of RLS, having a neurologic disease or movement disorder, having abnormal laboratory results, ECG or physical findings, being pregnant or lactating, and being a woman of childbearing potential who is not practicing an acceptable method of birth control.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease \"rhinitis, allergic, perennial.\" The associated ICD-10 codes for this disease are ['J30.0', 'J31.0', 'J30.89', 'J30.9', 'A50.05', 'J30.2', 'J30.1']. The drugs being studied are \"fluticasone furoate\" and \"placebo.\" The eligibility criteria for participants are listed, including age requirements, diagnosis criteria, and certain medical conditions that would exclude someone from participating. The sample also includes exclusion criteria, such as recent participation in other studies or certain medication usage.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease asthma. The associated ICD-10 codes for asthma are provided. The trial involves the use of three drugs: tiotropium high dose, placebo, and tiotropium low dose. The eligibility criteria for participants are listed, including age requirements, duration of asthma history, and specific medication usage. Inclusion criteria such as signing informed consent forms and being able to use the Respimat inhaler correctly are also mentioned. Exclusion criteria are listed, which include having significant diseases other than asthma, abnormal blood chemistry, history of heart disease, and certain medication usage. The sample also includes criteria related to pregnancy, drug use, and recent asthma exacerbations.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 3 and focuses on cardiovascular diseases and diabetes mellitus. The associated ICD-10 codes for these diseases are provided as well. The trial involves two drugs, namely mk0653a (ezetimibe (+) simvastatin) and atorvastatin, with a treatment duration of 6 weeks. The eligibility criteria for participants are also listed, including age requirements, specific treatment history, cholesterol levels, and exclusion criteria such as uncontrolled diabetes, elevated liver function tests, and drug or alcohol dependency. Additionally, there are criteria related to hormonal therapy, pregnancy, and breastfeeding.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is phase 3. The diseases being studied are chronic obstructive pulmonary disease, bronchitis, and emphysema. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in the trial are arformoterol tartrate inhalation solution, arformoterol 25 \u0173g bid, formoterol 12 \u0173g bid, and a placebo. The eligibility criteria for the trial are listed, including age requirements, smoking history, breathlessness severity, pregnancy test for females, and general health. There are also exclusion criteria, such as a history of asthma, high blood eosinophil count, recent febrile illness, and chest x-ray findings suggesting a diagnosis other than COPD.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is renal transplantation. The ICDCodes associated with this disease are N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, and Q60.1. The drugs being used in the trial are cyclosporin a, belatacept less intensive regimen (li), and belatacept more intensive regimen (mi). The eligibility criteria for this trial include specific inclusion and exclusion criteria. Some of the inclusion criteria are being a first-time recipient of a kidney transplant from a deceased donor and meeting specific donor criteria. Some of the exclusion criteria include donor age less than 10 years, receiving a concurrent solid organ or cell transplant, having a positive T-cell lymphocytotoxic crossmatch, being positive for Hepatitis B or C or HIV, having active tuberculosis, having a history of cancer in the last 5 years, having a history of substance abuse, having specific exclusionary laboratory results, having a mammography suspicious for cancer, being allergic to iodine, and for the long-term extension study, having completed three years of study treatment.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on studying the effects of a drug called capsaicin dermal patch on patients with HIV infections, peripheral nervous system diseases, and pain. The diseases are represented by their respective ICD-10 codes. \n\nThe eligibility criteria for participants in the trial include being at least 18 years old, having documented evidence of HIV-1 infection, and a diagnosis of painful HIV-associated distal symmetrical polyneuropathy. Other criteria include specific symptoms, absence or diminished ankle reflexes, and specific sensations in the legs. Participants must also meet certain requirements regarding their medication history, pain scores, performance score, and skin condition. Female participants of child-bearing potential must have a negative pregnancy test and agree to use birth control during the study.\n\nThere are also exclusion criteria, such as the use of certain opioid medications, substance abuse history, recent use of certain pain medications, and current use of investigational agents or specific drugs. Other exclusion criteria include having significant pain from other causes, evidence of other contributing causes for peripheral neuropathy, presence of certain medical devices, recent treatment for opportunistic infections, active malignant disease, and significant ongoing or untreated abnormalities in cardiac, renal, hepatic, or pulmonary function. Hypersensitivity to capsaicin or certain medications is also an exclusion criterion.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 3, and the diseases mentioned are sickle cell disease and sickle cell anemia. The ICDCodes associated with these diseases are D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, and D57.218. The drug mentioned is ICA-17043. The eligibility criteria for this sample include successfully completing a previous study, being on a stable dose of HU (hydroxyurea) for at least 3 months, being male or a female not capable of becoming pregnant or using appropriate birth control, and providing written informed consent. The exclusion criteria include having a positive urine pregnancy test on Day 1 and being presently unsuitable for participation in the long-term study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the disease phenylketonuria (PKU). The ICD-10 code for PKU is E70.0. The trial involves two drugs, sapropterin dihydrochloride and placebo. The eligibility criteria for participants include being at least 8 years old, having a confirmed diagnosis of PKU, and being willing to continue their current diet unchanged during the study. Other criteria include providing informed consent, using contraception if sexually active, and having negative pregnancy tests for females of childbearing potential. There are also exclusion criteria, such as hypersensitivity to sapropterin dihydrochloride, breastfeeding or planning to become pregnant during the study, and recent use of investigational products. The sample provides a comprehensive list of inclusion and exclusion criteria for potential participants in the trial.",
    "The sample from the table represents a phase 3 clinical trial for the treatment of lymphoma. The diseases column specifies that the trial is focused on intermediate- or high-grade non-Hodgkin's lymphoma. The icdcodes column provides a list of ICD-10 codes associated with the disease. The drugs column lists the medications being used in the trial, including the chop regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, and vincristine sulfate. The criteria column outlines the eligibility criteria for participants in the trial, including specific disease characteristics, patient characteristics such as age and health status, and restrictions on prior treatments.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 3.\n- Diseases: The trial is focused on studying various diseases, including colorectal cancer, depression, esophageal cancer, extrahepatic bile duct cancer, fatigue, gallbladder cancer, gastric cancer, liver cancer, lung cancer, and pancreatic cancer.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The trial involves the use of two drugs, namely escitalopram oxalate and placebo.\n- Criteria: The eligibility criteria for participants in the trial are listed. These include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.\n\nThe disease characteristics include different stages of lung cancer, pancreatic cancer, liver cancer, gallbladder cancer, bile duct cancer, esophageal cancer, gastric cancer, and colorectal cancer. Additionally, the criteria include meeting diagnostic criteria for major depressive disorder and having a certain duration of depressive symptoms.\n\nPatient characteristics include being able to swallow pills, not having substance abuse or certain mental disorders, and not having certain medical conditions or allergies. The prior concurrent therapy restriction states that participants should not be taking other antidepressant medications or psychostimulants concurrently.\n\nThis sample provides an example of the information stored in the table for a specific clinical trial.",
    "The sample is a phase 3 trial that focuses on insomnia and bipolar disorder. The trial includes subjects who are between 18 and 65 years old and have been diagnosed with bipolar I disorder. These subjects must have mild to moderate manic symptoms and a clinically significant sleep disturbance. They must also be receiving mood stabilizing medication for at least one week prior to the trial. The trial involves the use of the drug ramelteon and a placebo. \n\nThe inclusion criteria for the trial include signing the informed consent document, practicing effective contraception for female subjects, and having no current suicidal or homicidal ideation. Exclusion criteria include experiencing psychotic symptoms, having certain cognitive disorders or substance dependence disorders, and having serious general medical illnesses. Subjects with hypo- or hyperthyroidism must be stabilized on thyroid replacement for at least three months. Other exclusion criteria include allergies or hypersensitivity to ramelteon, taking medications that interact with ramelteon, being pregnant or nursing, and having received an experimental drug or used an experimental device within the past 30 days.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease impetigo. The icd-10 codes associated with impetigo are ['L01.00', 'L01.02', 'L01.03', 'L01.09', 'L01.01']. The drugs being tested in the trial are 'experimental: cd07223 1.5 % topical gel bid', 'experimental: cd07223 1.5% topical gel tid', 'placebo comparator: cd07223 vehicle gel bid', and 'placebo comparator: cd07223 vehicle gel tid'. The eligibility criteria for participants in the trial are listed, including requirements such as being 2 years of age or older, having a clinical diagnosis of primary impetigo, and having specific measurements and scores related to the target lesion. There are also exclusion criteria, such as having other active skin diseases, requiring oral antibiotic treatment, or having certain medical conditions.",
    "The sample from the table represents a phase 3 trial for the treatment of bipolar disorder and depression. The diseases included in the trial are bipolar disorder and depression with bipolar features. The corresponding ICD-10 codes for these diseases are provided. The drugs being studied are the regular tablet formulation and novel formulation of lamotrigine. \n\nThe eligibility criteria for the trial are as follows:\n- Participants must be 60 years or older.\n- Participants must have a diagnosis of Bipolar Disorder-I or II with a depressive episode.\n- Participants must have a HAM-D score greater than 18 (GRID-HAM-D 24-item version).\n- Availability of an informant is encouraged but not required for study participation.\n\nThe exclusion criteria for the trial are as follows:\n- Participants with chronic psychotic conditions such as schizophrenia, schizoaffective disorder, or delusional disorder.\n- Participants with contraindications to lamotrigine based on physician interview and medical assessment.\n- Participants with a documented history of intolerance to lamotrigine.\n- Participants who have previously failed to respond to at least 12 weeks of treatment with lamotrigine.\n- Participants with active substance dependence or substance-related safety issues.\n- Participants with mood disorder due to a general medical condition or treatment.\n- Participants with rapid cycling as defined in DSM-IV.\n- Participants with dementia or brain degenerative diseases.\n- Participants who are unable to communicate in English.\n- Participants with clinically significant sensory impairment.\n- Participants with a recent history of cardiovascular, peripheral vascular events, or stroke.\n- Participants at high risk for suicide.\n- Participants who are currently hospitalized.\n\nThis sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and is focused on the disease \"type 2 diabetes mellitus\". The corresponding ICD-10 codes for this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs being studied in this trial are \"sitagliptin 100 mg q.d./pioglitazone 30 mg q.d\" and a placebo that matches the sitagliptin/pioglitazone combination. The eligibility criteria for this trial include being at least 18 years old and having type 2 diabetes mellitus, while the exclusion criteria include having a history of type 1 diabetes mellitus or ketoacidosis, being on antihyperglycemic agent therapy within the past 4 months, and having been on more than 4 weeks of antihyperglycemic therapy over the past 2 years.",
    "The sample from the table represents a clinical trial for a drug aimed at treating benign prostatic hypertrophy (BPH). The trial is in phase 2/phase 3, indicating that it is in an advanced stage of testing. The diseases column specifies the disease being targeted, which in this case is BPH. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the names of the drugs being tested, which are ozarelix/placebo and placebo. The criteria column provides the eligibility criteria for participants in the study, including inclusion and exclusion criteria. The inclusion criteria specify conditions that must be met for a patient to participate, such as age, clinical signs and symptoms of BPH, specific test results, and agreement not to use other BPH treatments during the study. The exclusion criteria specify conditions that would disqualify a patient from participating, such as a history of prostate cancer, certain surgeries or radiation treatments, specific bladder volume or residual urine volume measurements, and use of certain medications.",
    "The sample is a phase 3 trial for patients with type 2 diabetes mellitus. The trial aims to evaluate the effectiveness of various drugs, including insulin glargine, ly2189265, metformin, and glimepiride, in controlling diabetes. The eligibility criteria for participants include having type 2 diabetes that is not well controlled on one, two, or three oral antidiabetic medications, with at least one of them being metformin or a sulfonylurea. Other criteria include stable weight, a body mass index (BMI) between 23 and 45 kg/m^2, and willingness to inject subcutaneous medication. Females of childbearing potential must test negative for pregnancy and use reliable birth control during the study. Exclusion criteria include having type 1 diabetes, chronic insulin use, certain medical conditions (such as heart failure or liver disease), and recent participation in another clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The trial involves the use of immune globulin IV (human) and albumin (human) 25% as potential drugs. \n\nThe eligibility criteria for participants in the trial are listed, including the requirement of a documented diagnosis of CIDP by a neurologist, fulfillment of specific neurophysiological criteria, and a certain level of disability in limb function. \n\nThere are also exclusion criteria, such as recent treatment with certain medications, respiratory impairment requiring mechanical ventilation, and the presence of other neurological disorders or systemic diseases. Other factors, such as pregnancy, cardiac conditions, and certain medical conditions, also exclude individuals from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific record, the phase of the trial is Phase 3. The disease mentioned is \"carcinoma, renal cell\" and its corresponding ICDCodes are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs involved in the trial are 'pazopanib' and 'placebo'. The eligibility criteria for this trial include various conditions such as a diagnosis of clear cell RCC, locally advanced or metastatic RCC, measurable disease, prior systemic treatment, and specific organ function requirements. There are also exclusion criteria listed, such as pregnancy, history of other malignancies, CNS metastasis, certain medical conditions, and recent use of certain medications or investigational drugs.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drugs being used, and the eligibility criteria for participants.\n\nIn this specific sample, the trial is studying two diseases: indolent non-Hodgkin's lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). The ICD-10 codes associated with these diseases are provided as well. The drugs being used in the trial are bendamustine at two different doses.\n\nThe eligibility criteria for participants with iNHL include having a biopsy-confirmed diagnosis of relapsed or refractory iNHL after rituximab-based therapy. The patient must have one of the specified types of indolent B-cell lymphoma and adequate hematologic function. \n\nFor participants with CLL, the eligibility criteria include having previously confirmed untreated symptomatic chronic B-cell lymphocytic leukemia of a certain stage and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n\nThere are also exclusion criteria listed, such as recent participation in another clinical study, certain medical conditions or history, and the likelihood of non-compliance with the protocol.\n\nIt is important to note that there may be additional inclusion and exclusion criteria that apply, but they are not specified in this sample.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The disease being studied is chronic pain. The corresponding ICD-10 codes for this disease are G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, and G89.3. The drugs being tested in this trial are oros hydromorphone and placebo. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a primary clinic diagnosis of osteoarthritis pain of the hip or knee for at least 6 months and requiring daily opioid medication for chronic osteoarthritis pain. Exclusion criteria include having undergone joint replacement surgery for hip or knee osteoarthritis pain, a history of drug or alcohol abuse, fibromyalgia, major depression or anxiety, and being pregnant or breastfeeding for women.",
    "The sample is from a table that contains information about clinical trials. In this specific sample, the trial is in phase 3 and focuses on the diseases of depression and cognition. The associated ICD-10 codes for these diseases are ['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']. The drugs being studied are duloxetine and placebo. The sample also includes the eligibility criteria for the trial, including both inclusion and exclusion criteria. Inclusion criteria state that participants must be able to visit the doctor's office for clinic visits, tests, and procedures, and they must have been diagnosed with major depression and have had at least one other episode in the past. Exclusion criteria state that participants cannot have a current or previous major psychiatric disorder other than depression, such as bipolar disorder or schizophrenia, and they cannot have taken a drug within the last 30 days that has not been approved for use by governmental authorities.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is bladder cancer. The ICDCodes associated with this disease are 'D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', and 'D41.4'. The drugs being used in the trial are 'epirubicin hydrochloride' and 'mitomycin c'. \n\nThe eligibility criteria for this trial include a diagnosis of non-muscle invasive bladder cancer, recurrent disease after undergoing induction or maintenance therapy with bacillus Calmette-Gu\u00e9rin (BCG), and specific staging and grading criteria. Other patient characteristics such as performance status, blood counts, kidney function, and imaging results are also considered. Patients must be available for long-term follow-up and willing to undergo a full or partial cystectomy. There are also various exclusion criteria, including allergies to certain medications, urinary tract infections, and certain medical conditions or treatments.\n\nPrior concurrent therapy, such as intravesical chemotherapy or pelvic irradiation, is also taken into account. The use of corticosteroids and concurrent chemotherapy is not allowed. Concurrent participation in other studies is allowed.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and focuses on post-traumatic stress disorder (PTSD). The associated ICD-10 codes for PTSD are ['F43.10', 'F43.11', 'F43.12']. The trial involves the use of two drugs: quetiapine fumarate and a placebo version of quetiapine fumarate. The eligibility criteria for participants include being hospitalized or non-hospitalized patients, veterans or civilians, and having experienced symptoms of PTSD for at least 12 months prior to giving consent to the study. The exclusion criteria include a history of psychotic conditions, previous ineffectiveness of quetiapine or other anti-psychotics, and taking prohibited medications such as mood stabilizers or substances of abuse.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is hypertension. The corresponding ICD-10 codes for hypertension are 'I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', and 'I10'. The drug being tested is nifedipine, which is also known as Adalat or Baya1040. The eligibility criteria for inclusion in the study are as follows: the participant must be 20 years or older, of Japanese nationality, an outpatient with essential hypertension, and currently taking Adalat CR 40 mg once daily along with at least one other antihypertensive drug (excluding calcium antagonists) for a minimum of 4 weeks prior to entering the study. The exclusion criteria include patients with a sitting diastolic blood pressure (DBP) of 110 mm Hg or higher, as well as those with secondary hypertension or hypertensive emergency.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease being studied is seasonal allergic rhinitis. The ICDCodes associated with this disease are 'J30.2'. The drugs being used in the trial are mometasone furoate and placebo. \n\nThe eligibility criteria for this trial include being 12 years of age or older, having a documented history of SAR for at least 2 years, having a positive skin-prick test response to a seasonal allergen, being symptomatic at the screening and baseline visits, being in good health as confirmed by clinical and laboratory testing, and not having any other clinically significant diseases that would interfere with the study evaluations.\n\nThe exclusion criteria for this trial include a history of severe reactions to skin testing, asthma requiring chronic use of corticosteroids, frequent sinusitis or chronic postnasal drip, rhinitis medicamentosa, allergies to multiple classes of medications or intolerance to nasal sprays, recent upper respiratory tract or sinus infection, nasal structural abnormalities, and dependence on certain nasal, oral, or ocular medications as determined by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease being studied is thromboembolism. The ICDCodes associated with this disease are O88.22, O88.23, O88.211, O88.212, O88.213, and O88.219. The drugs being tested in this trial are dabigatran and warfarin. The eligibility criteria for this trial include specific inclusion and exclusion criteria. The inclusion criteria state that patients must have acute symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) that occurred 3-12 months prior to screening and has been documented by objective testing. The exclusion criteria state that patients with symptomatic DVT or PE at screening, interruption of anticoagulant therapy for 2 or more weeks during the 3-12 months of treatment for the prior VTE, perceived excessive risk of bleeding, elevated AST or ALT levels, or severe renal impairment (estimated creatinine clearance <= 30 ml/min) will be excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied include prostate cancer, male erectile disorder, stage I prostate cancer, and stage II prostate cancer. The ICDCodes associated with these diseases are provided as well. The drugs being investigated are sildenafil citrate and alprostadil. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" These criteria include factors such as patients undergoing BNS-RAP for prostate cancer, ability to achieve erections prior to surgery, follow-up care at a specific medical center, willingness to participate for a minimum of 18 months, and various medical conditions or treatments that may exclude individuals from participating.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is asthma. The ICD-10 codes associated with the disease are 'J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', and 'J45.40'. The drugs being tested are budesonide and fluticasone. The eligibility criteria for inclusion in the trial include providing signed written informed consent, being diagnosed with bronchial asthma, being between 5-15 years old and able to inhale using specific devices, requiring treatment with inhaled steroids, and having at least 3 months of asthma history. The exclusion criteria include recent use of systemic steroids, exceeding a certain daily dose of inhaled steroids, recent respiratory infections, concurrent serious diseases, contraindications to the investigational drugs, participation in another clinical study, previous enrollment in the current study, current use of budesonide turbuhaler, pregnancy or planning to be pregnant, involvement of the legal representative/caregiver in the study, and being considered inappropriate to participate by the investigator.",
    "The sample in the table is for a phase 3 clinical trial. The diseases being studied include lipid metabolism, inborn errors, hypercholesterolemia, autosomal dominant, hyperlipidemias, metabolic diseases, hyperlipoproteinemia type ii, metabolism, inborn errors, genetic diseases, inborn, infant, newborn, diseases, metabolic disorder, congenital abnormalities, hypercholesterolemia, hyperlipoproteinemias, dyslipidemias, and lipid metabolism disorders. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in the trial are mipomersen and placebo. The eligibility criteria for inclusion in the trial include a diagnosis of Homozygous Familial Hypercholesterolemia (HoFH), stable lipid-lowering therapy for 12 weeks, stable weight for 6 weeks, and stable low-fat diet for 8 weeks. The exclusion criteria include significant health problems in the recent past such as heart attack, stroke, blood disorders, cancer, or digestive problems.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is phase 3. The diseases being studied are adenocarcinoma of the prostate, hormone-resistant prostate cancer, recurrent prostate cancer, and stage IV prostate cancer. The corresponding ICD-10 codes for these diseases are provided. The drugs being used in the trial are docetaxel and prednisone. The eligibility criteria for the trial are listed, including requirements for patients' disease progression, measurable and non-measurable disease criteria, prior treatments, medical history, laboratory values, and performance status.",
    "The sample provided is for a phase 3 clinical trial for breast cancer. The trial is looking at the effectiveness of the drugs doxorubicin, cyclophosphamide, and docetaxel in treating large resectable or locally advanced breast cancer. The eligibility criteria for participants include being women with measurable disease in the breast and/or lymph nodes, no prior surgery or chemotherapy/radiation therapy, age between 18 and 70 years, a Karnofsky Performance score of at least 70%, and estrogen and/or progesterone receptor analysis performed on the primary tumor. Adequate bone marrow, liver, and renal function are also required. Patients with advanced pulmonary disease, peripheral neuropathy above grade 2, evidence of distant metastases, a history of breast cancer or another malignancy within the past 5 years, and pregnant or lactating women are excluded from the trial. Written informed consent is also necessary.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied are bipolar disorder, bipolar depression, and depression. The corresponding ICDCodes for these diseases are provided as well. The drug being tested is quetiapine fumarate (seroquel\u2122), which is a mood stabilizer. The eligibility criteria for this trial include being diagnosed with bipolar I disorder or bipolar II disorder, currently being depressed, and being between the ages of 18 and 65. The patient must also be an outpatient at the time of enrollment and randomization. There are also exclusion criteria listed, such as having a current DSM-IV Axis I disorder other than bipolar disorder, a history of non-response to treatment, and posing a serious suicidal or homicidal risk. Pregnancy or lactation, as well as clinically relevant diseases or findings, are also listed as exclusion criteria.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is renal cell carcinoma. The ICDCodes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being used in the trial are sorafenib and temsirolimus (torisel). The eligibility criteria for this trial include having a confirmed diagnosis of metastatic renal cell carcinoma, having documented radiological progressive disease or clinical progressive disease while receiving first-line sunitinib therapy, and having at least one measurable lesion per RECIST criteria. There are also exclusion criteria, such as having metastatic CNS from RCC, discontinuing Sutent therapy due to intolerance, and having prior systemic therapy for metastatic RCC other than sunitinib.",
    "The sample is a phase 3 clinical trial for patients with unresectable locally advanced, recurrent, or metastatic biliary tract, gallbladder, or ampullary carcinoma. The trial aims to evaluate the effectiveness of cisplatin and gemcitabine hydrochloride as treatment options. The eligibility criteria include having histologically or cytologically confirmed cancer, no brain metastases, and a performance status of ECOG 0-2. Other criteria include specific requirements for hematopoietic, hepatic, renal, and other health parameters. Prior concurrent therapies, such as chemotherapy, radiotherapy, and surgery, have certain restrictions. The sample also mentions the allowance of prior photodynamic therapy under specific conditions. The trial excludes patients with certain medical conditions, active infections, or other malignancies within the past 5 years. Patients must not be pregnant or nursing, and fertile patients must use contraception during and after the study. The sample emphasizes the need for informed consent and the absence of psychiatric disorders that would hinder consent.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The diseases being studied are schizophrenia and schizoaffective disorder. The corresponding ICD-10 codes for these diseases are F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9 for schizophrenia, and F25.9, F25.0, F25.1, F25.8 for schizoaffective disorder. The drug being tested is lurasidone hcl. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. In this case, the inclusion criteria state that the subject must have completed 6 weeks of treatment and all required assessments on the final study visit of a previous study. The exclusion criteria state that the subject must not be considered at imminent risk of suicide or harm to self, others, or property, and must have a body mass index (BMI) within a specific range.",
    "The sample from the table is for a phase 3 trial. The disease being studied is major depressive disorder. The ICD-10 codes associated with this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested are aprepitant and a comparator drug, which is a placebo (unspecified). The eligibility criteria for this trial are patients with Major Depressive Disorder.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 3. The disease being studied is a gastrointestinal stromal tumor. The corresponding ICD-10 codes for this disease are listed as ['C49.A0', 'C49.A1', 'C49.A2', 'C49.A5', 'C49.A3', 'C49.A4', 'C49.A9']. The drug being tested is imatinib mesylate.\n\nThe eligibility criteria for this trial are described in detail. The criteria include histologically confirmed gastrointestinal stromal tumor, localized disease, and meeting specific criteria for high-risk or intermediate-risk of relapse based on tumor size and mitotic rate. Other criteria include positive staining for Kit (CD117), complete resection of the primary tumor within a specific time frame, absence of residual macroscopic disease, and no distant metastases.\n\nThe patient characteristics required for participation in the trial include being 18 years or older, having a performance status of WHO 0-2, and meeting specific hematopoietic, hepatic, renal, and cardiovascular criteria. Other criteria include not being pregnant or nursing, having effective contraception for fertile patients, and not having certain medical conditions or infections.\n\nThe prior concurrent therapy section specifies that no prior molecular targeted or biologic therapy should have been received, and no concurrent filgrastim or sargramostim should be used. Other criteria include no prior chemotherapy or radiotherapy, and no prior use of imatinib mesylate. The sample also mentions restrictions on concurrent therapeutic anticoagulation and other concurrent antitumoral therapy or investigational drugs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease being studied is heart failure, specifically congestive heart failure. The ICDCodes associated with this disease are I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, and I50.40. The drugs being used in the trial are rolofylline and a comparator drug called placebo (unspecified). \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having dyspnea (shortness of breath) at rest or with minimal exertion, fluid overload, estimated creatinine clearance between 20-60 mL/min, worsening renal function, anticipated need for IV diuretic treatment for at least 48 hours, B-type natriuretic peptide (BNP) levels above 500 pg/mL or NT-pro-BNP levels above 2000 pg/mL, and systolic blood pressure of at least 90 mmHg at randomization.\n\nExclusion criteria include recent IV radiographic contrast administration within 14 days, recent IV vasodilator use within 6 hours, low serum potassium levels (<3.5 meq/L), ongoing or planned therapy for heart failure with mechanical circulatory or ventilatory support, ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis, rapidly progressive acute renal failure, evidence of acute tubular necrosis or other causes of acute kidney injury unrelated to heart failure, severe pulmonary disease, significant stenotic mitral or aortic valvular disease, recent heart transplant or admission for cardiac transplantation or LVAD surgery, major surgery within 2 weeks prior, evidence of acute coronary syndrome in the past 2 weeks, low hemoglobin or hematocrit levels, active bleeding requiring transfusion, acute myocarditis or certain types of cardiomyopathy, known hepatic impairment, non-cardiac pulmonary edema, high temperature (>38\u00b0C), sepsis or active infection requiring IV antimicrobial treatment, recent administration of an investigational drug or device within 30 days, current or anticipated therapy with specific medications, recent administration of any vasopressor or inotropic drug within 72 hours, history of seizure or stroke within 2 years, history of brain tumor or surgery, encephalitis/meningitis within 2 years, history of head trauma or alcohol withdrawal seizures, advanced Alzheimer's disease, and advanced multiple sclerosis.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a phase 3 trial and focuses on the disease \"colorectal cancer\". The associated ICD-10 codes for this disease are \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\". The drugs being tested in this trial are \"bevacizumab, erlotinib\", \"bevacizumab\", \"bevacizumab\", and \"low dose capecitabine\". \n\nThe eligibility criteria for this trial are as follows:\n- The patient must have untreated metastatic colorectal carcinoma.\n- The patient must be 18 years or older.\n- The disease must be measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST criteria).\n- The patient's ECOG performance status must be 0 or 1.\n- The patient must have a life expectancy of more than 3 months.\n- The patient must have adequate hematological, renal, and liver function.\n- Tumor tissue must be available for determination of KRAS mutational status.\n- Blood sample and paraffin-embedded tumor tissue are required for translational research.\n\nThe exclusion criteria for this trial are as follows:\n- The patient must not have received adjuvant therapy within the past 6 months.\n- The patient must not have CNS metastases.\n- The patient must not have clinically significant atherosclerotic vascular disease.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3, and the disease being studied is osteoporosis. The ICD-10 codes associated with this disease are M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, and M80.80XS. The drugs being tested in this trial are odanacatib, placebo, vitamin D3, and calcium supplement. The eligibility criteria for participants are listed under inclusion and exclusion criteria. Inclusion criteria include being postmenopausal for 3 years, having a BMD t-score within a specific range, having evaluable hips for testing, and being ambulatory. Exclusion criteria include having a previous hip fracture, having multiple clinical vertebral fractures, being treated with certain medications, having a metabolic bone disorder other than osteoporosis, and having specific medical conditions such as renal stones, Parkinson's disease, multiple sclerosis, or active parathyroid disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is osteoporosis. The icd-10 codes associated with this disease are \"M81.6\", \"Z82.62\", \"Z13.820\", \"M81.8\", \"Z87.310\", \"M81.0\", and \"M80.80XS\". The drug being tested is zoledronic acid. The eligibility criteria for this trial include being a male between the ages of 25 and 85. Exclusion criteria include current use of bisphosphonates such as Aredia\u00ae (pamidronate), Didronel\u00ae (etidronate), Fosamax\u00ae (alendronate), Actonel \u00ae (residronate), Skelid\u00ae (tiludronate), and a history of severe liver, kidney, or eye disease. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on Parkinson's disease. The diseases column lists different variations of Parkinson's disease, along with their corresponding ICD-10 codes. The drugs column includes the names of the drugs being tested in the trial, which are preladenant and placebo. The criteria column provides the eligibility criteria for participants to be included or excluded from the trial. The inclusion criteria include having a diagnosis of idiopathic Parkinson's disease, prior therapy with L-dopa, stable dopaminergic treatment, experiencing motor fluctuations, and being capable of maintaining a symptom diary. The exclusion criteria include having drug-induced or atypical parkinsonism, cognitive impairment, bipolar disorder, untreated major depressive disorder, or other psychotic disorders. It also excludes participants with certain medical conditions, recent surgeries, high blood pressure, abnormal liver function, history of hepatic dysfunction, history of malignant disease, certain medication usage, excessive alcohol consumption, severe medical conditions, allergies to the investigational product, and participants who are pregnant, breastfeeding, or planning to become pregnant.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied are pain, chronic pain, and breakthrough pain. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in the trial is fentanyl buccal tablets. The eligibility criteria for participants in this trial include providing written informed consent, being between 18 and 80 years old, having chronic pain associated with various conditions, currently using a specific dosage of opioid therapy, experiencing a certain level of pain intensity and frequency, and meeting other specific requirements. There are also exclusion criteria listed, which include factors such as uncontrolled or rapidly escalating pain, allergies or contraindications to the study drug, history of substance abuse, certain medical conditions, pregnancy or lactation, recent participation in other studies, and others.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease mentioned is \"renal failure chronic requiring hemodialysis.\" The ICDCodes associated with this disease are ['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', 'Q60.0', 'Q60.1']. The drug mentioned is \"soluble ferric pyrophosphate (sfp)\". The eligibility criteria are divided into three stages. Each stage has its own set of inclusion and exclusion criteria. The criteria include factors such as age, duration of hemodialysis, iron therapy, hemoglobin levels, transferrin saturation, serum ferritin levels, administration of certain drugs, kidney transplant status, vascular access for dialysis, previous IV iron administration, changes in erythropoietin stimulating agent (ESA) dose, serum albumin levels, and recent blood transfusions.",
    "The sample provided is for a phase 3 clinical trial. The trial focuses on the disease \"diabetes mellitus, type 2\" and includes a list of associated ICD-10 codes. The drugs being studied are \"vildagliptin\" and a placebo. The eligibility criteria for participants are listed, including requirements such as not currently being on drug therapy for type 2 diabetes and meeting specific blood glucose criteria. There are also exclusion criteria, such as a history of type 1 diabetes, evidence of significant diabetic complications, and recent serious cardiovascular events. Other exclusion criteria may also apply as defined by the trial protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"type 2 diabetes mellitus\". The associated ICD-10 codes for this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The trial involves the use of drugs, including \"placebo / teneli (teneligliptin) + pio (pioglitazone)\" and \"teneli / teneli + pio\". \n\nThe record also includes eligibility criteria for the trial. The inclusion criteria state that patients must be between 20 and 75 years old, undergoing dietary management and therapeutic exercise for diabetes for at least 12 weeks prior to the trial, have an HbA1c level between 6.5% and 10.0%, have taken Thiazolidinedione for diabetes for at least 16 weeks prior to the trial, and have not taken any prohibited diabetes therapeutic drugs within 12 weeks before the trial.\n\nThe exclusion criteria state that patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (such as Cushing disease or acromegaly) are not eligible. Patients receiving treatments for arrhythmias, those with serious diabetic complications, excessive alcohol addicts, severe hepatic disorder, severe renal disorder, pregnant or lactating patients, and patients who cannot agree to contraception are also excluded from the trial.",
    "The sample provided is for a phase 3 clinical trial. The trial is focused on the treatment of chronic hepatitis B. The ICD-10 codes associated with the disease are B18.0, B18.1, B18.2, B18.8, and B18.9. The drug being tested in the trial is telbivudine (ldt). The eligibility criteria for inclusion in the trial include having completed a previous qualifying Idenix-Sponsored trial with telbivudine and not being discontinued from the previous study. The exclusion criteria include being pregnant or breastfeeding and being co-infected with hepatitis C, hepatitis D, or HIV.",
    "The sample from the table is for a phase 3 trial. The diseases being studied are sleep initiation and maintenance disorders, as well as sleep disorders. The corresponding ICD-10 codes for these diseases are Y93.E9, Y93.H9, G47.9, G47.21, G47.22, G47.23, G47.52, G47.29, and G47.20. The drugs being tested in this trial are zolpidem mr and zolpidem. The eligibility criteria for inclusion in the trial include having a clinical diagnosis of nonorganic insomnia and being able to swallow tablets. The exclusion criteria include having allergic reactions to zolpidem (Myslee) and having serious cardiac disorders, serious hepatic impairment, serious renal diseases, and so on.",
    "The sample from the table represents a phase 3 clinical trial for HIV infection. The diseases listed are \"infection, human immunodeficiency virus\" and \"HIV infections\". The corresponding ICD-10 codes for these diseases are \"Z21\" for both. The drugs being studied in the trial are \"gsk1349572\", \"raltegravir\", \"gsk1349572 placebo\", and \"raltegravir placebo\". The eligibility criteria for participants include being ART-experienced, at least 18 years old, capable of becoming pregnant (with appropriate contraception), having documented HIV-1 infection, having resistance to two or more classes of antiretroviral agents, being INI-na\u00efve, able to provide informed consent, and meeting certain criteria for French subjects. The exclusion criteria include not having fully active antiviral agents available, not yielding results from genotype/phenotype/tropism testing, breastfeeding, having an active AIDS-defining condition (except for certain cases), having moderate to severe hepatic impairment, recent gastrointestinal bleeding, anticipated need for hepatitis C therapy, history or presence of allergy or intolerance to the study drugs or their components, history of malignancy within the past 5 years (except for certain cases), recent treatment with an HIV-1 immunotherapeutic vaccine or certain other agents, recent exposure to experimental drugs or vaccines, and certain laboratory abnormalities.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on contraception. The diseases associated with this trial include contraception, ovulation inhibition, and oral contraceptives. The corresponding ICD-10 codes for these diseases are Z92.0, Z30.012, Z30.09, N92.3, T38.4X6S, T38.4X3S, T38.4X4S, T38.4X5S, T38.4X6A, T38.4X6D, and T38.4X1S. The drugs being studied in this trial are ee20/drsp (bay86-5300) and ee20/drsp (yaz, bay86-5300). The eligibility criteria for participants include being healthy women between 18 and 45 years old who are requesting oral contraception. However, smokers over the age of 35 are not eligible. The use of steroidal oral contraceptives or any other drugs that could affect oral contraception metabolism is prohibited during the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being investigated in this trial are Ly2189265, Sulfonylureas (SU), Biguanides (BG), Alpha-Glucosidase Inhibitor (A-GI), Thiazolidinedione (TZD), and Glinides. \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must have a prior diagnosis of Type 2 Diabetes Mellitus before screening.\n- Participants must have been taking Glibenclamide, Gliclazide, Glimepiride (SU), BG, TZD, A-GI, or glinides as monotherapy for at least 3 months before screening, and the dose must have been stable for at least 8 weeks before screening.\n- Participants must have a qualifying HbA1c value between 7.0% and 11.0% at screening.\n- Participants must have a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m^2).\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants with a diagnosis of Type 1 Diabetes.\n- Participants who have been treated with any other glucagon-like peptide-1 (GLP-1) analog within the 3 months before screening.\n- Participants who are currently taking insulin or have had previous insulin treatment within the 3 months before screening.\n- Participants who show obvious clinical signs or symptoms of pancreatitis, have a history of chronic pancreatitis, or have had acute pancreatitis at screening, as determined by the investigator. Participants with serum amylase concentration \u22653 times the upper limit of the reference range and/or serum lipase concentration \u22652 times the upper limit of the reference range, as determined by the central laboratory at screening, are also excluded.\n- Participants with a self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC) are excluded from the trial.",
    "The sample from the table represents a clinical trial in phase 3 for the treatment of anxiety disorders. The trial focuses on patients with generalized anxiety disorder (GAD) without major depressive disorder (MDD). The inclusion criteria specify that patients should not have an adjustment disorder or anxiety disorder not otherwise specified (NOS), and their symptoms of GAD should not be situational in nature.\n\nThe exclusion criteria state that patients with any current and primary diagnosis other than GAD are not eligible. Additionally, patients with a history of MDD within the past 6 months, panic disorder, post-traumatic stress disorder (PTSD), or an eating disorder within the past year, or diagnosed with obsessive-compulsive disorder (OCD), bipolar affective disorder, psychosis, factitious disorder, or somatoform disorders during their lifetime are excluded.\n\nPatients with a history of alcohol or psychoactive substance abuse or dependence within the past 6 months are also excluded. Serious medical illnesses, including cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic diseases, or clinically significant laboratory abnormalities that are not stabilized or anticipated to require hospitalization within 6 months, are considered exclusion criteria. Acute liver injury (such as hepatitis) or severe cirrhosis (Child-Pugh Class C) are also exclusion criteria.\n\nThe drugs being tested in the trial are duloxetine hydrochloride and placebo.",
    "The sample is a phase 3 trial for HIV infection. The trial is testing the drug combination of truvada/raltegravir. The eligibility criteria for participants include being 18 years or older, having a documented HIV-1 infection, signing the informed consent form, and being willing to comply with the protocol requirements. Other criteria include having a plasma viral load of less than 50 copies/mL, a CD4 cell count of more than 50 cells/mm3, and being on a stable antiretroviral therapy (ART) regimen for at least 12 weeks. Participants must also have a glomerular filtration rate of more than 50 ml/min and experience symptomatic toxicity associated with efavirenz (EFV) after at least 12 weeks of therapy. Female participants of childbearing potential must be using effective birth control methods, and male participants must also be using effective birth control methods if they are heterosexually active. Exclusion criteria include being infected with HIV-2, using any disallowed concomitant therapy, having a currently active AIDS-defining illness (with some exceptions), having acute viral hepatitis or chronic hepatitis B/C with elevated liver enzymes, and having received any investigational drug within 30 days prior to the trial. Other exclusion criteria include prior exposure to raltegravir or investigational integrase inhibitors, certain resistance mutations, clinically significant allergy or hypersensitivity to trial medication excipients, pregnancy or breastfeeding (for female participants), certain grade 3/4 toxicities, significantly decreased hepatic function or decompensation, unresolved central nervous system toxicity, and any condition or laboratory results that may interfere with assessments or completion of the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial focuses on patients who meet the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for schizophrenia and are currently experiencing an acute schizophrenic episode. The patients must have a Positive and Negative Syndrome Scale (PANSS) total score of 70 or higher at baseline. They must also be admitted to the hospital for treatment and agree to voluntary hospitalization for at least the first 7 days of the study.\n\nFemale participants must meet certain criteria, such as being postmenopausal, surgically sterile, abstinent, or practicing an effective method of birth control. They must also have a negative urine pregnancy test at screening.\n\nThere are exclusion criteria as well. Pregnant or breastfeeding female participants are excluded from the trial. Patients who have never received antipsychotic treatment before, have used an experimental drug or medical device within 30 days prior to the planned start of treatment, or are currently on clozapine or a long-acting injectable antipsychotic in the last 3 months are also excluded. Patients with a known hypersensitivity to paliperidone extended-release (ER) or risperidone, as well as those with a relevant history of significant or unstable cardiovascular, respiratory, neurologic, renal, hepatic, endocrine, or immunologic diseases, are excluded. Patients with a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome, along with those with substance dependence according to DSM-IV criteria in the past 6 months, are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is chronic obstructive pulmonary disease (COPD). The ICDCodes associated with this disease are \"J44.9\", \"J44.1\", and \"J44.0\". The drugs being tested in this trial are qva149, nva237, qab149, and placebo. The eligibility criteria for this trial include being a male or female adult aged 40 years or older, having a smoking history of at least 10 pack years, being diagnosed with moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, having specific lung function measurements (FEV1 and FEV1/FVC) within certain ranges, and meeting various exclusion criteria such as recent respiratory tract infection, concomitant pulmonary disease, history of asthma or lung cancer, certain cardiovascular co-morbid conditions, alpha-1 antitrypsin deficiency, active participation in a pulmonary rehabilitation program, and contraindications for inhaled anticholinergic agents and \u03b22 agonists.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"schizophrenia\". The associated ICD-10 codes for this disease are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drug being studied in this trial is \"paliperidone er\". \n\nThe record also includes eligibility criteria for the trial. Inclusion criteria for patients include being diagnosed with schizophrenia, having a Positive and Negative Syndrome Scale (PANSS) score of 80 to 120 at screening, not having taken any antipsychotics in the past, and being healthy based on physical and laboratory examinations. Female patients must have a negative pregnancy test and agree to use effective birth control throughout the study.\n\nExclusion criteria for the trial include having a serious unstable medical condition or clinically relevant laboratory abnormalities, being at high risk for adverse events, violence, or self-harm, inability to swallow the study medication whole, having biochemistry results outside the normal reference range, current or recent history of substance dependence, and a positive urine drug examination.",
    "The sample from the table is for a phase 3 trial. The diseases being studied are atrial fibrillation and vascular risk. The corresponding ICD-10 codes for atrial fibrillation are I48.0, I48.21, I48.91, I48.11, I48.19, and I48.20. The corresponding ICD-10 codes for vascular risk are G21.4, G95.19, I67.3, H34.9, I73.9, Q79.63, and Z98.62. The drug being tested is clopidogrel (sr25990c). \n\nThe inclusion criteria for the trial are:\n- Evidence of atrial fibrillation either on one current Electrocardiogram (ECG) or on two ECG recorded at two weeks apart during 6 months prior to study enrollment.\n- Evidence of high risk of vascular events, which can be met by meeting at least one of the following risk criteria:\n  - Being 75 years or older.\n  - Being on treatment for systemic hypertension.\n  - Having a history of stroke, TIA, or non-CNS systemic embolus.\n  - Having left ventricular dysfunction with left ventricular ejection fraction (EF) estimated to be less than 45%.\n  - Having peripheral vascular disease, which can be indicated by previous peripheral artery revascularization, limb and foot amputation, or the combination of current intermittent claudication and ankle arm systolic blood pressure ratio less than 0.9.\n  - Being between the ages of 55 and 74 and having either diabetes mellitus requiring drug therapy, or documented previous myocardial infarction, or documented coronary artery disease.\n\nThe exclusion criteria for the trial are:\n- Patients who require clopidogrel (such as recent coronary stent procedure).\n- Patients who require oral anticoagulant (such as prosthetic mechanical heart valve).\n- Patients with prior intolerance to ASA or clopidogrel.\n- Patients with documented peptic ulcer disease within the previous 6 months.\n- Patients with prior intracerebral hemorrhage.\n- Patients with significant thrombocytopenia (platelet count less than 50 x 10(9)/L).\n- Patients with psychosocial reasons or geographic reasons that make study participation impractical.\n- Patients with ongoing alcohol abuse.\n- Patients with mitral stenosis.\n- Pregnant or nursing women, or women of childbearing potential who are not on effective birth control for at least one month prior to the start of the study or not willing to continue on birth control for the duration of the study.\n- Patients with severe comorbid conditions that are not expected to survive 6 months.\n- Patients currently receiving an investigational pharmacologic agent.\n- Patients who require chronic (> 3 months) non-COX-2 inhibitor NSAID therapy.",
    "The sample from the table represents a phase 3 clinical trial for Alzheimer's disease. The trial focuses on patients aged 45 to 90 years who have been diagnosed with probable Alzheimer's disease and have been receiving Aricept (donepezil) at a dose of 10 mg for at least 3 months prior to the screening visit. The patients must also meet certain psychometric test criteria related to cognitive impairment.\n\nIn addition to the patient criteria, there are inclusion criteria for caregivers who must be familiar with the patient, have regular contact with them, and be able to observe for possible adverse events.\n\nThe sample also includes exclusion criteria for patients, such as not taking medication for Alzheimer's disease, having certain neurological or psychiatric disorders, or having conditions that affect the absorption or metabolism of the study medication. Exclusion criteria for caregivers include not meeting certain psychometric test criteria or having conditions that make them unsuitable for the study.\n\nOverall, the sample provides detailed information about the eligibility criteria for patients and caregivers participating in the phase 3 clinical trial for Alzheimer's disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding ICDCodes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drug mentioned is \"sitagliptin\". The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria specify that the participant must have renal impairment, a historical diagnosis of type 2 diabetes mellitus, inadequate glycemic control, and meet certain BMI, fasting C-peptide, and HbA1c requirements. The exclusion criteria list various conditions and factors that would disqualify a participant from the trial, such as a history of cancer, treated diabetic gastroparesis, biliary disease, pancreatitis, significant gastrointestinal surgery, recent cardiovascular or cerebrovascular disease, HIV infection, abnormal liver function, pregnancy or lactation, allergies to certain medications, and recent receipt of investigational drugs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3, and the disease being studied is colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are capecitabine, fluorouracil, and oxaliplatin. The eligibility criteria for this trial include various factors such as age, life expectancy, performance status, diagnosis method, tumor location, stage, and various medical tests and measurements. There are also exclusion criteria listed, which include findings of metastatic disease, involvement of the pelvic side wall, certain types of rectal cancers, history of invasive rectal malignancy, pregnancy or lactation, prior therapy for this cancer, and various other medical conditions that may preclude the patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICDCodes associated with this disease are J44.9, J44.1, and J44.0. The drugs being tested in this trial are nva237, tiotropium, placebo to tiotropium, placebo to nva237, and salbutamol/albuterol. The eligibility criteria for this trial include patients with moderate to severe stable COPD, a specific range of post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC), a smoking history of at least 10 pack years, and symptomatic patients according to daily electronic diary data. There are also exclusion criteria, such as being pregnant or nursing, having certain medical conditions, and receiving prohibited medications. Additional inclusion/exclusion criteria can be found in the study protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"major depressive disorder.\" The associated ICD-10 codes for this disease are ['F33.0', 'F33.1', 'F33.9', 'F32.0', 'F32.1', 'F32.9', 'F33.40']. The drugs being tested in this trial are 'saredutant (sr48968)', 'escitalopram', and 'placebo'. The eligibility criteria for this trial are listed, including inclusion and exclusion criteria. Inclusion criteria state that the trial is open to outpatients with recurrent Major Depressive Disorder. Exclusion criteria include factors such as the duration of depressive symptoms, suicide risk, lack of sexual activity, other psychiatric conditions, history of failed antidepressant treatment, and pregnancy or breastfeeding. It is important to note that the provided information may not cover all considerations relevant to a patient's potential participation in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied include leukemia, myelocytic, acute; leukemia, lymphocytic, acute; leukemia, myeloid, chronic; and myelodysplastic syndromes. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are tacrolimus, methotrexate, and sirolimus. The eligibility criteria for participants are listed under inclusion and exclusion criteria, which include factors such as HLA-matched sibling donors, performance status, ability to take oral medications, and various medical conditions that may exclude individuals from participating in the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is major depressive disorder. The icd-10 codes associated with this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested in this trial are quetiapine sr and escitalopram. The eligibility criteria for participants include being between the ages of 18 and 65, having a documented diagnosis of major depressive disorder, and not having certain other psychiatric disorders or specific durations of depression.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 3. The diseases being studied include adult malignant mesenchymoma, adult rhabdomyosarcoma, alveolar childhood rhabdomyosarcoma, childhood malignant mesenchymoma, embryonal childhood rhabdomyosarcoma, embryonal-botryoid childhood rhabdomyosarcoma, nonmetastatic childhood soft tissue sarcoma, previously untreated childhood rhabdomyosarcoma, stage I adult soft tissue sarcoma, and stage II adult soft tissue sarcoma, and stage III adult soft tissue sarcoma. \n\nThe ICDCodes associated with these diseases are provided as well. For example, the ICDCodes for the first disease are 'R18.0', 'C17.3', 'G21.0', 'J91.0', 'C05.2', 'C10.0', and 'C16.0'. \n\nThe drugs being used in the trial are vincristine sulfate, cyclophosphamide, and topotecan hydrochloride. \n\nLastly, the eligibility criteria for participants in this trial are listed, including specific disease types, stage classifications, age restrictions, and other medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on two diseases: orthostatic hypotension and Parkinson's disease. The corresponding ICD-10 codes for these diseases are \"I95.1\" and \"G20\" respectively. The trial involves the drug droxidopa. \n\nThe eligibility criteria for this trial are as follows:\n- Participants must be 18 years or older.\n- They must have a clinical diagnosis of Parkinson's disease and symptomatic neurogenic orthostatic hypotension.\n- At their baseline visit, participants must demonstrate a score of at least 3 on the OHQ composite, a score of at least 3 on the clinician CGI-S, and a fall of at least 20 mmHg in systolic blood pressure or 10 mmHg in diastolic blood pressure within 3 minutes of standing.\n- Participants must provide written informed consent and understand that they can withdraw from the study at any time without affecting their future medical care.\n\nThere are also exclusion criteria for the trial, which include:\n- A score of 23 or lower on the mini-mental state examination (MMSE).\n- Concomitant use of vasoconstricting agents for increasing blood pressure.\n- Concomitant use of anti-hypertensive medication for essential hypertension.\n- Recent changes in prescribed medication, except for specific exceptions.\n- Known or suspected alcohol or substance abuse within the past 12 months.\n- Pregnancy or breastfeeding for women.\n- Women of childbearing potential who are not using contraception.\n- Sexually active male patients who are not using contraception.\n- Untreated or treated closed angle glaucoma that may pose a risk.\n- Sustained severe hypertension or significant uncontrolled cardiac arrhythmia.\n- History of myocardial infarction, current unstable angina, or congestive heart failure.\n- Diabetic autonomic neuropathy or history of cancer within the past 2 years.\n- Gastrointestinal conditions that may affect drug absorption.\n- Recent major surgical procedure.\n- Previous treatment with droxidopa or current use of any investigational drug.\n- Any condition or laboratory test result that may increase the risk to the patient or affect their participation in the study.\n\nThe investigator also has the discretion to exclude a patient if they feel the subject is not a suitable candidate or unable to follow study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding ICDCodes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being studied are 'ly2605541' and 'insulin glargine'. The eligibility criteria for this trial include having type 2 diabetes for at least 1 year, receiving basal insulin and oral antihyperglycemic medications for at least 90 days, having a hemoglobin A1c less than or equal to 9.0%, having a body mass index less than or equal to 45.0 kg/m^2, and meeting certain requirements for women of childbearing potential. The exclusion criteria include specific medication usage, history of severe hypoglycemia or diabetic ketoacidosis, cardiac or renal diseases, liver disease, blood transfusion or severe blood loss, cancer, chronic glucocorticoid therapy, high fasting triglycerides, irregular sleep/wake cycle, and unstable lipid-lowering medication usage.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of schizophrenia and its cognitive effects on patients. The trial uses the drugs \"cyp-1020\" and \"risperidone\". The eligibility criteria for participants are listed, including age range, duration of schizophrenia symptoms, recent onset of worsening symptoms, specific PANSS scores, CGI-S score, previous response to antipsychotic treatment, and education level. The exclusion criteria are also listed, which include pregnancy or breastfeeding, duration of schizophrenia symptoms, treatment history, medical conditions, infectious diseases, allergies or intolerances to certain drugs, history of suicide attempts or substance dependence, and other psychiatric diagnoses or treatments. Additionally, abnormal ECG evaluation and abnormal clinical laboratory test results are considered exclusionary factors.",
    "The sample provided is a record from a table that contains information about clinical trials. \n\nIn this particular sample, the trial is in phase 3 and is focused on the disease \"type 2 diabetes mellitus\". The corresponding ICD-10 codes for this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. \n\nThe trial involves the use of two drugs: \"sitagliptin phosphate\" and a comparator drug called \"placebo\". \n\nThe eligibility criteria for this trial include having type 2 diabetes mellitus and meeting specific laboratory results such as having a Hemoglobin A1c (HbA1c) level between 7.5% and 11%, and a Fasting Plasma Glucose (FPG) level between 130 mg/dL and 280 mg/dL. \n\nPatients with type 1 diabetes mellitus or those who have required insulin therapy within the past 12 months are excluded from participating in this trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding ICDCodes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs involved in the trial are 'placebo for mitiglinide', 'mitiglinide', and 'mitiglinide'. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a diagnosis of type 2 diabetes for at least 6 months, stable metformin usage for at least 4 months, HbA1c levels between 7.5% and 10.5%, and no severe diabetic complications. Exclusion criteria include chronic insulin use, use of oral diabetic agents within the past 12 weeks, and the presence of acute or chronic conditions (excluding diabetes) that could affect the evaluation of the trial's endpoints.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 3 trial and the disease being studied is head and neck neoplasms. The associated ICD-10 codes for the disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being used in the trial are pemetrexed, cisplatin, and placebo. The sample also includes the eligibility criteria for participants, including requirements such as having head and neck cancer that cannot be treated with surgery or other treatments, having a certain performance status, normal liver, kidney, and blood cell function, and being at least 18 years old. There are also exclusion criteria listed, such as not having previously received treatment for cancer that has spread, not having any serious sickness that could interfere with the study, and not having certain types of cancer. Additionally, there are restrictions on taking certain medications like high dose aspirin or non-steroidal anti-inflammatory drugs.",
    "The sample from the table represents a phase 3 clinical trial for the treatment of restless legs syndrome (RLS). The trial includes patients diagnosed with RLS using the IRLS Study Group diagnostic criteria. The patients must currently be receiving treatment with a stable dose of ropinirole IR (ropinirole immediate-release) once daily for at least 2 weeks. The trial is specifically targeting patients who experience RLS symptoms during the evening and night or only at night.\n\nIn terms of eligibility criteria, patients must provide written informed consent to participate. However, there are certain exclusion criteria as well. Patients who require treatment for daytime RLS symptoms are not eligible. Additionally, patients with signs of secondary RLS or a serum ferritin level less than 10 mcg/L are excluded. Patients with movement disorders or clinically significant or unstable medical conditions are also not eligible. Abnormal laboratory results, electrocardiogram (ECG) findings, or physical findings can also lead to exclusion. Patients who are taking prohibited medications or have sleeping habits that are incompatible with the study design are not eligible. Intolerance to ropinirole or other dopamine agonists, pregnancy, lactation, and women of child-bearing potential who are not practicing an acceptable method of birth control are also exclusion criteria.\n\nThe trial involves the administration of various drugs, including ropinirole IR at different doses, ropinirole IR placebos, ropinirole CR (ropinirole controlled-release) at different doses, and ropinirole CR placebos.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is myocardial infarction. The corresponding ICD-10 codes for this disease are I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, and I23.8. The drug being tested is clopidogrel (known as iscover or plavix). \n\nThe eligibility criteria for this trial are as follows:\n- The patient must have had an acute STEMI (ST-elevation myocardial infarction) within 6 hours.\n- The patient must be planned for percutaneous coronary intervention.\n- The patient must be at least 18 years old.\n- The patient must have the ability to understand the nature, scope, and possible consequences of the study and have legal capacity.\n- The patient must provide informed consent.\n\nThe exclusion criteria for this trial are as follows:\n- The patient must not have received thrombolytic therapy within 24 hours before randomization.\n- The patient must not have effective oral or intravenous anticoagulation (INR>2 or PTT>2xcontrol).\n- The patient must not have a known hemorrhagic diathesis (tendency to bleed excessively).\n- The patient must not have had a stroke or transient ischemic attack (TIA) within the past 3 months.\n- The patient must not have evidence of active gastrointestinal or urogenital bleeding.\n- The patient must not have undergone major surgery (including coronary artery bypass grafting) within the past 6 weeks.\n- The patient must not have a contraindication to clopidogrel.\n- The patient must not have severe renal or hepatic insufficiency.\n- The patient must not have a contraindication to coronary angiography.\n- The patient must not be planned to receive a GP IIb/IIIa-Inhibitor before angiography.\n- The patient must not be pregnant or nursing (lactating) women.\n- The patient must not be women with childbearing potential.\n- The patient must not be currently treated with clopidogrel or ticlopidine within the last 10 days.\n- The patient must not have participated in another clinical or device trial within the previous 30 days.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is anal cancer. The ICDCodes associated with this disease are C21.1, C44.500, C44.590, D12.9, and C21.8. The drugs being used in the trial are cisplatin and fluorouracil. \n\nThe eligibility criteria for this trial include specific disease characteristics such as histologically proven nonmetastatic anal cancer, with the tumor located in the anal/rectal junction or anal/cutaneous junction. The tumor can be of the epidermoid or cloacogenic type, and it should be at Stage II or III. There are specific size and lymph node invasion requirements for the tumor. \n\nThe patient characteristics include an age limit of 80 and under, a performance status of WHO 0 or 1, and no specified life expectancy. Hematopoietic requirements include minimum levels of white blood cells, platelet count, and hemoglobin. There are no specified requirements for hepatic or renal function, but the creatinine level should not exceed 1.5 mg/dL. \n\nCardiovascular conditions that contraindicate the use of fluorouracil are not allowed. Other eligibility criteria include no prior malignancy within 5 years, except for specific types, and no serious medical or psychological conditions or immunosuppression. \n\nThe prior concurrent therapy section specifies that no prior biologic therapy, chemotherapy, endocrine therapy, pelvic or inguinal radiotherapy, or definitive colostomy should have been performed.",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 3. The diseases being studied are rhinoconjunctivitis, rhinitis, conjunctivitis, and allergy. The corresponding ICD-10 codes for these diseases are also provided. The drugs being used in the trial include placebo, loratadine 10 mg rescue treatment, olopatadine 0.1% rescue treatment, mometasone 50 mcg rescue treatment, prednisone 5 mg rescue treatment, albuterol sulfate 108 mcg, fluticasone propionate 44 mcg, and prednisone 5 mg.\n\nThe eligibility criteria for participants are listed under \"criteria\" and include age requirements (18 to 65 years), clinical history of significant allergic rhinoconjunctivitis to grass, positive skin prick test response to Phleum pratense, positive specific IgE against Phleum pratense, FEV1 >=70% of predicted value, normal safety laboratory tests, vital signs and ECG, willingness to give informed consent and adhere to dose and visit schedules, and use of medically acceptable birth control for female participants of childbearing potential. The criteria also include exclusion criteria such as history of other allergies, asthma, immunosuppressive treatment, severe asthma, anaphylaxis, chronic urticaria and angioedema, chronic sinusitis, severe atopic dermatitis, pregnancy or breastfeeding, previous immunotherapy treatment, known allergies or intolerances to the investigational medicinal products, and various other conditions that may interfere with the study or compromise the data.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample is from a table that contains information about clinical trials. The sample is for a phase 3 trial and includes two diseases, namely hepatitis B and cirrhosis. The corresponding ICD-10 codes for these diseases are provided. The trial involves the use of a drug called ldt (telbivudine) and lamivudine. The eligibility criteria state that patients with chronic hepatitis B and evidence of cirrhosis, who are between 18 and 70 years old, may be eligible to participate in this study.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is Parkinson's disease, which is identified by the ICD-10 code G20. The drugs being tested in the trial are safinamide and placebo. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include completing 24 weeks of treatment in a previous study, being compliant with taking study medication, and signing an informed consent form. Exclusion criteria include experiencing clinically significant adverse events, showing deterioration in a previous study, and discontinuing the previous study prematurely without returning for scheduled evaluations.",
    "The sample provided is for a phase 3 clinical trial for the treatment of acromegaly. The trial is focused on evaluating the effectiveness of a drug called lanreotide (autogel formulation) over a duration of 24-56 weeks, depending on the dose interval. The eligibility criteria for participants include having a documented diagnosis of active acromegaly and being adequately treated with a stable dose of Octreotide LAR for at least 6 months prior to the study. The diagnosis of active acromegaly is determined by having IGF-1 levels more than 30% higher than the normal age and sex adjusted value or GH level after OGTT (Oral Glucose Tolerance Test) > 2ng/mL while not under drug treatment. Patients who have undergone surgery or radiotherapy must have had the diagnosis performed after their most recent surgical or radiation treatment. The exclusion criteria include recent pituitary surgery within 6 months prior to the study entry and recent stereotactic or conventional radiotherapy for acromegaly within three to five years prior to the study entry.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and focuses on the disease \"epilepsy.\" The corresponding ICD-10 codes for epilepsy are listed as \"G40.803,\" \"G40.804,\" \"G40.911,\" \"G40.919,\" \"G40.B11,\" \"G40.B19,\" and \"G40.801.\" The drug being studied in this trial is \"pregabalin.\" \n\nThe sample also includes eligibility criteria for participants. The inclusion criteria state that participants must have completed a previous protocol and wish to continue receiving pregabalin. They must also have a diagnosis of epilepsy with partial seizures. \n\nOn the other hand, the exclusion criteria state that participants who withdrew early from the previous protocol, experienced an episode of status epilepticus, or have primary generalized epilepsy are not eligible for this trial.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The diseases being studied are non-small cell lung cancer and lung cancer. The corresponding ICD-10 codes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are docetaxel and vandetanib. The eligibility criteria for the trial are listed, including inclusion criteria such as having a confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer and having received 1st line anti-cancer therapy. Exclusion criteria include not having non-small cell lung cancer, having received treatment with docetaxel, and having received 2nd line anti-cancer therapy.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is psoriasis. The ICD-10 codes associated with psoriasis are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being used in the trial are 'cnto 1275 45 mg', 'cnto 1275 90 mg', and 'etanercept 50 mg'. The eligibility criteria for participants in the trial are listed under inclusion and exclusion criteria. Inclusion criteria include having a diagnosis of plaque-type psoriasis for at least 6 months, having at least 10% of the body surface area affected by psoriasis, and specific scores on the Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA). Exclusion criteria include having nonplaque forms of psoriasis, current drug-induced psoriasis, recent use of certain medications or treatments, and recent use of a biologic.",
    "The sample from the table is for a phase 3 trial. The disease being studied is asthma, and the corresponding ICD-10 codes for asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested in the trial are montelukast sodium and a placebo. The eligibility criteria for inclusion in the trial are individuals with acute asthma, while the exclusion criteria include women of childbearing age and individuals with a history of Chronic Obstructive Pulmonary Disease (COPD).",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on major depressive disorder and depression. The associated ICD-10 codes for these diseases are provided. The trial involves two drugs, tc-5214 and placebo. The eligibility criteria for the trial are also listed, including requirements for informed consent, a clinical diagnosis of major depressive disorder with inadequate response to one antidepressant, and outpatient status. The exclusion criteria include a history of bipolar disorder, psychotic disorder, post-traumatic stress disorder, suicide attempts in the past year, and renal insufficiency or impairment.",
    "The sample is a phase 3 trial for patients with diabetes. The trial is specifically for patients with type 2 diabetes who have inadequate control of blood glucose with diet and/or exercise therapy. The trial excludes patients with type 1 diabetes, those who require insulin treatment, and those with severe diabetic complications such as neuropathy, retinopathy, or nephropathy. Patients with severe ketosis, diabetic coma or precoma, severe hepatic diseases, severe renal diseases, severe hypertension, severe cardiac disease, and pregnant or nursing women are also excluded from the trial. The drug being tested in this trial is mitiglinide.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease mentioned is \"tumor lysis syndrome\" and its corresponding ICDCodes is \"E88.3\". The drugs being studied are \"febuxostat\" and \"allopurinol\". The eligibility criteria for this sample include patients scheduled for their first cytotoxic chemotherapy cycle for hematologic malignancies at intermediate or high risk of TLS. The patients should either be candidates for Allopurinol treatment or have no access to Rasburicase. They should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 and a life expectancy of more than 1 month. The exclusion criteria include patients who are hypersensitive to Febuxostat or Allopurinol, patients with sUA levels \u2265 10 mg/dL at randomization, patients who have received Febuxostat, Allopurinol, or any other urate lowering therapy within 30 days prior to randomization, patients with severe renal and/or hepatic insufficiency, and patients diagnosed with LTLS or CTLS at randomization.",
    "The sample from the table represents a phase 3 clinical trial for the treatment of dry eye disease. The trial includes patients who have a patient-reported history of dry eye in both eyes. The trial involves the use of two drugs, lifitegrast and placebo. The eligibility criteria for inclusion in the trial include being at least 18 years of age, willing and able to comply with all study procedures, and having used artificial tears within the past 30 days. Exclusion criteria include having any ocular condition that could affect the study parameters, unwillingness to avoid wearing contact lenses during the study, recent blood donation or significant blood loss, history of immunodeficiency disorder or certain infections, use of prohibited medications, significant illness that could interfere with the study, history of certain eye surgeries, known history of alcohol or drug abuse, and dry eye secondary to scarring or destruction of conjunctival goblet cells.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific record, the phase of the trial is Phase 3. The disease mentioned is \"neoplasms, gastrointestinal tract.\" The ICDCodes associated with this disease are A21.3, A22.2, B46.2, K92.2, K92.81, K91.0, and P54.3. The drugs mentioned in this record are lapatinib and paclitaxel. The eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" The inclusion criteria include factors such as signed informed consent, specific disease confirmation, prior treatment history, organ function, and ability to swallow medication. The exclusion criteria include factors such as pregnancy, concurrent anti-cancer therapy, unresolved toxicity from prior treatment, and various medical conditions that would make the subject inappropriate for the study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is advanced non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are erlotinib, cisplatin, and gemcitabine. The eligibility criteria for this trial include a diagnosis of cytologically or histologically confirmed non-small cell lung cancer, metastatic or locally advanced stage, certain blood count levels, normal or low bilirubin level, and other specific requirements. The exclusion criteria include prior exposure to certain drugs, prior chemotherapy or systemic anti-neoplastic therapy, unstable systemic disease, other malignancies within the past 5 years, brain metastasis or spinal cord compression, HIV positive status, and other specific conditions.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and focuses on the disease psoriasis. The icd-10 codes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being studied in this trial are 'clobetasol propionate spray 0.05%' and 'calcitriol ointment'. The eligibility criteria for participants include having a diagnosis of moderate to severe plaque psoriasis with a treatable body surface area of 3% - 20% and an overall disease severity of at least 3 (moderate). Exclusion criteria include having a surface area involvement larger than 20% and psoriasis limited to the scalp, groin, axillae, and/or other intertriginous areas.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on studying the effects of simvastatin and placebo on patients with optic neuritis and multiple sclerosis. The diseases are represented by their names and corresponding ICD-10 codes. The eligibility criteria for inclusion in the trial include having acute optic neuritis, an abnormal contrast sensitivity score, a symptom duration of maximum 4 weeks, being between 18 and 59 years old, being physically and mentally able to participate for a duration of 6 months, and signing a written consent form. The exclusion criteria include having had optic neuritis earlier in the same eye, being pregnant or nursing, not using contraception for fertile women, planning to become pregnant during the study, receiving steroid or immune-suppressor treatment within specific timeframes, having active liver disease or unexplained liver enzyme increase, kidney failure, myopathy, hyperthyroidism, diabetes mellitus, alcoholism, taking fibrates or statins for other diseases, and participating in other studies simultaneously.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is hypertension, and the corresponding ICD-10 codes associated with the disease are 'I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', and 'I10'. The drug being tested is valsartan plus hydrochlorothiazide. \n\nThe inclusion criteria for this trial are being diagnosed with severe hypertension. The exclusion criteria include being unable to discontinue all prior antihypertensive medications, having any kind of heart failure, a history of stroke, transient ischemic attack, myocardial infarction, chest pain, abnormal heart rhythm, liver, kidney, or pancreas disease, diabetes with poor glucose control, and having an allergy to certain medications used to treat high blood pressure. \n\nIt is also mentioned that there may be other protocol-defined exclusion criteria that could apply.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on cardiovascular disease. The ICD-10 codes associated with the disease are ['A52.00', 'A52.09', 'A50.54', 'Z01.810', 'Q87.418', 'Z13.6', 'R94.30']. The drugs being studied are eptifibatide and placebo. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being able to understand and sign a consent form, being at least 18 years old, having stable or unstable angina pectoris, and meeting specific angiographic requirements. Exclusion criteria include being a female of childbearing potential, having ongoing or recent unstable coronary artery disease, having certain medical conditions or taking specific medications, and having undergone major surgery within the previous 6 weeks. There are also angiographic exclusion criteria related to previous treatments and vessel size.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is rheumatoid arthritis. The ICDCodes associated with this disease are \"M06.9\", \"M05.9\", \"M06.08\", \"M06.00\", \"M06.011\", \"M06.012\", and \"M06.019\". The drugs being used in the trial are mabthera/rituxan and methotrexate. The eligibility criteria for participants include being adults aged 18-80 with active rheumatoid arthritis for at least 6 months, having an inadequate response or intolerance to at least one anti-TNF alpha therapy, and having received stable treatment with MTX for at least 12 weeks. Other criteria include specific joint counts, radiographic evidence of joint erosion, and the use of reliable contraceptive methods for participants of reproductive potential. The exclusion criteria include recent bone or joint surgery, certain functional status of RA, previous treatment with specific therapies, recent use of corticosteroids or live vaccines, concurrent treatment with certain drugs, history of severe allergic reactions, significant uncontrolled concomitant diseases, contraindications to receiving rituximab, active infections, immunodeficiency, history of cancer, pregnancy or breastfeeding, history of substance abuse, certain neuropathies or neurovasculopathies, poor peripheral venous access, and intolerance or contraindications to corticosteroids.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease mentioned is \"rhinitis, allergic, perennial.\" The ICDCodes associated with this disease are \"J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1.\" The drugs being tested in this trial are \"beclomethasone dipropionate hydrofluoroalkane hfa nasal aerosol\" and \"placebo nasal aerosol.\" The eligibility criteria for this trial include having informed consent, a documented history of perennial allergic rhinitis, a demonstrated sensitivity to at least one allergen known to induce PAR, a minimum subject-reported reflective total nasal symptom score (rTNSS) of at least 6, and other criteria that apply. The exclusion criteria include a history of nasal pathology, participation in any investigational drug study within 30 days preceding the screening visit, a history of respiratory infection/disorder within 14 days preceding the screening visit or during the run-in period, and the use of any prohibited concomitant medications.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the treatment of non-small-cell lung carcinoma. The trial is investigating the use of two drugs, afatinib and erlotinib. The eligibility criteria for participants are listed, including requirements such as having a diagnosis of advanced stage NSCLC squamous histology, receiving platinum-based doublet chemotherapy as the first-line treatment, and having measurable disease according to RECIST 1.1. There are also exclusion criteria listed, such as prior treatment with EGFR-directed small molecules or antibodies, active brain metastases, and known pre-existing interstitial lung disease. The sample also includes additional criteria related to organ function, age, informed consent, and contraception for female patients.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer (NSCLC). The trial is focused on patients with a new diagnosis of NSCLC in stage IIIB with a positive pleural or pericardial effusion, or stage IV. The patients must not have received any prior chemotherapy for NSCLC and should have an ECOG Performance Status of 2. They should also have measurable disease, with lesions that can be accurately measured. \n\nThe inclusion criteria include being at least 3 weeks since major surgery and at least 1 week since surgery such as mediastinoscopy, pleuroscopy, or thoracostomy. \n\nThe exclusion criteria include any prior radiation therapy to the thoracic area, active and ongoing systemic infection, prior radiation to more than 25% of the bone marrow, ECOG Performance Status other than 2, and known hypersensitivity to the drugs gemcitabine and carboplatin.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"chronic obstructive pulmonary disease\" (COPD). The ICD-10 codes associated with this disease are \"J44.9\", \"J44.1\", and \"J44.0\". The trial involves several drugs, including \"qva149\", \"tiotropium\", \"placebo to qva149\", \"placebo to tiotropium\", and \"salbutamol/albuterol\". The eligibility criteria for this trial include patients with moderate to severe stable COPD, a smoking history of 10 pack years, a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 30 - 80%, the ability to use a computer mouse and display, and an mMRC grade greater than 2. There are also exclusion criteria, such as a history of long QT syndrome, Type I or uncontrolled Type II diabetes, recent COPD exacerbation or respiratory tract infection, history of asthma, pulmonary lobectomy, lung volume reduction surgery, lung transplantation, concomitant pulmonary disease, and the need for long-term oxygen therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is depressive disorder. The ICDCodes associated with this disease are F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, and F32.9. The drugs being used in the trial are 323u66 (bupropion hydrochloride sustained release) and placebo. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being diagnosed with Major Depressive Disorder, Single Episode or Major Depressive Disorder, Recurrent, having a HAM-D (17 items) total score of at least 16, being treated with paroxetine at a certain dosage for a specific duration, being within a certain age range, and providing informed consent. \n\nExclusion criteria include having complications of glaucoma, using drugs that increase the risk of bleeding, having a predisposition to seizures, having certain disorders such as anorexia nervosa or schizophrenia, starting psychotherapy or cognitive behavior therapy within a specific timeframe, having a diagnosis of substance abuse or dependence, having received electroconvulsive therapy or taken certain medications within a specific timeframe, being pregnant or nursing, having a history of suicide attempts or high suicide risk, having a history of hypersensitivity to the drugs being used, having serious cerebral or cardiac conditions, having serious physical symptoms or a history/complication of cancer, having major depressive disorder due to physiological effects of a medical condition, and having high blood pressure. \n\nThese criteria are specific to the start of the pretreatment phase and the start of the treatment phase.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on the disease \"Parkinson's disease.\" The associated ICD-10 code for this disease is \"G20.\" The trial involves two drugs, namely \"ropinirole prolonged release\" and \"ropinirole immediate release.\" The eligibility criteria for this trial are listed under inclusion and exclusion criteria. Inclusion criteria state that patients must have a diagnosis of advanced idiopathic Parkinson's disease (according to modified Hoehn & Yahr criteria Stages II-IV) and their symptoms should not be adequately controlled with L-dopa. Exclusion criteria include patients with late-stage advanced Parkinson's disease with incapacitating dyskinesias on a stable dose of L-dopa, as well as those with certain psychiatric, haematological, renal, hepatic, endocrinological, neurological, or cardiovascular diseases, active malignancy, severe dizziness or fainting on standing, dementia, neurotic behavior, crippling degenerative arthritis or limb amputations, prior or current major psychosis, recent history or current evidence of drug abuse or alcoholism, use of a dopamine agonist within 4 weeks of starting the study, and personal or family history of an allergic reaction to ropinirole.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and the diseases being studied are hypercholesterolemia and dyslipidemia. The corresponding ICD-10 codes for these diseases are E78.01, E78.00, and Z83.42. The drug being tested in this trial is pitavastatin. \n\nThe record also includes eligibility criteria for the trial. The inclusion criteria state that patients must have completed 12 weeks of treatment in a previous study, have not experienced any significant adverse events related to pitavastatin, and have been following a fat and cholesterol restrictive diet. \n\nThe exclusion criteria state that any conditions causing secondary dyslipidemia should be reassessed, uncontrolled diabetes mellitus should be reassessed, abnormal pancreatic, liver, or renal function is not allowed, abnormal serum ALAT/SGPT/ALT, ASAT/SGOT/AST, or creatine kinase (CK) levels above a specified level are not allowed, and significant heart disease is not allowed.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The disease being studied is \"migraine disorders\". The corresponding ICD-10 codes for the disease are \"G43.B1\", \"G43.D1\", \"G43.B0\", \"G43.D0\", \"G43.A1\", \"G43.411\", and \"G43.419\". The drug being tested is \"sumatriptan succinate\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion criteria:\n- The participant must have a diagnosis of migraine (with or without aura) or cluster headache according to the International Classification of Headache Disorders, Version 2 (ICHD-II).\n- The participant must have a history of migraine or cluster headache persisting for at least 6 months.\n- For migraine, the participant must have experienced one to six attacks of moderate or severe headaches per month during the 2 months prior to enrollment.\n- For cluster headache, each attack must persist for at least 45 minutes.\n- The participant or their proxy consenter (e.g., person with parental authority) must provide written informed consent.\n\nExclusion criteria:\n- The participant must not have a history of hypersensitivity to any of the ingredients of 5-HT1B/1D receptor antagonists (e.g., triptans) or serious adverse events due to treatment with these drugs.\n- The participant must not have a history of serious adverse events attributable to treatment with Imigran\u00ae Injection 3.\n- The participant must not have a history of myocardial infarction, current or previous history of ischemic heart disease or its symptoms/signs, or current history of atypical variant angina (coronary arteriospasm).\n- The participant must not have a previous history of cerebrovascular disorder or transient cerebral ischemic attack.\n- The participant must not have a current or previous history of peripheral angiopathy (including Raynaud's syndrome).\n- The participant's systolic blood pressure (SBP) must not be greater than 160 mmHg or diastolic blood pressure (DBP) greater than 95 mmHg at the start of the treatment period.\n- The participant must not have current familial hemiplegic migraine, basilar migraine, or sporadic hemiplegic migraine.\n- The participant must not be currently abusing ergotamine- or dihydroergotamine-containing preparations or triptans.\n- Pregnant women, lactating mothers, women who may be pregnant, or women of childbearing potential not using appropriate contraceptive measures are excluded.\n- The participant must not have epilepsy or organic cerebral disorder that may lead to convulsion.\n- The participant must not have a previous history of hypersensitivity to sulfonamides.\n- The participant must not have a known drug allergy or idiosyncrasies.\n- The participant must not have a known drug dependency or alcoholism.",
    "The sample provided is for a phase 3 clinical trial focused on kidney diseases. The ICD-10 codes associated with the diseases are ['I12.9', 'N18.9', 'Q61.9', 'I12.0', 'D63.1', 'N18.1', 'N18.5']. The drug being studied is methylprednisolone. \n\nThe inclusion criteria for the trial are as follows:\n- Age of participants must be less than 18 years.\n- Boys must have a bone age of less than 15 years, and girls must have a bone age of less than 13 years.\n- Patients must be 12-24 months post-renal transplantation with stable transplant function.\n- This can be the first or second kidney transplant, either from a living or cadaver donor.\n- Patients must be on triple immunosuppression with cyclosporine (CyA), MMF, and daily steroids at the start of the study.\n- Patients and their parents must have given written consent after being informed about the trial.\n\nThe exclusion criteria for the trial are as follows:\n- Patients who have experienced irreversible rejection of a previous transplant within the last 6 months.\n- Patients with highly reactive (> 80%) lymphocytotoxic antibodies within the last 12 months prior to transplantation.\n- Patients with a history of steroid-resistant rejection of the current transplant.\n- Patients who have had more than 2 acute rejection reactions prior to study entry or 1 acute rejection reaction within the last 6 months before study entry.\n- Patients with a glomerular filtration rate (GFR) less than 40 ml/min/1.73 m\u00b2 (calculated using the Schwartz formula) at the start of the study.\n- Patients who have experienced an acute rejection reaction or unstable transplant function (increase of serum creatinine > 20%) within the last 6 months before study entry, or have histologically confirmed chronic rejection.\n- Patients suspected of not complying with medication.\n- Patients who are receiving a different basic immunosuppression regimen than the one prescribed in the study protocol.\n- Patients who are simultaneously undergoing growth hormone therapy after renal transplantation.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and focuses on patients with type 2 diabetes mellitus. The trial is investigating the effects of three drugs: ipragliflozin, placebo, and pioglitazone. The eligibility criteria for participants are listed, including requirements such as being on pioglitazone mono-therapy for at least 4 weeks, having an HbA1c value between 7.0 and 9.5%, and having a body mass index (BMI) between 20.0 and 45.0 kg/m2. The exclusion criteria are also provided, which specify conditions that would disqualify potential participants, such as having type 1 diabetes mellitus, having certain renal or cardiovascular diseases, or experiencing severe gastrointestinal diseases or heart failure.",
    "The sample in the table represents a clinical trial for breast cancer patients in phase 2/phase 3. The trial aims to evaluate the effectiveness of capecitabine and hormonal treatment (tamoxifen, exemestane, anastrozole, or letrozole) in patients with infiltrating breast cancer that has spread to distant parts of the body or is locally advanced and cannot be operated on. The patients must have a positive estrogen receptor, and the status of progesterone and HER-2 neu receptors should be known. They should also have experienced disease progression during first-line hormonal therapy or recurrence of the disease during adjuvant hormonal therapy. Patients who have received prior chemotherapy for metastatic disease are not eligible. The trial requires participants to provide written informed consent and be willing to participate in a Quality of Life investigation. There are exclusion criteria, such as having another malignancy (except carcinoma in situ) within the past 5 years, pregnancy or breastfeeding, contraindications to the use of capecitabine, and known central nervous system metastases.",
    "The sample provided is for a phase 3 clinical trial. The specific disease being studied is ankylosing spondylitis. The ICD-10 codes associated with this disease are M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, and M45.7. The drugs being tested in the trial are placebo and golimumab, with the latter also being administered to the placebo group. The eligibility criteria for participants are as follows:\n\nInclusion Criteria:\n- Participants must have a diagnosis of definite ankylosing spondylitis for at least 3 months.\n- Participants must exhibit symptoms of active disease during screening and at baseline.\n- Participants must not have any active infections.\n\nExclusion Criteria:\n- Participants must not have any other inflammatory diseases that could affect the evaluation of golimumab's benefits.\n- Participants must not have complete ankylosis of the spine.\n- Participants must not have a history of latent or active granulomatous infection.\n- Participants must not have had a serious infection, been hospitalized for an infection, or received intravenous antibiotics for an infection within 2 months prior to the first administration of the study agent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is \"postmenopausal symptoms.\" The ICDCodes associated with this disease are \"N95.0\" and \"N95.2.\" The drugs being tested in this trial are \"brisdelle (paroxetine mesylate)\" and \"placebo capsules.\" The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a female aged 40 or older, experiencing a certain number of moderate to severe hot flashes per day or week, and meeting specific menopause criteria. Exclusion criteria include having a history of non-response to certain medications, self-injurious behavior, clinical diagnosis or treatment for depression or borderline personality disorder, recent use of investigational study medication, concurrent participation in another trial, or being a family member of investigational-site staff.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is multiple sclerosis. The ICDCodes associated with this disease are 'G35' and 'C81.18'. The drugs being used in the trial are fingolimod and placebo. The eligibility criteria for this trial include being a male or female patient between the ages of 18-55 with a diagnosis of multiple sclerosis, having a relapsing-remitting disease course, and having an expanded disability status scale (EDSS) score of 0-5.5. There are also exclusion criteria, such as having other chronic diseases of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc., and being pregnant or nursing. Additionally, there is a requirement for patients to have completed a 24-month core study with or without 24 months on the study drug to be included in the extension phase. Patients who discontinued the study drug during the core study due to adverse events, serious adverse events, laboratory abnormalities, etc., would be excluded from the extension phase. It is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease being studied is chronic obstructive pulmonary disease (COPD). The icd-10 codes associated with this disease are G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, and N13.8. The drugs being tested in the trial are indacaterol, salmeterol, placebo to indacaterol, and placebo to salmeterol. \n\nThe eligibility criteria for this trial include being a male or female adult aged 40 years or older who has signed an Informed Consent Form. The patient must be a cooperative outpatient with a diagnosis of moderate to severe COPD according to the Global initiative for chronic obstructive lung disease (GOLD) Guidelines from 2006. They must also have a smoking history of at least 20 pack years. Additional criteria include having a post-bronchodilator FEV1 (forced expiratory volume in 1 second) less than 80% and greater than or equal to 30% of the predicted normal value, as well as a post-bronchodilator FEV1/forced vital capacity (FVC) less than 70%.\n\nExclusion criteria for this trial include being pregnant or lactating, having been hospitalized for a COPD exacerbation in the 6 weeks prior to the trial or during the run-in period, requiring long-term oxygen therapy for more than 15 hours a day, having had a respiratory tract infection 6 weeks prior to a specific visit, having concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis, having a history of asthma, having Type I or uncontrolled Type II diabetes, having clinically relevant laboratory abnormalities or a clinically significant abnormality, having active cancer or a history of cancer with less than 5 years disease-free survival time, having a history of long QT syndrome or a prolonged QTc interval, having a hypersensitivity to any of the study drugs or drugs with similar chemical structure, having been treated with an investigational drug, having had a live attenuated vaccination within 30 days prior to a specific visit or during the run-in period, having a known history of non-compliance to medication, and being unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements.\n\nIt is important to note that there may be other protocol-defined inclusion/exclusion criteria that apply to this trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on the disease \"atrial fibrillation.\" The associated ICD-10 codes for this disease are \"I48.0,\" \"I48.21,\" \"I48.91,\" \"I48.11,\" \"I48.19,\" and \"I48.20.\" The trial involves the drugs \"indobufen\" and \"aspirin.\" The eligibility criteria for this trial include having chronic or paroxysmal non-rheumatic atrial fibrillation with cardioembolic risk factors such as hypertension, ischemic cardiopathy, congestive heart failure, and diabetes mellitus. The exclusion criteria include having clinically relevant organ disease, a creatinine clearance of less than 30 ml/min, gastric or duodenal ulcer, and severe anemia or polycythemia.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the treatment of neurogenic urinary bladder disorder. The diseases associated with the trial include various conditions related to the bladder and urinary system. The icd-10 codes provided further specify the diseases being studied.\n\nThe trial involves the use of two drugs: propiverine hydrochloride er (extended release) and propiverine hydrochloride ir (immediate release). The eligibility criteria for participants are listed, including age restrictions, specific medical conditions, and exclusion criteria such as certain medical disorders, recent surgeries, and contraindications for anticholinergics.\n\nThe sample also includes inclusion and exclusion criteria, which outline the specific requirements for participants to be included or excluded from the trial. Inclusion criteria include being a Caucasian patient aged 18 to 70, having neurogenic detrusor overactivity with reflex detrusor contractions, and intact reflex arcs in the S2-S4 segments. Exclusion criteria include conditions such as multiple sclerosis, augmented reflex bladder, and acute urinary tract infection, among others.\n\nOverall, the sample provides a snapshot of the trial, including the phase, diseases being studied, drugs involved, and the eligibility criteria for participants.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is idiopathic pulmonary fibrosis. The corresponding ICD-10 code for this disease is J84.112. The drugs being tested in the trial are pirfenidone and placebo. The eligibility criteria for participants in the trial include a diagnosis of idiopathic pulmonary fibrosis, age between 40 and 80 years, certain lung function measurements within specified ranges, no improvement in the past year, ability to walk a certain distance while maintaining a minimum oxygen saturation level, and meeting certain exclusion criteria such as inability to undergo pulmonary function testing, presence of certain medical conditions, and withdrawal from other IPF trials.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on HIV infections. The ICD-10 code for HIV infection is \"Z21\". The trial involves the use of two drug combinations: darunavir/ritonavir once daily along with raltegravir twice daily, and darunavir/r once daily along with tenofovir/emtricitabine once daily (fixed dose combination). \n\nThe eligibility criteria for the trial include being a patient with confirmed HIV infection, being at least 18 years old, providing written informed consent, being male or a non-pregnant/non-lactating female, having no previous treatment with any antiretroviral drugs, having an HIV-1 RNA level greater than 1000 copies/ml, and having an indication to start antiretroviral treatment with a CD4 cell count of 500/mm3 or less. Additionally, there should be no major IAS-USA mutations on genotypic testing.\n\nThe non-inclusion criteria include being a woman without an effective contraception method, being pregnant or breastfeeding, expecting to conceive during the study, having HIV-2 co-infection, having certain abnormal laboratory values, having significant impairment of hepatic function, having a CD4 count greater than 500/mm3 at screening (unless symptomatic HIV disease is present), having certain major IAS-USA mutations on genotypic testing, being under treatment for mycobacteriosis or malignancy requiring chemotherapy or radiotherapy, testing positive for HBs Ag, having ongoing or planned HCV infection treatment during the first year of the trial, having known hypersensitivity to the trial drugs or their excipients, having contraindicated concomitant treatment, anticipating non-compliance with the protocol, participating in another clinical trial with an ongoing exclusion period at screening, being under legal guardianship or incapacitation, or being unable to complete the study period according to the investigator's opinion.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is diabetes mellitus, specifically type 2. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drug being tested in this trial is rosiglitazone (brl49653c). \n\nThe eligibility criteria for this trial are as follows:\n- Inclusion criteria: Patients with type 2 diabetes mellitus who are managed by SU (sulfonylurea) will be considered for this study. These candidates will undergo clinical laboratory tests and must have adequate blood, liver, and kidney function.\n- Exclusion criteria: Patients with serious cardiovascular disease or serious hepatic disease will not be eligible for this trial.",
    "The sample is a phase 3 clinical trial that focuses on patients with multiple sclerosis and neuropathic pain. The trial aims to evaluate the effectiveness of a drug called Sativex compared to a placebo. The inclusion criteria for the trial include being 18 years or older, having a diagnosis of multiple sclerosis, experiencing central neuropathic pain for at least three months, and having a pain severity score of four or more. Participants must also be willing to reduce the dosage of certain medications and abstain from using cannabinoids during the study. Female participants of childbearing potential must use effective contraception during the study and for three months afterward. The trial also has exclusion criteria, such as a history of certain psychiatric disorders, severe non-neuropathic pain, alcohol or substance abuse, and significant cardiovascular disorders. Other exclusion criteria include epilepsy, significant renal or hepatic impairment, and pregnancy or lactation. Participants must be willing to comply with all study requirements and have their general practitioner and consultant notified of their participation.",
    "The sample from the table is for a phase 3 clinical trial for bladder cancer. The ICD-10 codes associated with the disease are D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, and D41.4. The drugs being studied in the trial are cephalexin and ciprofloxacin. The eligibility criteria for the trial include having stage Ta (any grade) transitional cell carcinoma of the bladder, no greater than T1 recurrent disease, and not being at high risk for upper tract transitional cell cancers. Other criteria include being 18 years or older, having a performance status of SWOG 0-2, and not being pregnant or nursing. Prior to the trial, patients must not have had any other malignancy in the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission. There are also specific criteria related to prior and concurrent therapies.",
    "The sample is a phase 3 trial for the treatment of various conditions including breast cancer, hot flashes, and psychosocial effects of cancer and its treatment. The trial is focused on the drug citalopram hydrobromide. The eligibility criteria for participants include having a history of breast cancer or bothersome hot flashes, being postmenopausal, having an ECOG performance status of 0-1, and a life expectancy of at least 6 months. Participants must also be willing to provide blood samples during the study. There are restrictions on prior and concurrent therapies, including a minimum time since prior chemotherapy and antidepressant use. Concurrent use of tamoxifen, raloxifene, or aromatase inhibitors is allowed if on a constant dose for at least 4 weeks. Other concurrent agents for treating hot flashes are not allowed, except for a stable dose of vitamin E or concurrent soy. Gabapentin is allowed if used for reasons other than hot flashes and on a constant dose for at least 1 month.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is diabetes mellitus, type 2. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are bi 1356, voglibose placebo, bi 1356 placebo, and voglibose. \n\nThe eligibility criteria for this trial are as follows:\nInclusion criteria:\n1. Japanese patients with a diagnosis of type 2 diabetes mellitus. Their antidiabetic therapy must have been stable for at least 10 weeks before Visit 1.\n2. The patients' glycosylated haemoglobin A1 (HbA1c) levels should be between 7.0% and 10.0% at Visit 3, which marks the beginning of the 2-week placebo run-in phase.\n3. The patients' age should be between 20 and 80.\n4. The patients' Body Mass Index (BMI) should be less than or equal to 40 kg/m2.\n\nExclusion criteria:\n1. Patients who have had a myocardial infarction, stroke, or transient ischemic attack (TIA) within 6 months before Visit 1.\n2. Patients with impaired hepatic function.\n3. Patients with a history of severe allergy or hypersensitivity.\n4. Patients who have been treated with anti-diabetic, anti-obesity drugs, etc., within 3 months before Visit 1.\n5. Patients with fasting blood glucose levels greater than 240 mg/dl (=13.3 mmol/L) at Visits 2 or 3.",
    "The sample from the table is for a phase 3 trial. The disease being studied is psychosis. The corresponding ICD-10 codes for the disease are 'F53.1' and 'F29'. The drug being tested is asenapine. The eligibility criteria for this sample include elderly subjects with psychosis as the inclusion criteria. The exclusion criteria state that subjects should not have an uncontrolled, unstable clinically significant medical condition and should not have an established diagnosis of dementia.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease mentioned is acute myelogenous leukemia. The ICDCodes associated with this disease are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01. The drug mentioned is decitabine. The eligibility criteria for this trial include various conditions such as being an adult patient with AML, having unfavorable risk cytogenetics, being in the first or subsequent complete response, having a performance status of 0, 1, or 2, and meeting certain organ function requirements. The exclusion criteria include being pregnant or lactating, being HIV positive, having active and uncontrolled disease/infection, being unable or unwilling to sign the consent form, and not having received any other investigational therapy within the past 14 days.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and the disease being studied is sarcoma. The ICD-10 codes associated with the disease are C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, and C92.32. The drugs being tested in the trial are ombrabulin (ave8062) and a placebo. The eligibility criteria for the trial are listed, including inclusion criteria such as histologically proven soft tissue sarcoma and failure of previous anthracycline-based and ifosfamide therapies. Exclusion criteria include recent treatment with radiotherapy, surgery, or chemotherapy, brain metastases, uncontrolled hypertension, and known platinum hypersensitivity. It is important to note that the provided information may not include all relevant considerations for potential participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 3. The diseases being studied are cancer and breast cancer. The ICDCodes associated with these diseases are provided as well. For cancer, the ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. For breast cancer, the ICDCodes are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60.\n\nThe drugs being investigated in this trial are ixabepilone + capecitabine and capecitabine. \n\nThe eligibility criteria for this trial include:\n- Patients must have received prior treatment that included both an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel).\n- Patients must have received no more than two prior chemotherapy regimens. If patients have not received treatment for metastatic disease, they must have relapsed within one year.\n- Patients should not have any history of brain and/or leptomeningeal metastases.\n- Patients should not have Grade 2 or worse neuropathy at the time of study entry.\n- Patients should not have had prior treatment with any epothilones and/or capecitabine (such as Xeloda).",
    "The sample is a phase 3 trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drugs exenatide and taspoglutide. The eligibility criteria for inclusion in the trial include being an adult between the ages of 18 and 75, having type 2 diabetes and receiving metformin and/or pioglitazone or rosiglitazone for at least 12 weeks, having an HbA1c level between 7.0% and 10% at screening, having a BMI between 25kg/m2 and 45kg/m2 (or >23kg/m2 for Asians) at screening, and having a stable weight within 5% for at least 12 weeks prior to screening. The exclusion criteria include having type 1 diabetes, a history of acute metabolic diabetic complications within the previous 6 months, clinically significant diabetic complications, proliferative diabetic retinopathy, recent myocardial infarction, coronary artery bypass surgery, post-transplantation cardiomyopathy, or stroke within the past 6 months, any abnormality in clinical laboratory tests or ECG that would prevent safe involvement in the study, known hemoglobinopathy or chronic anemia, and clinically significant gastrointestinal disease.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The disease being studied is hypertension. The corresponding ICD-10 codes for hypertension are ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']. The drugs being tested are a fixed-dose combination of telmisartan 40mg+amlodipine 10mg and a fixed-dose combination of telmisartan 80mg+amlodipine 10mg. The eligibility criteria for this trial include specific inclusion and exclusion criteria. The inclusion criteria state that participants must have a diagnosis of essential hypertension. The exclusion criteria include factors such as pregnancy, breastfeeding, unwillingness to use effective contraception (for females of child-bearing potential), development of worsened conditions from previous trials, known or suspected secondary hypertension, high blood pressure levels, hepatic or renal impairment, hyperkalemia, volume or sodium depletion, primary aldosteronism, fructose or lactose intolerance, congestive heart failure, previous symptoms of angioedema from ACE inhibitors or ARBs, new drug or alcohol dependency, concurrent participation in another trial or investigational therapy, hypertrophic obstructive cardiomyopathy, relevant valve stenosis, known allergies to the trial medications, non-compliance with study medication, and any other clinical condition that may hinder the safe completion of the trial or administration of telmisartan and amlodipine.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The diseases being studied are \"autistic disorder\" and \"behavioral symptoms\". The corresponding ICD-10 code for \"autistic disorder\" is \"F84.0\". The drug being used in the trial is \"aripiprazole\". The eligibility criteria for the trial are listed, including inclusion and exclusion criteria. Inclusion criteria include having completed 8 weeks of treatment in a previous double-blind clinical trial and meeting the diagnostic criteria for autistic disorder. Exclusion criteria include being treatment resistant to neuroleptic medication, having a current diagnosis of another disorder on the autism spectrum, and having certain psychiatric disorders or medical conditions. Non-pharmacologic therapy should be stable prior to screening and throughout the study.",
    "The sample is a phase 3 trial for multiple sclerosis. The trial is looking at the effectiveness of the drug teriflunomide compared to a placebo. The eligibility criteria for participants include having multiple sclerosis with a relapsing clinical course, meeting McDonald's criteria for MS diagnosis, and experiencing at least 1 relapse in the past year or 2 relapses in the past 2 years. Participants should also be clinically stable without recent relapse or treatment with ACTH or systemic steroids. Exclusion criteria include having significant cardiovascular, hepatic, neurological, endocrine, or other major systemic diseases, impaired bone marrow function, being pregnant or nursing, having alcohol or drug abuse issues, and having used certain immunosuppressant agents before enrollment. Any known condition or circumstance that would prevent compliance or completion of the study is also an exclusion criterion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding ICDCodes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs involved in the trial are 'ly2605541', 'insulin glargine', and 'insulin lispro'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as having type 2 diabetes, specific HbA1c and BMI values, being on a glucose-lowering regimen with daily insulin injections, and meeting certain requirements for women of childbearing potential. There are also exclusion criteria, such as previous use of certain insulin therapies, excessive insulin resistance, and various medical conditions that would prevent participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is schizophrenia. The ICDCodes associated with schizophrenia are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drug being tested is Seroquel SR. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include patients who consider their current antipsychotic treatment inadequate in terms of efficacy or tolerability, female patients of childbearing potential who have a negative pregnancy test and are willing to use a reliable method of birth control, and patients who are able to understand and comply with the study requirements. \n\nExclusion criteria include patients who have any other diagnosis apart from schizophrenia, substance abuse or dependence that is not in full remission, risk of transmitting HIV or hepatitis B, and patients who are deemed to be at imminent risk of suicide or a danger to themselves or others.",
    "The sample is a phase 3 trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of two drugs, insulin degludec and insulin glargine, in combination with basal-oral therapy (BOT). The inclusion criteria for the trial include having clinically diagnosed type 2 diabetes for at least 6 months, a maximum HbA1c level of 10%, and current treatment with insulin glargine and stable oral antidiabetic (OAD) medication. The exclusion criteria include recent use of certain medications, cardiovascular disease, recurrent severe hypoglycemia, pregnancy or breastfeeding, previous participation in the trial, and known or suspected hypersensitivity to the trial products.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on Parkinson's disease. The ICD-10 code for Parkinson's disease is \"G20\". The drug being studied is called istradefylline (kw-6002). The record also includes eligibility criteria for participants. Inclusion criteria include having completed a specific study, not being pregnant or using contraception, and not having a history of psychotic illness. Exclusion criteria include having variant/atypical Parkinson's disease, having had cancer within the past 5 years, having ALT/AST levels higher than 1.5 times the upper limit of normal, having a seizure disorder, and having neuroleptic malignant syndrome.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is gastroesophageal reflux disease. The ICDCodes associated with this disease are 'K21.9', 'K21.00', and 'K21.01'. The drugs being tested in this trial are dexlansoprazole mr and placebo. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include subjects who identify their main symptom as a burning feeling in the mid epigastric area and/or chest area (heartburn), have a history of heartburn episodes for 6 months or longer, and have experienced heartburn episodes for 4 or more days in the 7 days prior to Day -1. \n\nExclusion criteria include subjects with certain conditions such as endoscopic Barrett's esophagus, erosive esophagitis, uncontrolled systemic disease, Zollinger-Ellison syndrome, abnormal laboratory values, active gastric or duodenal ulcers, acquired immunodeficiency syndrome (AIDS), hypersensitivity to proton pump inhibitors (PPIs) or dexlansoprazole MR, use of certain medications like PPIs, histamine (H2) receptor antagonists, or sucralfate, chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors, use of antacids (except for study-supplied Gelusil\u00ae), use of drugs with significant anticholinergic effects, inability to discontinue the use of misoprostol or prokinetics, need for continuous anticoagulant therapy, pregnancy or lactation in females, history of gastrointestinal surgery (except for simple oversew of ulcer), history of cancer within 3 years prior to screening, previous participation in a Dexlansoprazole study, and subjects who are unable to comply with the study requirements or are unsuitable for any reason.",
    "The sample is a phase 3 trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drugs ipragliflozin, placebo, and metformin. The inclusion criteria for the trial are as follows: patients must be receiving metformin mono-therapy for at least 6 weeks, have an HbA1c value between 7.0 and 9.5%, and have a body mass index (BMI) between 20.0 and 45.0 kg/m2. The exclusion criteria include patients with type 1 diabetes mellitus, serum creatinine levels above the upper limit of normal, estimated glomerular filtration rate (GFR) below 60ml/min/1.73m2, proteinuria (albumin/creatinine ratio above 300mg/g), dysuria and/or urinary tract infection, genital infection, significant renal, hepatic or cardiovascular diseases, and severe gastrointestinal diseases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3, and the disease being studied is sepsis. The ICDCodes associated with sepsis are A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, and B37.7. The drugs being used in the trial are metoclopramide, zinc, and selenium. \n\nThe eligibility criteria for enrollment in the trial are described in two sections: one for the initial accrual period and another after the first interim analysis. During the initial accrual period, patients between 12 months and less than 18 years old, within the first 48 hours of PICU admission, and with specific medical devices (endotracheal tube, central venous catheter, or Foley catheter) are eligible. They should also be anticipated to have an indwelling arterial or central venous catheter for blood sampling during the first three days of study enrollment.\n\nAfter the first interim analysis, a decision will be made regarding the enrollment of infants between 40 weeks gestational age and 12 months. If approved, the eligibility criteria for this group are similar to the initial accrual period, with the age range adjusted.\n\nThe exclusion criteria are also provided for both periods. Patients who are less than 1 year old or equal to or greater than 18 years old, have a known allergy to metoclopramide, are planned to have the removal of specific medical devices within 72 hours of study enrollment, have suspected intestinal obstruction, have had intestinal surgery or bowel disruption, are on chronic metoclopramide therapy prior to enrollment, fail to enroll within 48 hours of PICU admission, have been readmitted to the PICU in the previous 28 days, have previously enrolled in this study, or lack commitment to aggressive intensive care therapies are ineligible for enrollment.\n\nOverall, this sample provides information about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on sepsis treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is acromegaly. The icd-10 code associated with this disease is E22.0. The drug being used in the trial is lanreotide autogel 120 mg. \n\nThe eligibility criteria for this trial include the patient giving written informed consent, being between the ages of 18 and 75, having a diagnosis of acromegaly based on specific criteria for GH and IGF-1 levels, having a pituitary adenoma with a diameter of 10 mm or greater based on MRI, and not having any visual field defects related to the pituitary adenoma. \n\nThere are also exclusion criteria, such as a history of hypersensitivity to the drug being used, recent use or scheduled use of unlicensed drugs, and the likelihood of requiring treatment with other somatostatin analogues or prohibited drugs during the study. Other exclusion criteria include pregnancy or lactation, history of alcohol abuse, mental conditions that may affect understanding of the study, abnormal baseline findings or medical conditions that may jeopardize safety or data collection, previous pituitary surgery or radiotherapy, previous treatment with somatostatin analogues or GH receptor antagonists, and the expectation of requiring pituitary surgery or radiotherapy during the study period. \n\nAdditional exclusion criteria include high prolactin levels, allergy to MRI contrast agent, severe renal insufficiency, and known optic nerve disease or visual abnormalities that may worsen during the study.",
    "The sample is a phase 3 clinical trial for the treatment of multiple sclerosis. The trial is evaluating the drug laquinimod. The inclusion criteria for the trial include having a confirmed diagnosis of relapsing-remitting multiple sclerosis, being ambulatory with a certain level of disability, and having experienced relapses or specific MRI findings within a certain timeframe. The trial is open to individuals between the ages of 18 and 55. Women of child-bearing potential must use a reliable method of birth control. Participants must be willing to comply with the study requirements and provide informed consent. The exclusion criteria include having progressive forms of multiple sclerosis, recent use of corticosteroids or other treatments, previous use of certain medications, and various medical conditions or factors that may interfere with participation. The sample also mentions exclusion criteria related to pregnancy, breastfeeding, and previous use of certain medications.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is hepatocellular carcinoma. The ICD-10 codes associated with the disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drugs being tested in the trial are sorafenib (nexavar, bay43-9006) and a placebo. The eligibility criteria for the trial include being 18 years or older, having a life expectancy of at least 12 weeks, having histologically or cytologically documented hepatocellular carcinoma, having at least one tumor lesion that meets certain criteria, and having an ECOG PS (Performance Status) of 0, 1, or 2. The exclusion criteria include having a previous or concurrent cancer that is different from hepatocellular carcinoma, renal failure requiring dialysis, history of cardiac disease, active serious infections, known HIV infection, known central nervous system tumors, and clinically significant gastrointestinal bleeding within 30 days prior to the study entry.",
    "The sample from the table represents a clinical trial in phase 3. The trial focuses on patients with brain edema and brain tumors. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of two drugs, namely hcrf and placebo hcrf. The eligibility criteria for the trial include a confirmed diagnosis of a primary malignant glioma, symptomatic peritumoral brain edema requiring dexamethasone treatment, stable dexamethasone dose, confirmation of peritumoral brain edema through MRI or similar technology, and the ability to self-administer subcutaneous injections or have assistance from a caregiver. The exclusion criteria include recent surgery, radiosurgery, radiation therapy, or introduction of new chemotherapeutic regime, use of systemic steroids for indications other than peritumoral brain edema, current use of dexamethasone or anticonvulsant therapy, presence of serious concomitant cardiovascular, pulmonary, renal, gastrointestinal, or endocrine metabolic diseases, CNS infection, and conditions that are considered contradictions for receiving niacin.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on breast cancer. The associated ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The trial involves the use of two drugs, bevacizumab (Avastin) and chemotherapy. The eligibility criteria for the trial are listed, including requirements for female patients aged 18 or older, confirmed HER2-negative breast cancer, disease progression after previous treatment with Avastin and chemotherapy, specific dosage and duration of Avastin treatment, ECOG performance status, and a minimum time since prior radiation therapy or surgery. The exclusion criteria are also provided, which include restrictions on previous anti-angiogenic therapy, active malignancies, inadequate renal function, relevant cardiovascular disease, known CNS disease (except for treated brain metastases), chronic daily treatment with high-dose aspirin or clopidogrel, and pregnancy or lactation.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The disease being studied is major depressive disorder. The corresponding ICD-10 codes for this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested in this trial are paroxetine and lithium. The sample also includes the eligibility criteria for participants. The inclusion criteria include not currently participating in another clinical trial, being over the age of 18, having a DSM-IV diagnosis of major depression, and having a positive family history of bipolar disorder or completed suicide. The exclusion criteria include not being able to give informed consent, being pregnant or breastfeeding, having additional psychiatric diagnoses such as panic disorder, PTSD, or psychosis, having a history of mania or hypomania, having active substance abuse or dependence in the last 6 months, having a current depressive episode that is less than 4 weeks or greater than 12 months in duration, having a current or prior adequate trial of lithium or paroxetine, using other medications for the treatment of depression, and having clinically significant medical illness, particularly kidney problems.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on the disease \"diabetic macular edema.\" The associated ICD-10 codes for this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. The trial involves the drugs \"ranibizumab\" and \"sham to ranibizumab\". The eligibility criteria for this trial include visual acuity impairment, presence of diabetic macular edema in at least one eye, type 1 or type 2 diabetes mellitus, and stable medication for diabetes treatment for the last 3 months. The exclusion criteria include uncontrolled systemic or ocular diseases, laser photocoagulation in the study eye within the last 3 months, any history of intraocular surgery in the study eye within the past 3 months, and blood pressure higher than 160/100 mmHg. Additionally, there are extension inclusion criteria that require completion of the Core Study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3, and the disease being studied is pancreatic cancer. The ICDCodes associated with this disease are 'C25.3'. The drugs being used in the trial are 'gemcitabine plus ts-1', 'ts-1', and 'gemcitabine'. \n\nThe eligibility criteria for this trial include the following:\n- The patient must have histologically confirmed adenocarcinoma or adenosquamous carcinoma of the pancreas.\n- The pancreatic cancer must be advanced and unresectable.\n- Patients should not have received any previous treatment for pancreatic cancer, except for resection.\n- The age range for eligible patients is 20 to 79 years.\n- Patients should have an ECOG Performance Status of 0 or 1.\n- The patient's major organs should be functioning within specified parameters, as determined by laboratory tests.\n- The patient should be able to take capsules orally.\n- There should be no clinically abnormal ECG findings within 28 days before registration.\n- The patient must have voluntarily signed the written consent form.\n\nThe exclusion criteria for this trial include the following:\n- The patient should not have pulmonary fibrosis or interstitial pneumonia.\n- The patient should not have watery diarrhea.\n- The patient should not have active infections, excluding viral hepatitis.\n- The patient should not have serious complications such as heart failure, renal failure, hepatic failure, etc.\n- The patient should not have moderate or severe ascites or pleural effusion requiring treatment.\n- The patient should not have metastasis in the CNS.\n- The patient should not have active double cancer, except for certain cases.\n- The patient should not be under treatment with flucytosine, phenytoin, or warfarin potassium.\n- Pregnant females, possibly pregnant females, females wishing to become pregnant, and nursing mothers are not eligible. Males attempting to produce a pregnancy are also not eligible.\n- The patient should not have a severe mental disorder.\n- The patient should not be judged ineligible by physicians for participation in the study from a safety viewpoint.",
    "The sample from the table is for a phase 3 trial focused on the disease psoriasis. The icd-10 codes associated with this disease are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drug being studied in this trial is etanercept. The eligibility criteria for this trial include being male or female, aged between 18 and 70. Healthy volunteers are excluded from participating in this trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is hepatitis C virus. The corresponding ICD-10 codes for the disease are B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, and B17.2. The drugs being used in the trial are asunaprevir (ASV), daclatasvir (DCV), pegylated-interferon alfa 2a (PegIFN), and ribavirin (RBV). The eligibility criteria for the trial include being 18 years or older, having HCV genotype 1b, and having previously failed treatment with peginterferon alfa and ribavirin or being intolerant or ineligible for those drugs. Other criteria include having HCV RNA levels of at least 10,000 IU/mL, being seronegative for HIV and Hepatitis B surface antigen, and allowing subjects with compensated cirrhosis. The exclusion criteria include prior treatment with HCV direct acting antiviral, presence of other medical conditions contributing to chronic liver disease, decompensated liver disease, hepatocellular carcinoma or other malignancies, and uncontrolled diabetes or hypertension.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is phase 3. The diseases being studied are depression, depressive disorder, and major depressive disorder. The corresponding ICD-10 codes for these diseases are F32.A, F53.0, P91.4, Z13.31, Z13.32 for depression, and F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9 for depressive disorder. The drugs being tested in this trial are desvenlafaxine succinate sustained-release (dvs sr) and escitalopram. The eligibility criteria for participants include being postmenopausal women between the ages of 40 and 70, having a primary diagnosis of MDD without psychotic features, and having a Montgomery-Asberg Depression Rating Scale (MADRS) total score of 22 or higher at the screening and baseline visit. There are also exclusion criteria, such as not using certain drug products in the 8 weeks before baseline, not having a history of substance abuse or dependence, and not having clinically important medical diseases.",
    "The sample is a phase 3 clinical trial for patients with schizophrenia or schizoaffective disorders. The trial aims to evaluate the effectiveness of the drugs olanzapine, amantadine, metformin, and zonisamide in treating these conditions. The eligibility criteria for participants include having a diagnosis of schizophrenia or schizoaffective disorder, being able to visit the doctor's office regularly, and having been on a stable medication regimen for at least 30 days. Female participants must also have a negative pregnancy test and use contraception. Exclusion criteria include having certain medical conditions such as bipolar disorder, diabetes, or heart disease, as well as having certain allergies or a history of Parkinson's disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease being studied is dermatitis, atopic. The ICDCodes associated with this disease are 'L20.89' and 'L20.9'. The drug being used in the trial is tacrolimus ointment. The eligibility criteria for this sample include being male or female of any ethnic group, having moderate to severe atopic dermatitis, being responsive to topical steroids, providing written informed consent, and agreeing to maintain adequate birth control if female and of childbearing potential. The patient should not have a genetic epidermal barrier defect, be pregnant or breastfeeding, have a skin infection on the affected area, have hypersensitivity to macrolides or tacrolimus, be participating in another drug trial, have substance abuse or psychiatric disorders, or be HIV positive.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and the disease being studied is thyroid cancer. The corresponding ICD-10 codes for the disease are 'C73', 'D34', 'D44.0', and 'Z85.850'. The drug being tested in this trial is zd6474 (vandetanib). The record also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must have a confirmed diagnosis of unresectable, locally advanced, or metastatic hereditary or sporadic Medullary Thyroid Cancer, have measurable tumor, and be able to swallow medication. The exclusion criteria include recent major surgery, recent chemotherapy, recent radiation therapy (except for palliative radiotherapy), brain metastases or spinal cord compression (unless treated and stable), significant cardiac events, and previous treatment with ZD6474.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is \"multiple myeloma and plasma cell neoplasm.\" The ICDCodes associated with this disease are \"C96.20,\" \"C96.29,\" and \"D47.09.\" The drugs being used in the trial are \"prednisone\" and \"thalidomide.\" \n\nThe eligibility criteria for this trial include the following disease characteristics: histologically confirmed multiple myeloma, detectable serum M-component or urinary excretion of light chain protein, and previous treatment with autologous stem cell transplantation. \n\nThe patient characteristics required for participation in the trial include being 16 years or older, having an ECOG performance status of 0-2, and a life expectancy of at least 6 months. \n\nThere are also specific requirements for hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other health conditions. Additionally, there are restrictions on prior or concurrent malignancies, pregnancy or nursing, and certain medical illnesses or conditions. \n\nThe prior concurrent therapy section specifies that the patient should not have undergone double autologous or allogeneic hematopoietic stem cell transplantation or received prior thalidomide. There are no specific requirements mentioned for chemotherapy, endocrine therapy, radiotherapy, or surgery. Other concurrent anti-cancer therapy or investigational therapy is not allowed.",
    "The sample from the table is for a phase 3 trial. The disease being studied is \"sleep initiation and maintenance disorders\". The corresponding ICD-10 codes for this disease are \"Y93.E9\" and \"Y93.H9\". The drugs being tested in this trial are \"zolpidem-mr (modified release)\", \"zolpidem (sl800750)\", and \"placebo\". The eligibility criteria for this trial include a diagnosis of primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is ovarian cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are carboplatin and cisplatin. The eligibility criteria for participants include having histologically or cytologically confirmed recurrent ovarian epithelial cancer after first-line chemotherapy, measurable disease, no leptomeningeal or brain metastases, and meeting certain age, performance status, and laboratory requirements. The sample also includes information about prior concurrent therapies, such as limitations on the number of prior chemotherapy regimens.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are cetuximab and folfox. The eligibility criteria for this sample include being a patient included in the PETACC08 study, having signed informed consent for the translational study, and having an available FFPE tumor sample for miR-31-3p and miR-31-5p expression testing. The exclusion criteria include patients who have withdrawn their consent for the PETACC08 study and/or the translational study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the treatment of chronic pain. The ICD-10 codes associated with the disease are ['G89.29', 'G89.4', 'R39.82', 'G89.22', 'G89.28', 'G89.21', 'G89.3']. The drug being studied is oxymorphone extended release. \n\nThe sample also includes the eligibility criteria for participants. Inclusion criteria include being 18 years or older, being opioid naive, having a pain intensity score of at least 50 mm VAS, being in good health, having moderate to severe chronic non-neuropathic lower back pain for at least three months, and not making any changes to current adjunct therapies for back pain. \n\nExclusion criteria include being pregnant or lactating, having specific conditions such as radiculopathy or fibromyalgia, not being able to stop local regional pain treatments during the study, intending to alter physical therapy regimen during the study, having had surgical procedures for back pain within the past six months, having pain secondary to neoplasm, having difficulty swallowing medication, having a history of substance or alcohol abuse, having used investigational medication within the past 30 days, having previous exposure to oxymorphone, having a history of seizure, having an ileostomy or colostomy, having used MAO inhibitors within the past 14 days, or having other clinically significant conditions as determined by the investigator.",
    "The sample from the table represents a clinical trial with a phase 2/phase 3 design. The trial focuses on patients with transient ischemic attack (TIA) or stroke. The diseases are further specified with ICD-10 codes. The drugs being studied in the trial are aspirin, clopidogrel, and simvastatin. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Patients must have TIA or minor acute ischemic stroke with a NIHSS score of less than 4 at the time of randomization.\n- Patients must not be candidates for acute thrombolysis or other acute intervention that is considered the current standard of care.\n- Patients must be aged 40 years or older.\n- Patients must have weakness or language disturbance at the time of TIA/minor stroke, and the duration of neurological deficit (TIA) must be greater than 5 minutes.\n- Patients can be randomized within 24 hours of symptom onset, defined by the \"last seen well\" principle.\n- Patients must provide written, informed consent to participate in the trial.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with pure sensory symptoms, pure vertigo or dizziness, pure ataxia, or pure visual loss.\n- Patients for whom thrombolysis or other acute intervention is indicated as the current standard of care.\n- Patients who are currently on statin therapy, antiplatelet therapy (excluding aspirin), long-term non-steroidal anti-inflammatory drugs (NSAIDs, but not COX inhibitors), or anticoagulation.\n- Patients who, in the opinion of the site Investigator, should be commenced on statin therapy.\n- Patients with neurological deficit due to intracranial hemorrhage, tumor, infection, or any finding not consistent with acute brain ischemia as the cause of presenting symptoms.\n- Patients with a presumed cardiac source of embolus (e.g., atrial fibrillation, prosthetic cardiac valve, known/suspected endocarditis).\n- Patients with a concomitant acute coronary syndrome (acute myocardial infarction or unstable angina).\n- Patients with a Modified Rankin Score of 3 or more (pre-morbid historical assessment).\n- Patients in whom the qualifying event was due to a complication of cerebral angiography, a revascularization procedure, or trauma.\n- Patients with uncontrolled hypertension at baseline (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg), or malignant hypertension defined by brain plus acute organ involvement due to acute hypertension.\n- Women who are breastfeeding or pregnant. Women of childbearing potential must have a negative pregnancy test prior to randomization and must plan on not becoming pregnant during the study while practicing a suitable method of birth control.\n- Patients with evidence of contraindication for the use of Trial Medication, such as serious systemic bleeding precluding antiplatelet therapy, hypersensitivity to aspirin, clopidogrel, or statins, renal insufficiency, hepatic dysfunction, thrombocytopenia, neutropenia, or bleeding diathesis or coagulopathy.\n- Patients with a life expectancy of less than 90 days.\n- Patients who have participated in another clinical therapeutic trial (drug or device) either concurrently or within the previous 30 days, or have previously participated in the FASTER trial.\n- Patients with geographical or other factors that make follow-up impractical or evaluation of outcome events impossible, such as severe dementia. However, patients who could and are willing to complete their follow-up at a participating center may still be randomized.",
    "The sample in the table is for a phase 3 clinical trial. The disease being studied is reflux esophagitis. The corresponding ICD-10 codes for this disease are 'K21.9', 'K21.00', and 'K21.01'. The drugs being used in the trial are esomeprazole and omeprazole. The eligibility criteria for inclusion in the trial include having healed reflux esophagitis verified by EGD in a previous study and receiving general treatment with a PPI. The exclusion criteria include having a gastric or duodenal ulcer verified by EGD within 12 weeks before randomization and using any PPI from 14 days before the screening visit to the day of randomization.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 3 trial for the disease \"myocardial infarction\". The ICD-10 codes associated with this disease are \"I25.2\", \"I21.9\", \"I21.A1\", \"I21.A9\", \"I21.4\", \"I22.2\", and \"I23.8\". The drugs being studied in this trial are \"bivalirudin\" and \"unfractionated heparin\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include specific symptoms, ST-segment elevation, and patient consent. The exclusion criteria include contraindications to certain medications, prior administration of specific therapies, bleeding disorders, recent surgeries, and other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease mentioned is chronic kidney disease, stage 5. The ICDCodes associated with this disease are N18.5, I12.0, I13.11, and I13.2. The drugs being studied in this trial are fosrenol (lanthanum carbonate) and sevelamer hydrochloride. The eligibility criteria for this trial include inclusion criteria such as being an adult with end-stage renal disease receiving dialysis, and exclusion criteria such as having significant gastrointestinal disorders, being pregnant or nursing, currently taking specific medications, being HIV positive, or having clinically significant liver disease.",
    "The sample is a phase 3 trial for the treatment of depression in patients with bipolar I disorder. The trial is investigating the effectiveness of the drug armodafinil compared to a placebo. The inclusion criteria for the trial include having a diagnosis of bipolar I disorder, currently experiencing a major depressive episode, having had at least 1 previous manic or mixed episode, and having no more than 6 mood episodes in the last year. The patient's current major depressive episode must have started between 2 weeks and 12 months prior to the screening visit. The patient must also be taking one or two specific mood stabilizers and be in good health. Women of childbearing potential must use contraception during the study. The patient must be willing and able to comply with study restrictions and attend scheduled clinic visits. Exclusion criteria include having any Axis I disorder apart from bipolar I disorder, recent psychotic symptoms, current active suicidal ideation, history of eating disorder or OCD, history of alcohol or substance abuse, and various other medical and treatment-related factors. Pregnant or lactating women are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease being studied is Parkinson's disease. The corresponding ICDCodes for Parkinson's disease is \"G20\". The drug being used in the trial is ropinirole. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The participant must have idiopathic Parkinson's disease.\n- The participant must be at Modified Hoehn and Yahr Scale Stages II - IV.\n- The participant must have been on a stable dose of L-dopa for at least 4 weeks prior to screening.\n- The participant must have a lack of control with L-dopa therapy.\n- Women of child-bearing potential must use a clinically accepted form of birth control.\n\nExclusion Criteria:\n- The participant must not have any significant and/or uncontrolled medical conditions (excluding Parkinson's disease) within 3 months of screening.\n- Any abnormality at screening that is considered clinically relevant by the Investigator is an exclusion criterion.\n- Dementia is an exclusion criterion.\n- Use of dopamine agonists within 4 weeks of the screening visit is an exclusion criterion.\n- Participation in other investigational drug studies is an exclusion criterion.",
    "The sample from the table represents a phase 3 clinical trial. The trial focuses on patients with diseases such as constipation and pain. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of drugs like oxycodone naloxone and oxycodone pr tablets. The eligibility criteria for the trial include being 18 years or older, having cancer pain or non-cancer pain, and currently receiving or requiring a specific level of opioid medication. Additionally, patients must have opioid-related constipation and be able to comply with the study protocol. Women of childbearing potential must have a negative pregnancy test and use effective birth control. Exclusion criteria include pregnancy or breastfeeding, contraindications or hypersensitivity to certain substances, and significant impairment of cardiovascular, respiratory, liver, or kidney function. Other exclusion criteria involve specific medical conditions, ongoing treatments, and participation in other clinical trials.",
    "The sample is from a table that contains information about clinical trials. In this specific sample, the trial is in phase 3 and focuses on the treatment of painful diabetic peripheral neuropathy. The associated ICD-10 codes for this disease are A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, and I73.9. The drugs being studied are pregabalin and a placebo. The eligibility criteria for participants include having type 1 or type 2 diabetes with painful neuropathy, currently being treated with an NSAID for another pain condition, and meeting a specific level of pain severity. Exclusion criteria include a history of failed pregabalin treatment, participation in previous or ongoing pregabalin trials, and the presence of neurologic disorders unrelated to diabetic neuropathy that could affect the assessment of distal neuropathic pain.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and is focused on early rheumatoid arthritis. The associated ICD-10 codes for the disease are ['M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019', 'M06.021']. The drugs being studied are methotrexate and a methotrexate placebo. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The subject must be 18 years or older and in good health, as determined by the investigator.\n- The subject must have a diagnosis of rheumatoid arthritis (RA) according to the 1987-revised American College of Rheumatology (ACR) criteria. The disease duration should be less than 3 years, with at least 8 swollen joints out of the 66 assessed, at least 10 tender joints out of the 68 assessed, at least 1 joint erosion or rheumatoid factor (RF) positivity, and an erythrocyte sedimentation rate (ESR) of >= 28 mm/1h or a C-reactive protein (CRP) level of >= 1.5 mg/dl.\n\nExclusion Criteria:\n- The subject must not have been diagnosed with chronic arthritis before the age of 16.\n- The subject must not have received previous treatment with methotrexate, cyclophosphamide, cyclosporin, azathioprine, or more than 2 other disease-modifying anti-rheumatic drugs (DMARDs).\n- The subject must not have previously received anti-tumor necrosis factor (TNF) therapy.\n- The subject must not be permanently wheelchair-bound or bedridden.\n- The investigator may exclude a subject if they consider them unsuitable for the study for any reason.\n- Female subjects who are pregnant, breastfeeding, or considering becoming pregnant are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and the disease being studied is type 2 diabetes mellitus. The icd-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are vildagliptin and placebo. \n\nThe record also includes eligibility criteria for participants in the trial. The inclusion criteria include having a confirmed diagnosis of type 2 diabetes mellitus, being on stable oral anti-diabetic therapy for at least 12 weeks, having an HbA1c level between 7.5% and 11.0%, and having a body mass index (BMI) between 22 and 45 kg/m2. \n\nThe exclusion criteria include having a fasting plasma glucose level of 270 mg/dL or higher, experiencing acute metabolic diabetes complications within the past 6 months, having a history of myocardial infarction, transient ischemic attack (TIA) or stroke, coronary artery bypass surgery, or percutaneous coronary intervention within the past 6 months, having a history of hypersensitivity to any of the study drugs or drugs of similar chemical classes, and having acute infections that may affect blood glucose control within 4 weeks prior to screening. Other inclusion/exclusion criteria may also apply as defined by the protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on bipolar disorder and mania. The ICD-10 codes associated with these diseases are ['F31.81', 'F31.89', 'F31.9', 'F25.0', 'F31.0', 'F31.31', 'F31.32']. The drugs being studied are cariprazine and placebo. The sample also includes the eligibility criteria for the trial, including inclusion criteria such as patients providing informed consent, meeting the DSM-IV-TR criteria for bipolar I disorder, and being voluntarily hospitalized for a current manic episode. The exclusion criteria state that patients with a diagnosis of an axis I disorder other than bipolar I disorder within the previous six months are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is Hepatitis B. The ICDCodes associated with this disease are B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, and B16.1. The drugs being used in the trial are Telbivudine (LDT) and Peginterferon Alpha-2a. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include having a documented chronic hepatitis B, detectable serum Hepatitis B Surface Antigen (HBsAg), being HBeAg-positive, having Hepatitis B 'e' Antibody (HBeAb)-negative, having a history of chronic liver inflammation, elevated serum Alanine aminotransferase (ALT) level, serum HBV DNA level \u2265 6 log10 copies/mL, and chronic liver inflammation on previous liver biopsy within the previous 24 months.\n\nThe exclusion criteria include co-infection with Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), or Human Immunodeficiency Virus (HIV), previous treatment with telbivudine, previous nucleoside or nucleotide therapy, previous immunomodulatory treatment within the past 12 months, medical conditions requiring prolonged or frequent use of certain medications, current alcohol or illicit drug abuse or history of substance abuse within the past two years, use of other investigational drugs, current use of methadone, history of hepatic decompensation or malignancy within the past 5 years, additional known causes of liver disease other than hepatitis B, history of chronic pancreatitis, abnormal laboratory values during screening, pregnancy or breastfeeding, and unwillingness to practice birth control for women of child-bearing potential.\n\nThis sample provides a detailed description of the trial phase, disease, associated ICDCodes, drugs, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is hypertension. The ICDCodes associated with this disease are \"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", and \"I10\". The drugs being used in the trial are \"azilsartan medoxomil and amlodipine\" and \"amlodipine\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having essential hypertension with a specific range of systolic blood pressure, being a sexually active female of childbearing potential who agrees to use contraception, having normal clinical laboratory evaluations, and being willing to discontinue current antihypertensive medications. Exclusion criteria include having high diastolic blood pressure, insufficient quality of baseline ambulatory blood pressure monitoring reading, hypersensitivity to angiotensin II receptor blockers or calcium channel blockers, recent history of certain cardiovascular conditions, clinically significant cardiac conduction defects, left ventricular outflow obstruction, secondary hypertension, non-compliance with study medication, severe renal dysfunction or disease, renal artery stenosis, history of drug or alcohol abuse, history of cancer within the past 5 years, type 1 or poorly controlled type 2 diabetes mellitus, hyperkalemia, elevated alanine aminotransferase level, abnormal upper arm circumference, working night shift, current or recent participation in another investigational study, presence of any other serious disease or condition that may compromise subject safety, previous participation in a TAK-491 study, and use of disallowed medications or treatments that may interfere with the evaluation of the study medication.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease of hypertension. The ICD-10 codes associated with this disease are ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']. The drugs being studied in this trial are placebo, valsartan, and fimasartan. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include subjects who have provided written informed consent, are aged between 20 and 75 years, have essential hypertension with specific blood pressure measurements, and are able to understand and cooperate throughout the trial. Exclusion criteria include patients with severe hypertension, orthostatic hypotension, secondary hypertension, certain blood pressure differences between arms, certain medical conditions, severe diabetes or heart disease, significant arrhythmias, certain cardiac and cerebrovascular conditions, certain diseases and infections, history of alcohol or drug abuse, allergies to angiotensin II antagonists, pregnancy or breastfeeding, recent medication use or participation in other trials, and certain abnormal laboratory test results. The final criterion states that the investigator has the discretion to judge if a subject is unsuitable for participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 3.\n- Diseases: The disease mentioned in this record is \"idiopathic restless legs syndrome.\"\n- ICD Codes: The ICD-10 codes associated with the disease are \"E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3.\"\n- Drugs: The drugs mentioned in this record are \"spm 962\" and \"placebo of spm 962.\"\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The criteria include factors such as diagnosis of RLS, previous treatment response, IRLS total score, symptom frequency, contraception, exclusion of certain diseases and conditions, cardiac health, ECG abnormalities, laboratory values, allergies, pregnancy/nursing, lifestyle factors, and other medical history.\n\nOverall, this sample provides information about a Phase 3 clinical trial for idiopathic restless legs syndrome, including the diseases, drugs, and eligibility criteria involved.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is phase 3, and the disease being studied is rheumatoid arthritis. The ICD-10 codes associated with this disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drugs being tested in this trial are fostamatinib and a placebo, which is also fostamatinib. \n\nThe eligibility criteria for participants in this trial include having a diagnosis of active rheumatoid arthritis after the age of 16, currently taking methotrexate, having 6 or more swollen joints and 6 or more tender/painful joints, and having either an Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or a C-Reactive Protein (CRP) blood result of 10mg/L or more. Additionally, participants must meet at least one of the following criteria: a documented history of positive rheumatoid factor, current presence of rheumatoid factor, radiographic erosion within 12 months prior to study enrollment, or presence of serum anti-cyclic citrullinated peptide antibodies.\n\nThere are also exclusion criteria for this trial, which include being pregnant or breastfeeding for females, having poorly controlled hypertension, having liver disease or significant liver function test abnormalities, having certain inflammatory conditions, connective tissue diseases, or chronic pain disorders, having recent or significant cardiovascular disease, having significant active or recent infection including tuberculosis, having previous failure to respond to a TNF alpha antagonist or anakinra, or having previous treatment with other biological agents. Other exclusion criteria include severe renal impairment and neutropenia.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"type 2 diabetes\". The corresponding ICD-10 codes for this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The trial involves the drugs \"saxagliptin\" and \"placebo\". The eligibility criteria for this trial include being diagnosed with type 2 diabetes, having a documented history of CrCl (creatinine clearance) less than 50 ml/min within the 3 months prior to enrollment, and having an HbA1c level between 7.0% and 11.0%. The exclusion criteria include having type 1 diabetes, a history of diabetic ketoacidosis or hyposmolar non-ketonic coma, and previous or current treatment with any DPP-IV inhibitor and/or GLP-1 mimetic.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease mentioned is pulmonary hypertension, and its corresponding ICDCodes are ['I27.0', 'I27.20', 'I27.21', 'I27.24', 'I27.29', 'P29.30', 'I27.22']. The drugs being tested are 'oral treprostinil (ut-15c) sustained release tablets' and 'placebo'. The eligibility criteria for this trial include age between 12 and 70, body weight of at least 45 kg, specific types of pulmonary arterial hypertension (PAH), a baseline 6-minute walk distance between 150 and 450 meters, currently receiving approved medications for PAH, previous testing consistent with the diagnosis of PAH, and being reliable and cooperative with the protocol requirements. The exclusion criteria include being nursing or pregnant, recent use of a prostacyclin, having PAH due to conditions not mentioned in the inclusion criteria, history of certain medical conditions, and recent use of an investigational drug.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. \n\nThe eligibility criteria for this trial include having histologically confirmed colorectal adenocarcinoma, metastatic or unresectable disease, and progression during or after first-line chemotherapy for metastatic disease. Other criteria include measurable disease, no prior or concurrent CNS metastasis, specific patient characteristics such as ECOG performance status, life expectancy, blood counts, liver function, kidney function, and absence of certain medical conditions. \n\nThe sample also includes information about prior concurrent therapy, such as the time since prior radiotherapy and surgery, restrictions on prior chemotherapy and investigational agents, and the absence of certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease being studied is chronic obstructive pulmonary disease (COPD), and the corresponding ICDCodes are 'J44.9', 'J44.1', and 'J44.0'. The drugs being tested in this trial are indacaterol, formoterol, placebo to indacaterol, and placebo to formoterol. \n\nThe eligibility criteria for this trial include being a male or female adult aged 40 years or older, having a diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2005, and meeting specific criteria such as a smoking history of at least 20 pack years, certain lung function measurements (FEV1 and FEV1/FVC), and not having certain exclusion criteria like recent hospitalization for a COPD exacerbation, respiratory tract infection, concomitant pulmonary disease, history of asthma, certain cardiovascular co-morbid conditions, lung cancer, or uncontrolled diabetes.\n\nAdditionally, the sample mentions that there are other protocol-defined inclusion/exclusion criteria applied to the study, but those are not specified in the provided information.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drugs being used in the trial are degarelix and goserelin acetate. The sample also includes the eligibility criteria for participants, including inclusion and exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 2/phase 3 and is focused on the disease \"glaucoma\". The ICD-10 codes associated with this disease are \"H40.9\", \"Q15.0\", \"B73.02\", \"H40.823\", \"H40.89\", \"H44.513\", and \"H40.821\". The drugs being studied in this trial are \"ranibizumab\" and \"mitomycin (mmc)\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being 18 years or older, requiring first-time glaucoma filtering surgery, being phakic or pseudophakic, and providing written informed consent. Exclusion criteria include being pregnant, lactating, or premenopausal without adequate contraception, having previous glaucoma surgery or other eye surgeries, having an abnormality preventing reliable applanation tonometry, having a current eye infection or inflammation, or being enrolled in another investigational study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is epilepsy. The icd-10 codes associated with epilepsy are ['G40.803', 'G40.804', 'G40.911', 'G40.919', 'G40.B11', 'G40.B19', 'G40.801']. The drugs being used in the trial are brivaracetam. The eligibility criteria for this trial include subjects aged 16 to 75 years with well-characterized focal epilepsy or epileptic syndrome, having at least 2 but not exceeding 40 partial onset seizures per 4 weeks during the 8-week Baseline Period, and being on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED \u2264 50% of the minimum recommended maintenance dose. There are also exclusion criteria, such as having seizure type IA non-motor as the only seizure type, a history or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding the trial, and other serious uncontrolled diseases.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the treatment of vomiting and nausea, specifically chemotherapy-induced nausea and vomiting. The diseases included in the trial are vomiting, nausea, and nausea and vomiting, chemotherapy-induced. The corresponding ICD-10 codes for these diseases are provided. The drugs being studied in the trial include casopitant (gw679769) oral tablets, casopitant (gw679769) intravenous, dexamethasone intravenous, ondansetron oral tablets, and placebo. \n\nThe eligibility criteria for participants in the trial are listed, including requirements such as understanding the study procedures and signing an informed consent form, being at least 18 years old, scheduled to receive a specific chemotherapy regimen, having a certain performance status, and meeting certain hematologic and metabolic criteria. Participants must also be willing and able to complete a daily diary during each study cycle. \n\nThere are also exclusion criteria, which include factors such as previous cytotoxic chemotherapy, pregnancy or lactation, recent radiation therapy, scheduled taxane therapy during the first cycle, recent emesis or clinically significant nausea, central nervous system malignancy, certain medical conditions, known hypersensitivity to certain medications, previous use of an NK-1 receptor antagonist, recent use of certain medications with antiemetic activity, and recent use of certain inhibitors or inducers of specific enzymes. \n\nAdditionally, there are specific cautionary notes regarding the use of certain medications and their potential interactions with the investigational product.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The disease being studied is smoking cessation. The corresponding ICD-10 codes for this disease are Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, and Y36.891A. The drugs being tested in this trial are placebo and varenicline. The eligibility criteria for participants are listed, including requirements such as having stable, documented cardiovascular disease and smoking more than 10 cigarettes per day. There are also exclusion criteria, such as unstable cardiovascular disease, recent cardiovascular events, and moderate or severe chronic obstructive pulmonary disease (COPD).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is ovarian cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are trabectedin, doxil, and dexamethasone. The eligibility criteria for this trial include requirements such as histologically proven epithelial ovarian cancer, prior treatment with only one platinum-based chemotherapy regimen, Eastern Cooperative Oncology Group status of not more than 2, and progression more than 6 months after the start of initial chemotherapy treatment. The exclusion criteria include factors such as treatment with more than one prior chemotherapy regimen, progression within 6 months after starting initial chemotherapy, prior exposure to anthracyclines, unwillingness or inability to have a central venous catheter, and known clinically relevant central nervous system metastasis.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on studying the effects of a drug called \"sativex\" compared to a placebo in patients with pain and peripheral neuropathy. The diseases included in the trial are pain and peripheral neuropathy, which are identified by their corresponding ICD-10 codes. The eligibility criteria for participants are listed, including requirements such as being 18 years or older, having been diagnosed with peripheral neuropathy for at least six months, experiencing pain that is not fully relieved by current therapy, and having specific underlying conditions that cause peripheral neuropathic pain. The criteria also mention the need for stable doses of regular pain medication and non-pharmacological therapies, as well as the agreement for primary care physicians and consultants to be notified of participation. The exclusion criteria are also listed, which include factors such as having other types of pain that may interfere with the assessment of peripheral neuropathic pain, using prohibited medications, having certain medical conditions or disorders, and having abnormal test results or physical exam findings that would prevent safe participation in the study.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the phase of the trial is phase 3. The disease being studied is type 1 diabetes. The corresponding ICD-10 codes for this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drug being tested is candesartan cilexetil. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must have been diagnosed with type 1 diabetes before the age of 36 and require continuous insulin treatment within 1 year of diagnosis.\n- The duration of diabetes should be between 1 and 15 years, and the patient should have had stable diabetic therapy within the last 6 months.\n- Patients must have an untreated resting mean sitting systolic blood pressure (SBP) below 130 mmHg, mean sitting diastolic blood pressure (DBP) below 85 mmHg, and a retinal photograph grading level of 10/10 on the ETDRS severity scale.\n\nThere are also exclusion criteria for this trial, which include:\n- Patients with cataract or media opacity that prevents taking gradable retinal photographs.\n- Patients with angle closure glaucoma that prevents pharmacological dilatation of the pupil.\n- Patients with a history of retinopathy or clinical significant macular edema (CSME).\n- Patients with a history or evidence of photocoagulation of the retina or other retinal conditions that may mask assessment, such as retinal vein occlusion.\n- Patients with a positive micral dipstick test or secondary diabetes.\n- Pregnant or lactating women or women of childbearing potential who are not practicing adequate contraception.\n- Patients who require treatment with an ACE-inhibitor.\n- Patients with haemodynamically significant aortic or mitral valve stenosis, known renal artery stenosis, or kidney transplantation.\n- Patients with hypersensitivity to the study drug.\n- Patients with severe concomitant diseases that may interfere with the assessment of the patient, such as malignancy, as judged by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3. The disease being studied is \"chronic hepatitis b virus, pediatric.\" The ICDCodes associated with this disease are ['B00.81', 'B25.1', 'B26.81', 'B58.1', 'K75.4', 'A51.45', 'B17.2']. The drugs being used in the trial are 'entecavir' and 'placebo'. The eligibility criteria for this trial include specific age requirements (2 to <18 years), being positive for hepatitis B surface antigen, having detectable hepatitis B e (HBe) antigen and no detectable anti-HBe antibodies, specific levels of alanine aminotransferase (ALT) at screening, evidence of the presence of hepatitis B virus DNA, and exclusion criteria such as prior therapy with entecavir, previous nucleoside or nucleotide antiviral agent therapy, recent therapy with interferon alpha, thymosin alpha, or nucleotide antiviral agents, coinfection with HIV, hepatitis C virus, or hepatitis D virus, decompensated liver disease, liver transplant recipients, other conditions causing increased ALT levels, and children breastfed while their mothers received lamivudine or whose mothers received lamivudine during pregnancy.",
    "The sample provided is for a phase 3 clinical trial. The trial focuses on the disease of schizophrenia, which is indicated in the \"diseases\" field. The corresponding ICD-10 codes for schizophrenia are listed in the \"icdcodes\" field. The drugs being studied in this trial are ziprasidone and risperidone, as mentioned in the \"drugs\" field. The eligibility criteria for participants are also provided, including inclusion criteria such as a diagnosis of schizophrenia and a CGI-S score of 4 or less at baseline. Exclusion criteria include concurrent antipsychotic treatment, recent use of antidepressants or mood stabilizers, and an acute exacerbation of schizophrenia within 3 months of baseline.",
    "The sample from the table represents a clinical trial for the treatment of metastatic colorectal cancer. The trial is in phase 2/phase 3, indicating that it is in an advanced stage of testing. The diseases column specifies the disease being targeted, which in this case is metastatic colorectal cancer. The icdcodes column provides the ICD-10 codes associated with the disease. The drugs column lists the names of the drugs being used in the trial, which are mitomycin c, capecitabine, and bevacizumab. The criteria column outlines the eligibility criteria for participants in the trial. The inclusion criteria include having a histological diagnosis of colorectal cancer, having metastatic disease that is not resectable, being over 18 years old, and meeting certain performance status and laboratory test requirements. The exclusion criteria include having certain medical or psychiatric conditions, having physical integrity issues with the upper gastrointestinal tract, and having uncontrolled hypertension or bleeding disorders, among others.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the disease asthma. The associated ICD-10 codes for asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The trial involves testing multiple drugs, including 'fluticasone furoate/vilanterol inhalation powder', 'fluticasone furoate inhalation powder', and 'fluticasone propionate inhalation powder'. The eligibility criteria for participants are listed, including age, gender, lung function measurements, and current asthma therapy. There are also exclusion criteria, such as a history of life-threatening asthma, recent asthma exacerbation, and allergies to the study drugs. Additionally, participants should not be taking any other investigational medication or prohibited medication during the study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 3, and the disease mentioned is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs mentioned in the sample are Exenatide and Placebo. The eligibility criteria for this trial include specific requirements for participants, such as being treated with a stable dose of certain medications, having a specific HbA1c range, and having a specific BMI range. There are also exclusion criteria listed, which include previous participation in similar studies, recent participation in other medical studies, contraindications for certain medications, recent use of weight loss drugs, and recent use of exogenous insulin.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is Parkinson's disease. The corresponding ICD-10 code for Parkinson's disease is G20. The drug being tested in the trial is rotigotine. The eligibility criteria for inclusion in the trial are having early and advanced idiopathic Parkinson's disease with early morning motor impairment. The exclusion criteria are having atypical Parkinsonian syndromes.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 3. The diseases listed are \"ds stage i plasma cell myeloma,\" \"ds stage ii plasma cell myeloma,\" \"ds stage iii plasma cell myeloma,\" \"refractory plasma cell myeloma,\" and \"smoldering plasma cell myeloma.\" The ICDCodes associated with these diseases are \"D46.4,\" \"D46.1,\" \"D46.A,\" \"D46.0,\" \"D46.20,\" \"D46.21,\" and \"D46.22.\" The drugs mentioned are \"lenalidomide\" and \"melphalan.\" The eligibility criteria include various conditions such as having active multiple myeloma, no more than 12 months of prior therapy, specific performance status, lung function, and cardiac function requirements, among others. Additionally, there are criteria related to pregnancy and contraception for women of childbearing potential.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is schizophrenia. The corresponding ICD-10 codes for schizophrenia are F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, and F20.9. The drug being tested is Seroquel (quetiapine). \n\nThe inclusion criteria for the trial are stable schizophrenic patients who have provided written informed consent and are between the ages of 18 and 65. These patients should also remain clinically stable after switching to a stable dose of Seroquel.\n\nThe exclusion criteria for the trial include patients with a risk of suicide, other disorders, or substance abuse that might interfere with their ability to cooperate. Patients with expected non-compliance to treatment, known diabetes mellitus, contraindications, intolerance or non-responsiveness to Seroquel, or other safety issues are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease mentioned is \"pulmonary disease, chronic obstructive\" and its corresponding ICDCodes are \"J44.9\", \"J44.1\", and \"J44.0\". The drugs involved in the trial are \"olodaterol (bi1744) low\", \"placebo (for olodaterol bi1744)\", \"placebo (for tiotropium)\", \"olodaterol (bi1744) high\", and \"tiotropium 18 mcg\". \n\nThe eligibility criteria for this trial are as follows:\nInclusion criteria:\n- Patients willing to participate with a confirmed diagnosis of COPD\n- 40 years of age or older\n- Having a 10 pack year smoking history\n- Able to perform serial pulmonary function tests\n- Able to use both a Dry powder inhaler (DPI) and Respimat device\n\nExclusion criteria:\n- Significant other disease\n- Clinically relevant abnormal hematology, chemistry, or urinalysis\n- History of asthma\n- Diagnosis of thyrotoxicosis\n- Paroxysmal tachycardia related to beta agonists\n- History of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year\n- Active tuberculosis, cystic fibrosis, clinically evident bronchiectasis\n- Significant alcohol or drug abuse\n- Pulmonary resection\n- Taking oral beta adrenergics\n- Taking unstable oral steroids\n- Daytime oxygen\n- Enrolled in a rehabilitation program\n- Enrolled in another study or taking investigational products\n- Pregnant or nursing women, women of childbearing potential not willing to use two methods of birth control\n- Those who are not willing to comply with pulmonary medication washouts",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is insomnia. The ICDCodes associated with insomnia are \"F51.01\", \"F51.02\", \"F51.03\", \"F51.04\", \"G47.00\", \"G47.09\", and \"A81.83\". The drugs being tested are suvorexant and a dose-matched placebo to suvorexant. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must have a diagnosis of primary insomnia.\n- The participant should be able to read, understand, and complete questionnaires and diaries.\n- If the participant is female, both the participant and her partner must agree to use acceptable contraception. If the male partner does not use effective contraception, the female participant must use two acceptable forms of contraception.\n- If the participant is 65 years or older, they must score 25 or higher on the Mini Mental State Examination (MMSE).\n\nExclusion Criteria:\n- If the participant is female, she must not be pregnant.\n- The participant should not expect to donate eggs or sperm during the study.\n- The participant should not have a recent or active history of a confounding neurological disorder.\n- The participant should not have a history of clinically unstable cardiovascular disorder within the last 6 months.\n- The participant should not have a lifetime history of bipolar disorder.\n- The participant should not have a psychiatric condition that requires treatment with a prohibited medication or any other psychiatric condition that would interfere with their ability to participate in the study.\n- The participant should not have a history of substance abuse/dependence.\n- The participant should not have a history of cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.\n- The participant should not show evidence of suicidality based on a score of 2 on the Quick Inventory of Depressive Symptomatology Self-Report 16-Item (QIDS-SR16) suicide item #12.\n- The participant should not have traveled across more than 3 time zones or experienced a time difference of more than 3 hours in the last 2 weeks.\n- The participant should not have a history of permanent night shift work or rotating day/night shift work in the past 2 weeks.\n- The participant's Body Mass Index (BMI) should not be greater than 40 kg/m^2.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and is focused on breast cancer. The ICD-10 codes associated with the disease are provided. The trial involves the use of drugs such as docetaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide. The eligibility criteria for participants are also listed, including requirements for histologically proven breast cancer and specific surgical treatments. There are also exclusion criteria, such as prior systemic anticancer therapy or prior use of certain drugs.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease \"dermatitis, atopic.\" The ICD-10 codes associated with this disease are \"L20.89\" and \"L20.9.\" The drugs being studied in this trial are \"placebo\" and \"levocetirizine.\" The eligibility criteria for participants are listed, including age requirements, duration of symptoms, severity scoring, and family history of atopy. The sample also includes exclusion criteria, such as specific medical conditions, medication usage, and previous treatments.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial in this sample is in phase 3 and focuses on the disease melanoma. The ICD-10 codes associated with this disease are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being studied in this trial are temozolomide and dacarbazine. The eligibility criteria for participants are listed, including requirements such as having stage IV melanoma, being 18 years or older, having a specific performance status, meeting certain laboratory values, being able to take oral medication, and being disease-free from cancer for a period of 5 years. Other criteria include practicing contraception, providing informed consent, having recovered from major surgery or adjuvant treatment, and not having clinically uncontrolled infectious diseases or certain conditions like ocular melanomas, brain metastases, prior cytokine or chemotherapy for stage IV disease, or being pregnant or nursing.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is attention deficit hyperactivity disorder (ADHD). The icd-10 codes associated with ADHD are F90.2, F90.8, F90.9, F90.0, and F90.1. The drugs being tested in this trial are atomoxetine hydrochloride and placebo. The eligibility criteria for participants include being at least 6 years old but not yet 16, meeting the diagnostic criteria for ADHD according to the DSM-IV-TR, having specific scores on assessment scales, and having a newly diagnosed case of ADHD within the past 3 months. There are also exclusion criteria, such as having a history of ADHD diagnosis longer than 3 months prior to the trial and weighing less than 20 kg at the start of the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on studying the effects of the drugs irbesartan and placebo on patients with atrial fibrillation and cardiovascular disease. The diseases are represented by their names and corresponding ICD-10 codes. The eligibility criteria for the trial are listed, including requirements for blood pressure, previous medication usage, and indications for angiotensin receptor blocking agents. The exclusion criteria are also provided, which include factors such as the need for certain medications, medical conditions, psychosocial reasons, and pregnancy.",
    "The sample provided is for a phase 3 clinical trial. The trial focuses on the disease \"acute coronary syndromes\" and the corresponding ICD-10 code is \"I24.0\". The drugs being studied are \"placebo\" and \"prasugrel\". The eligibility criteria for inclusion in the trial include having non-ST-segment elevation acute coronary syndrome with elevated troponin, being scheduled for coronary angiography/PCI within a specific time frame, being eligible for treatment with prasugrel, aspirin, and a glycoprotein IIb/IIIa receptor inhibitor, and being enrolled at a cardiac catheterization laboratory hospital or affiliated hospital/ambulance service. The exclusion criteria include having ST-segment elevation myocardial infarction, cardiogenic shock, refractory ventricular arrhythmias, New York Heart Association Class IV congestive heart failure, or having had a cardiac arrest within 1 week prior to entry or randomization into the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 3 trial and includes various details such as the diseases being studied, the corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 3. The diseases being studied include \"adenocarcinoma of the pancreas,\" \"advanced solid tumors,\" \"cancer,\" and others. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drugs being tested in this trial are \"amg 479\" and \"gemcitabine,\" with \"placebo\" also mentioned. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having untreated metastatic adenocarcinoma of the pancreas, adequate hematologic, renal, and liver function, and an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. Exclusion criteria include prior chemotherapy or radiotherapy for pancreatic cancer, central nervous system metastases, and external biliary drain.\n\nOverall, this sample provides a snapshot of a phase 3 clinical trial focusing on various diseases, using specific drugs, and outlining the eligibility criteria for potential participants.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and focuses on the disease called familial hypercholesterolemia. The corresponding ICD-10 codes for this disease are \"E78.01\" and \"Z83.42\". The drugs being studied in this trial are rosuvastatin and a placebo. The eligibility criteria for participants include being male or female aged 10-17 years with heterozygous familial hypercholesterolemia. There are also exclusion criteria, such as having certain medical conditions or lab test results, a history of adverse reactions to rosuvastatin or other statin drugs, and the use of specific disallowed medications.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied in this trial is insomnia. The corresponding ICD-10 codes for insomnia are F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, and A81.83. The drugs being tested in this trial are esmirtazapine and placebo. The eligibility criteria for participants in this trial are listed under inclusion and exclusion criteria. Inclusion criteria include having a documented diagnosis of chronic primary insomnia. Exclusion criteria include having other sleep disorders, significant medical or psychiatric illnesses causing the sleep disorder, diagnosed major depressive disorder, substance abuse within the past year, being a night worker or working on rotating shifts, having had a serious head injury, stroke, epilepsy, having a history of bipolar disorder or family history of suicide, smoking more than 15 cigarettes per day and unable to abstain from smoking during the night or in the sleep laboratory, and consuming beverages containing more than 500 mg of caffeine per day.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3, focusing on the disease schizophrenia. The associated ICD-10 codes for schizophrenia are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are 'sm-13496 (lurasidone hcl)', 'placebo', and 'risperidone'. The record also includes the eligibility criteria for participants. The main inclusion criteria include meeting DSM-IV criteria for schizophrenia, being between 18 and 75 years old, and providing written informed consent. The main exclusion criteria include a history of neuroleptic malignant syndrome, water intoxication, paralytic ileus, Parkinson's disease, or any history or complication of malignancy.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The disease being studied is Type 2 diabetes mellitus. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are ta-7284 low, ta-7284 high, and placebo. The eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Men or women age \u226520 years old\n- Diagnosed with Type 2 diabetes mellitus at least 3 months before the run-in period\n- HbA1c of \u22657.0% and \u226410.0%\n\nExclusion Criteria:\n- Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus\n- Past or current history of severe diabetic complications\n- Fasting plasma glucose > 270 mg/dL before treatment start\n- History of hereditary glucose-galactose malabsorption or primary renal glucosuria\n- Patients requiring insulin therapy",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is schizophrenia. The ICDCodes associated with schizophrenia are listed as \"F20.0\", \"F20.1\", \"F20.2\", \"F20.3\", \"F20.5\", \"F20.89\", and \"F20.9\". The drugs being used in the trial are paliperidone er tablets, quetiapine tablets, and a placebo, all of which are encapsulated. The eligibility criteria for inclusion in the trial include having a DSM-IV diagnosis of schizophrenia (paranoid, disorganized, or undifferentiated type), scoring at least 4 on two selected PANSS items and a total score of at least 17 on these five items, scoring at least 5 on the CGI-S (clinical global impression - severity), having a body weight of at least 60kg, and being willing to be hospitalized for 9 days initially. The exclusion criteria include having a primary active mental illness diagnosis other than schizophrenia, having psychotic symptoms that can be explained by substance intake or medical illness, being pregnant, breastfeeding, or planning to become pregnant, having a history of treatment resistance, and having unstable or significant medical illness that would increase the risk of taking study medication or confuse the interpretation of the study.",
    "The sample provided is for a phase 3 clinical trial. The trial focuses on patients who are undergoing their first kidney transplant. The specific disease being studied is kidney transplant, and the corresponding ICD-10 codes associated with this disease are T86.11, T86.12, T86.13, Z94.0, T86.10, T86.19, and Z48.22. The drug being investigated in this trial is sirolimus. \n\nThe eligibility criteria for inclusion in the trial are as follows: \n- The patient must be a dialysis patient who will be receiving their first kidney transplant.\n- The patient's weight must be over 88 pounds (lbs.).\n\nThe exclusion criteria for the trial are as follows:\n- Patients with very high cholesterol levels are not eligible.\n- Patients who are obese are not eligible.\n- If the organ donor is living, they must be under 65 years of age. If the organ donor is cadaveric, they must be under 60 years of age.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the treatment of attention deficit hyperactivity disorder (ADHD). The associated ICD-10 codes for ADHD are ['F90.2', 'F90.8', 'F90.9', 'F90.0', 'F90.1']. The drugs being studied are oros methylphenidate hcl, Ritalin, and a placebo. \n\nThe eligibility criteria for participants in this trial include having completed a previous screening protocol, taking a specific dosage of methylphenidate (Ritalin) in the past, agreeing to only use the study drug during the treatment phase, being able to attend study visits, and having normal urinalysis, hematological, and blood chemistry values. \n\nExclusion criteria include having gastrointestinal problems, glaucoma, a seizure disorder, a psychotic disorder, clinical depression, or Tourette's syndrome. Participants with known allergies to methylphenidate or experiencing significant adverse effects from it are also excluded. Additionally, participants with high blood pressure measurements or females who have started menstruation are excluded from the trial.",
    "The sample is a phase 3 trial for asthma. The diseases column contains the name of the disease, which in this case is 'asthma'. The icdcodes column contains a list of icd-10 codes associated with the disease. The drugs column contains a list of drug names, including 'fluticasone furoate/ vilanterol 200/25 mcg', 'fluticasone furoate/ vilanterol 100/25 mcg', and 'fluticasone furoate 100 mcg'. The criteria column contains the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria include factors such as age, diagnosis of asthma, and lung function measurements. The exclusion criteria include factors such as history of life-threatening asthma, recent asthma exacerbations, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on the treatment of type 2 diabetes mellitus and cardiovascular disease with the drug dapagliflozin. The trial also includes a placebo group. The eligibility criteria for this trial include having type 2 diabetes mellitus, cardiovascular disease, and uninterrupted anti-diabetic treatment for at least 8 weeks prior to enrollment. Patients with type 1 diabetes or diabetes insipidus, those with poorly controlled diabetes or taking multiple oral anti-hyperglycemic drugs, and those with any clinically significant illness that could compromise their safety or participation are excluded from the trial.",
    "The sample is a phase 3 trial for the treatment of type 2 diabetes. The trial is testing the effectiveness of the drug liraglutide compared to a placebo. The inclusion criteria for participants include being between the ages of 30 and 75, having a diagnosis of type 2 diabetes for up to 7 years, and not having anti-GAD antibodies. Participants should also be on 0-2 oral anti-diabetic medications and have an A1c level between 5.5% and 9.0% if on oral medications, or between 6.0% and 10.0% if not on oral medications. \n\nExclusion criteria include the use of insulin, GLP-1 agonist, or DPP-4 inhibitor, having type 1 diabetes or secondary forms of diabetes, having a major illness with a life expectancy of less than 5 years, being involved in another study requiring drug therapy, having hypersensitivity to insulin, liraglutide, or metformin, having renal or hepatic dysfunction, having a history of pancreatitis, having a family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma, having a personal history of non-familial medullary thyroid carcinoma, having a malignant neoplasm requiring chemotherapy, surgery, radiation, or palliative therapy within the previous 5 years (except for basal cell skin cancer), excessive alcohol consumption, unwillingness to undergo multiple daily insulin injection therapy, unwillingness to perform capillary blood glucose monitoring at least 4 times per day during intensive insulin therapy, having congestive heart failure, or being pregnant.",
    "The sample provided is a phase 3 trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drug linagliptin compared to a placebo. The inclusion criteria for the trial include patients who are currently being treated with a stable dose of metformin and a sulphonylurea drug, have a glycosylated haemoglobin A1c (HbA1c) level between 7.0 and 10.0%, are between the ages of 18 and 80, and have a body mass index (BMI) of 40 kg/m2 or less. Patients must also provide written informed consent. The exclusion criteria include recent myocardial infarction, stroke, or transient ischaemic attack (TIA), impaired hepatic function, renal failure or impairment, recent treatment with certain medications, current treatment with systemic steroids or a change in thyroid hormone dosage, pre-menopausal women who are pregnant or not practicing an acceptable method of birth control, known hypersensitivity or allergy to the investigational product or its excipients, dehydration, and current acute or chronic metabolic acidosis.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is mentioned as \"phase 2/phase 3\". The disease being studied is \"HIV infections\" and its corresponding ICD-10 code is \"Z21\". The drug being tested is \"tipranavir\". The eligibility criteria for this trial are listed under \"INCLUSION CRITERIA\" and \"EXCLUSION CRITERIA\". The inclusion criteria include factors such as the ability and willingness to provide informed consent, completion of a previous tipranavir/ritonavir trial, and adherence to previous dosing protocols. The exclusion criteria include factors such as pregnancy, substance abuse, medical conditions that may interfere with participation, and allergies or illnesses that may pose additional risks.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The diseases being studied are peripheral neuropathy and HIV infections. The corresponding ICD-10 codes for these diseases are G90.09 and Z21, respectively. The drug being tested is pregabalin. The sample also includes eligibility criteria for the trial. The inclusion criteria state that participants must have met the entry criteria for a previous double-blind trial and completed that trial through visit 7. The exclusion criteria include experiencing a serious adverse event during the previous trial that was considered related to the study medication, being non-compliant during the previous trial, and having a clinically significant or unstable medical condition that would compromise participation in the study.",
    "The sample from the table is for a phase 3 trial. The diseases being studied are menorrhagia and heavy menstrual bleeding. The corresponding ICD-10 codes for these diseases are 'G43.831', 'G43.839', 'G43.821', 'G43.829', 'N94.9', and 'N94.89'. The drug being tested is tranexamic acid tablets (xp12b). The eligibility criteria for inclusion in the trial are being a woman with menorrhagia, being between 18-49 years of age, and having regularly occurring menstrual periods. The exclusion criteria include having a history or presence of clinically significant disease or abnormalities that might confound the study, and having a history of bilateral oophorectomy or hysterectomy.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is bipolar disorder. The ICD-10 codes associated with bipolar disorder are F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, and F31.32. The drugs being tested in the trial are placebo and ziprasidone. The eligibility criteria for the trial include having a primary diagnosis of Bipolar I Disorder, a Young Mania Rating Scale score of 18 or higher, and actively receiving lithium or divalproex for bipolar disorder. The exclusion criteria include having a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder not otherwise specified. Additionally, individuals with other Axis I or Axis II disorders are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6-month period prior to screening.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on cardiovascular diseases. The diseases included in the trial are cardiovascular diseases, heart diseases, cerebrovascular accident, coronary disease, atherosclerosis, and myocardial infarction. The corresponding ICD-10 codes for these diseases are also provided. The trial involves the use of two drugs, extended-release niacin and simvastatin. The eligibility criteria for participants include being aged 45 or older with established vascular disease and atherogenic dyslipidemia. Established vascular disease is defined as documented coronary artery disease, cerebrovascular or carotid disease, or symptomatic peripheral arterial disease. Atherogenic dyslipidemia is defined by specific levels of LDL-C, HDL-C, and TG. There are also specific criteria for patients already on a statin. The exclusion criteria include recent coronary artery bypass graft surgery, recent percutaneous coronary intervention, recent hospitalization for acute coronary syndrome, high fasting glucose or hemoglobin A1C levels, refusal to use a glucometer for blood glucose monitoring, and concomitant use of certain drugs that may increase the risk of hepatotoxicity or myopathy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease mentioned is gastroesophageal reflux disease. The ICDCodes associated with this disease are K21.9, K21.00, and K21.01. The drugs being used in the trial include rabeprazole 20mg, placebo dinner and bedtime; rabeprazole 20 mg two times, placebo at bedtime; and rabeprazole 20mg, placebo dinner, low dose tricyclic antidepressant. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must currently be treated with a PPI (Proton Pump Inhibitor) but still experience GERD symptoms (such as heartburn) at least 2 times per week.\n\nExclusion Criteria:\n- The participant must not have a known allergy or intolerance to TCA (Tricyclic Antidepressant).\n- The participant must not have a history of serious arrhythmia or use of anti-arrhythmics.\n- The participant must not have a history of seizures.\n- The participant must not have significant co-morbidities in various body systems.\n- The participant must not have evidence or history of drug abuse within the past 6 months.\n- The participant must not have certain conditions like erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus, or adenocarcinoma of the esophagus.\n- The participant must not have a history of esophagogastric surgery.\n- The participant must not have gastric or duodenal lesions (ulcer, tumor, etc.).\n- Women who are pregnant or of childbearing age and not on contraception are not eligible.\n- Patients who are unwilling or unable to provide informed consent are not eligible.\n- Patients with insulin-dependent diabetes are not eligible.",
    "The sample is a phase 3 trial for colorectal cancer. The trial is looking for patients who have histologically confirmed adenocarcinoma of the rectum within 15 cm of the anal verge and locally advanced disease. The patients must have undergone complete resection of the primary tumor within the past 12 weeks, with specific criteria for the histology, circumferential resection margin, and absence of residual disease. They must have also received neoadjuvant fluoropyrimidine-based chemoradiotherapy with a planned total radiation dose of at least 45 Gy, using one of the specified treatment methods.\n\nThe patient characteristics include a WHO performance status of 0-1, specific blood count requirements, adequate kidney function, and normal levels of bilirubin, AST, and ALT. The patients must not be pregnant or nursing, and fertile patients must use effective contraception during and after the study treatment. They must not have a known dihydropyrimidine dehydrogenase deficiency, hypersensitivity to platinum compounds, or preexisting peripheral neuropathy. They must also not have any physical integrity issues with the upper gastrointestinal tract or malabsorption syndrome. Additionally, they must not have any other serious uncontrolled medical conditions or concurrent illnesses that would compromise life expectancy or study compliance.\n\nPrior to the trial, the patients must not have received chemotherapy exceeding 6 weeks in duration, except for neoadjuvant treatment which may last up to 11-12 weeks. They must not have received prior oxaliplatin, but prior mitomycin C, irinotecan hydrochloride, or cetuximab is allowed. Concurrent use of warfarin, antiviral agents, or phenytoin is not allowed.",
    "The sample is a phase 3 trial for the treatment of lymphoma. The disease being targeted is previously untreated follicular stage III or IV non-Hodgkin's lymphoma with at least one measurable mass. The trial is open to patients aged 18 to 65 with a WHO performance status of 0-2 and a life expectancy that is not specified. The eligibility criteria include specific requirements for hematopoietic, hepatic, renal, cardiovascular, neurologic, and pulmonary health. Patients must not be pregnant, have prior malignancies (except nonmelanoma skin cancer or carcinoma in situ of the cervix), be HIV positive, or have psychiatric or metabolic diseases. The trial does not allow concurrent use of immunotherapeutic drugs, chemotherapy, or radiotherapy. The drugs being tested in this trial are cyclophosphamide, prednisone, and vincristine sulfate.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is type 2 diabetes mellitus. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are rimonabant (sr141716) and a placebo. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Patients must be male or female and at least 18 years old.\n- Patients must have a diagnosis of type 2 diabetes according to WHO criteria.\n- Patients must have been treated with insulin for at least 3 months, with a minimum insulin dose of 30 U/day for at least 4 weeks.\n- Patients must have an HbA1C level of 7% or higher.\n- Patients must have signed the informed consent form.\n\nThe exclusion criteria for the trial are as follows:\n- Patients who have lost more than 5 kg of weight within the 3 months prior to the screening visit.\n- Patients who are pregnant or lactating.\n- Female patients of childbearing potential who do not have medically approved contraceptive methods.\n- Patients who have taken other investigational drugs within 30 days prior to the screening visit.\n- Patients who have previously participated in a Rimonabant study.\n- Patients who have a history of allergic reaction or intolerance to multiple drugs.\n\nThere are additional exclusion criteria related to endocrine and metabolic disorders, other disorders, laboratory findings, and previous or concomitant medications. These criteria are listed in the provided sample.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease \"dermatitis, atopic\". The corresponding ICD-10 codes for this disease are \"L20.89\" and \"L20.9\". The trial involves the use of two drugs, namely \"fluticasone, cream\" and \"placebo\". The eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Children between the ages of 2 and 10 years with a mild or moderate acute flare of atopic dermatitis (AD) and no prior treatment for this episode of AD.\n- Written informed consent from the parents of the patients.\n\nExclusion Criteria:\n- Patients with more than 30% of their body surface area affected by AD.\n- Patients with AD on the head.\n- Patients with allergies to fluticasone or the vehicle used in the trial.\n- Patients with any medical condition for which topical corticosteroids are contraindicated.\n- Patients with other dermatological conditions that may interfere with the accurate assessment of AD.\n- Patients receiving any concomitant medications that might affect the outcome of the study.\n- Patients with any other medical history that could interfere with the evaluation of the study treatment.",
    "The sample from the table represents a clinical trial in phase 3. The trial is focused on treating patients with certain diseases, including mediastinal cancer, metastatic cancer, and testicular germ cell tumor. The diseases are identified by their corresponding ICD-10 codes. The trial involves the administration of drugs such as cisplatin, etoposide, and ifosfamide. The eligibility criteria for participants include having histologically proven germ cell cancer, being within the age range of 16 to 50, being male, and having a performance status of WHO 0-3. Other criteria include specific laboratory values, absence of certain medical conditions, and no prior chemotherapy. Concurrent radiotherapy and surgery for brain metastases are allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is Type 2 Diabetes. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drug being tested in this trial is vildagliptin. \n\nThe eligibility criteria for this trial are as follows:\n- Patients with Type 2 Diabetes who have not achieved adequate control with diet, exercise, and previous medications such as metformin, thiazolidinedione, \u03b1-GI, or glinides monotherapy.\n- The age of the patients should be 20 years or older.\n- The HbA1c level should be between 6.5% and 10%.\n\nThe exclusion criteria for this trial are:\n- Patients with Type 1 Diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes.\n- Patients with significant heart diseases.\n- Patients with significant diabetic complications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is allergic rhinoconjunctivitis. The ICDCodes associated with this disease are D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, and H10.45. The drugs being tested in this trial are depiquick birch (dpg103) and placebo. The eligibility criteria for this trial include specific requirements for inclusion and exclusion. Inclusion criteria include experiencing significant allergic symptoms, having a medical history of allergic rhinitis and/or rhinoconjunctivitis with sensitization to tree allergens, and having specific IgE against birch allergens (CAP RAST \u2265 2). Exclusion criteria include a history of significant clinical manifestations of allergy due to sensitization against grass or weed pollen and perennial allergens, FEV1 or PEF value \u2264 80%, and persistent asthma (GINA \u2265 2). It is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The diseases being studied are anxiety, anxiety disorders, anxiety neuroses, and anxiety states. The corresponding ICDCodes for these diseases are F41.1, F41.9, F40.8, F40.9, F41.3, F41.8, and F43.22. The drugs being tested in this trial are placebo and quetiapine fumarate xr. The eligibility criteria for participants include providing informed consent, having a documented diagnosis of Generalized Anxiety Disorder, not being pregnant (for female patients) and being willing to use a reliable method of birth control, and being able to understand and comply with study requirements. The exclusion criteria include having other psychiatric disorders that could affect the study results, moderate to severe depression, other clinically relevant diseases, and taking certain medications as determined by the study doctor.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is goserelin. The eligibility criteria for participants in this trial are listed, including age restrictions, specific requirements related to the breast cancer diagnosis, hormone-receptor status, premenopausal status, and previous chemotherapy treatment. Other criteria include performance score, consent for preservation of ovarian function, and willingness to use barrier contraception. The exclusion criteria are also listed, which include pregnancy, hypersensitivity to a specific drug, previous chemotherapy treatment, advanced stage breast cancer, abnormal prothrombin and partial prothrombin time, and low platelet count.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The disease being studied is insomnia, and its corresponding ICD-10 codes are F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, and A81.83. The drugs being tested in this trial are 20 mg vec-162, 50 mg vec-162, 100 mg vec-162, and a placebo. The eligibility criteria for participants in this trial include being healthy with no medical, psychiatric, or current sleep disorders, and signing a written consent form. The exclusion criteria include having a recent history of night shift work or jet lag, prior experience sleeping in a sleep lab environment, and a history of sleep disorders.",
    "The sample from the table represents a phase 3 clinical trial for the treatment of metastatic castration-resistant prostate cancer. The trial is investigating the effectiveness of different drugs in treating this disease. The eligibility criteria for participants include having experienced disease progression after one or two prior cytotoxic chemotherapies, with at least one containing docetaxel. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or lower, undergoing medical or surgical castration, and having adequate bone marrow, hepatic, and renal function. Participants must also have a potassium level of at least 3.5 mmol/L, be able to swallow the study drug whole as a tablet, and provide informed consent. Exclusion criteria include having undergone more than two prior cytotoxic chemotherapy regimens, previous use of ketoconazole or abiraterone acetate, uncontrolled hypertension, active or symptomatic viral hepatitis or chronic liver disease, history of pituitary or adrenal dysfunction, clinically significant heart disease, presence of other malignancies, known brain metastasis, gastrointestinal disorder affecting absorption, and unwillingness to use contraception.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the disease \"hypercholesterolemia\". The corresponding ICD-10 codes for this disease are \"E78.01\", \"E78.00\", and \"Z83.42\". The drugs being studied in this trial are \"ezetimibe and atorvastatin\", \"atorvastatin\", and \"placebo (unspecified)\". \n\nThe eligibility criteria for this trial are as follows:\n- The patient must be 65 years of age or older.\n- The patient must be willing to maintain a cholesterol-lowering diet.\n- The patient must have hyperlipidemia with LDL levels greater than 70 mg/dl or 100 mg/dl, depending on their CHD risk category.\n\nThe exclusion criteria for this trial are as follows:\n- The patient must not have any condition that, in the opinion of the investigator, would pose a risk or interfere with participation in the study.\n- The patient must be likely to comply with taking the study medication.\n- The patient must not have any chronic or unstable medical condition.\n- The patient must not be taking unstable doses of medication.\n- The patient must not consume more than 2 alcoholic drinks per day.\n- The patient must not have elevations in certain laboratory values (CK, AST, ALT).",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The disease being studied is primary insomnia, and its corresponding ICD-10 code is F51.01. The drugs being tested in this trial are almorexant, almorexant, placebo, and zolpidem. The eligibility criteria for participants in this trial include being an adult between the ages of 18 and 64 with a diagnosis of primary insomnia. Exclusion criteria include having a history of any sleep disorder or any other mental disorder, sleep apnea, restless legs syndrome, excessive daytime napping, recent substance abuse, and unwillingness to refrain from certain medications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 2/phase 3.\n- Diseases: The trial is focused on hepatocellular carcinoma.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8'].\n- Drugs: The drugs being tested in the trial are menatetrenone and placebo.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe \"Inclusion Criteria\" include factors such as age, performance status, diagnosis of hepatocellular carcinoma, number of previous onsets or recurrences, previous therapies, liver function, and consent for study participation.\n\nThe \"Exclusion Criteria\" include factors such as extrahepatic metastasis, portal invasion, previous treatments for hepatocellular carcinoma, hepatitis, systemic conditions, drug administration, and other factors like pregnancy, participation in other clinical studies, and eligibility judgment by the investigator.\n\nOverall, this sample record provides specific information about the phase, diseases, ICD codes, drugs, and eligibility criteria for a clinical trial focused on hepatocellular carcinoma.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3, and the disease being studied is plaque psoriasis. The icd-10 codes associated with this disease are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being used in the trial are apremilast and placebo. \n\nThe eligibility criteria for this trial include being at least 18 years old, having a diagnosis of chronic plaque psoriasis for at least 12 months, having moderate to severe plaque psoriasis, meeting all laboratory criteria, and having a negative pregnancy test for females of childbearing potential. Male subjects must also use barrier contraception. \n\nThe exclusion criteria include having any other clinically significant or uncontrolled disease, being pregnant or breastfeeding, having an allergy to any component of the study drug, testing positive for hepatitis B surface antigen or anti-hepatitis C antibody, having active tuberculosis or a history of incompletely treated tuberculosis, having clinically significant abnormalities on 12-Lead ECG or chest x-ray, having positive HIV or immunodeficiency, having active substance abuse or a history of substance abuse within 6 months, having recent bacterial, viral, or fungal infections, having a history of malignancy (except for certain treated skin carcinomas and cervical intraepithelial neoplasia), experiencing a psoriasis flare or rebound within 4 weeks prior to screening, having skin conditions that would interfere with clinical assessments, using topical or systemic therapy for psoriasis within specific timeframes, using certain medications within specific timeframes, using any investigational drug within 4 weeks prior to randomization, having prolonged sun exposure or using tanning booths or UV light sources, and having prior treatment with apremilast.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 3. The diseases being studied are pain, nausea, and vomiting. The corresponding ICDCodes for these diseases are ['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52'] for pain, ['R11.0', 'R11.11', 'R11.2'] for nausea, and ['R11.10', 'R11.12', 'R11.14', 'R11.11', 'K91.0', 'O21.2', 'O21.8'] for vomiting.\n\nThe drugs being tested in this trial are 'cl-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)' and 'placebo'. \n\nThe eligibility criteria for this trial include being likely or possibly nausea-prone, being male or a non-pregnant and non-lactating female, having undergone surgical extraction of at least 2 impacted third molar teeth, being a female of child-bearing potential with a negative urine pregnancy test and using an acceptable method of birth control, and having at least moderate post-operative pain.\n\nThe exclusion criteria include having a serious medical condition, active local infection, a history of hypersensitivity to opioids, promethazine, or acetaminophen, recent caffeine use, use of an IND drug within the past 30 days, previous participation in this study, being pregnant or lactating, and being an employee or relative of an employee of the PI, sub-investigator, or Charleston Labs.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 3. The disease being studied is depressive disorder, major. The corresponding ICD-10 codes for this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drugs being tested in this trial are duloxetine hydrochloride and placebo. The eligibility criteria for participants in this trial include having a diagnosis of Major Depressive Disorder according to DSM-IV criteria with at least one previous depressive episode in their medical history, as well as experiencing painful physical symptoms as measured by the Brief Pain Inventory-Short Form. Exclusion criteria include having any anxiety disorder as a primary diagnosis within the past 6 months (such as panic disorder, OCD, PTSD, generalized anxiety disorder, and social phobia), as well as having a diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders.",
    "The sample from the table represents a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial aims to evaluate the effectiveness of different drugs in treating COPD. The eligibility criteria for the trial include patients who have signed an informed consent, have a diagnosis of COPD, meet specific spirometric criteria, are 40 years of age or older, have a smoking history of more than 10 pack years, can perform pulmonary function tests, and can maintain records. \n\nExclusion criteria include patients with significant diseases other than COPD, abnormal baseline blood tests, a history of asthma, thyrotoxicosis, paroxysmal tachycardia, recent myocardial infarction, unstable or life-threatening cardiac arrhythmia, recent hospitalization for heart failure, active tuberculosis, recent malignancy treatment, history of life-threatening pulmonary obstruction, cystic fibrosis, bronchiectasis, significant alcohol or drug abuse, recent thoracotomy with pulmonary resection, use of certain medications, regular daytime oxygen therapy, recent completion or current participation in a pulmonary rehabilitation program, recent use of investigational drugs, known hypersensitivity to certain drugs or components, pregnancy or nursing, and previous randomization in the study or current participation in another study. Patients who are unable to comply with pulmonary medication restrictions prior to randomization are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied are pain and low back pain. The ICDCodes associated with these diseases are N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52 for pain, and M54.50, M54.51, M54.59 for low back pain. The drugs being used in the trial are buprenorphine and placebo. \n\nThe eligibility criteria for this trial include being a male or non-pregnant and non-nursing female aged 18 or older, having a history of moderate to severe chronic low back pain for at least 3 months with a pain intensity of 5 or higher on a numerical rating scale, currently taking up to 60 mg of oral morphine per day or an equivalent dose of another opioid, having stable health as determined by the investigator, and using a recognized effective method of birth control for female subjects of childbearing potential. Written informed consent is also required.\n\nThe exclusion criteria for this trial include having certain specific conditions such as reflex sympathetic dystrophy, acute spinal cord compression, or meningitis, having had a surgical procedure for back pain within 2 months prior to screening, having hypokalemia or clinically unstable cardiac disease, having a corrected QT interval of more than 450 milliseconds on an electrocardiogram, having a history of long QT syndrome or an immediate family member with this condition, having a diagnosis of moderate to severe hepatic impairment, having a history of severe emesis with opioids, or having clinically significant sleep apnea.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on early Parkinson's disease. The trial involves the use of two drugs, \"spm 962\" and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being diagnosed with Parkinson's disease, being between 30 and 80 years old, having a Hoehn & Yahr stage of 1-3, and having a total sum score of over 10 on the UPDRS Part 2 and 3 screening test. Exclusion criteria include having previously participated in a trial with SPM 962, being on L-dopa treatment for over 6 months, having psychiatric symptoms, orthostatic hypotension, a history of epilepsy or serious cardiac disorder/arrhythmia, being treated with certain anti-arrhythmic drugs, having abnormal ECG values, having congenital long QT syndrome, having low serum potassium or high levels of bilirubin, BUN, or serum creatinine, having an allergy to topical medicine, being pregnant, nursing, or of childbearing potential, receiving therapy with prohibited drugs, having a history of certain brain surgeries, having dementia, being unable to give consent, participating in another investigational drug trial, or being deemed inappropriate for the study by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and is focused on the disease of type 2 diabetes. The corresponding ICD-10 codes for this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being studied in this trial are saxagliptin and placebo. The eligibility criteria for participants in this trial include being between the ages of 18 and 77, having type 2 diabetes, taking metformin immediate release (IR) or XR at a dosage of at least 1500 mg for at least 8 weeks as monotherapy, having a glycosylated hemoglobin (A1C) level between 7% and 10%, and having a body mass index (BMI) of 40 kg/m2 or less. The exclusion criteria include women of childbearing potential who are unable or unwilling to use acceptable birth control, pregnant or breastfeeding women, individuals with a significant cardiovascular history, those with active liver disease, and those with renal impairment.",
    "The sample from the table is for a phase 3 trial. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are 'J44.9', 'J44.1', and 'J44.0'. The drugs being tested in the trial are budesonide/formoterol and prednisolone. The eligibility criteria for inclusion in the trial are patients with COPD and an acute exacerbation, with a pulmonary function test showing a value of 30%-60% of the predicted normal value after acute treatment. Patients who are candidates for a course of oral steroids for the treatment of acute symptoms due to COPD are also included. The exclusion criteria include a diagnosis/history of asthma, oxygen uptake (saturation) below 92% after initial treatment, a requirement for regular use of oxygen therapy, and regular treatment with any inhaled steroid over 1,000 \u00b5g/day at study entry. Additional inclusion and exclusion criteria will be evaluated by the investigator.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the treatment of epilepsy, specifically drug-resistant epilepsy. The ICD-10 codes associated with the diseases being studied are provided. The only drug mentioned in the sample is levetiracetam. The eligibility criteria for participants are listed, including age requirements, duration and type of epilepsy, previous treatment history, and other medical conditions that may exclude someone from participating. The sample also includes exclusion criteria, such as intolerance to levetiracetam, certain medication combinations, and various medical and psychiatric conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 3, and the disease being studied is HIV infection. The ICDCodes associated with this disease are \"Z21\". The drug being tested is \"gw873140\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". Inclusion criteria include being HIV-infected, having a screening viral load of at least 5000 copies/mL, having a R5/X4-tropic virus at screening, having at least 3 months of prior antiretroviral experience, having documented resistance to at least one drug in each of the specified classes, being on a stable antiretroviral regimen (or no treatment) for at least 4 weeks before screening, being able to receive a ritonavir-boosted protease inhibitor during treatment studies, and women of childbearing potential must use specific forms of contraception.\n\nExclusion criteria include having acute laboratory abnormalities, a history of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Other exclusion criteria include specific viral tropism, recent changes to antiretroviral therapy, pregnancy or breastfeeding, recent participation in an experimental drug trial, prior use of a CCR5 or CXCR4 antagonist, significant ECG abnormalities or history of certain medical conditions, current use of certain medications, and additional qualifying criteria and laboratory test requirements to be assessed by the study physician.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the treatment of chronic plaque psoriasis. The ICD-10 codes associated with this disease are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being studied in this trial are placebo, secukinumab (ain457), and etanercept. The eligibility criteria for participants are listed, including requirements such as having chronic, plaque-type psoriasis for at least 6 months, having moderate to severe psoriasis based on specific measurements, and being inadequately controlled by previous treatments. There are also exclusion criteria listed, such as having forms of psoriasis other than chronic, plaque-type, and having certain medical conditions or allergies. Additional inclusion/exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and focuses on the treatment of pulmonary disease, specifically chronic obstructive pulmonary disease (COPD). The trial involves the use of multiple drugs, including \"gsk573719/gw642444 125/25\", \"gsk573719/gw642444 62.5/25\", \"gsk573719 125\", \"gsk573719 62.5\", and \"gw642444 25\". The eligibility criteria for participants are listed, including age, gender, smoking history, diagnosis of COPD, severity of disease, dyspnea score, and resting lung volumes. The exclusion criteria are also provided, which include pregnancy, asthma, other respiratory disorders, and various other medical conditions. The sample also mentions specific requirements related to chest X-rays, ECG findings, screening labs, medication use, oxygen therapy, nebulized therapy, pulmonary rehabilitation, and history of drug or alcohol abuse. Additionally, there is a note about individuals who are affiliated with the investigator site being excluded from participation.",
    "The sample provided is for a phase 3 trial. The diseases being studied are coronary artery disease, myocardial infarction, and cerebrovascular stroke. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being tested in the trial include folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine), and a placebo. \n\nThe eligibility criteria for the trial are as follows:\nInclusion Criteria:\n- Adults who are 18 years or older and able to give informed consent.\n- Patients who are willing to undergo long-term follow-up.\n- Patients who have undergone coronary angiography just before being included in the trial, regardless of whether they have significant coronary artery disease (CAD) or not.\n\nExclusion Criteria:\n- Patients who are not available for follow-up.\n- Patients who have previously participated in this study.\n- Patients with known alcohol abuse or serious mental illness.\n- Patients with known active malignant disease.\n- Patients who have undergone coronary angiography for specific reasons, such as assessment for cardiac transplantation, kidney donor, heart donor, or diagnostic assessment of cardiomyopathy.",
    "The sample provided is for a phase 3 trial. The diseases being studied include cardiovascular diseases, heart diseases, peripheral vascular diseases, thromboembolism, vascular diseases, and venous thromboembolism. The corresponding ICD-10 codes for these diseases are also listed. The drug being tested in the trial is warfarin. The eligibility criteria for the trial include patients with venous thromboembolism, including those with factor V Leiden. These patients should have completed prescribed anticoagulation therapy within the last two years before the trial and should not be currently on anticoagulation therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied include adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage ii pancreatic cancer, stage iii pancreatic cancer, and stage iv pancreatic cancer. The corresponding ICDCodes for these diseases are also provided. The drug being used in the trial is gemcitabine hydrochloride. The eligibility criteria for participants in this trial include specific requirements related to the type and stage of the disease, prior treatments received, cardiovascular health, recent medical procedures, infections, hypersensitivity, and other factors. Various medical tests and diagnostic procedures are also mentioned as part of the criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and the disease being studied is prostate cancer. The ICD-10 codes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are docetaxel, zd4054, and placebo. The eligibility criteria for this trial include a confirmed diagnosis of prostate cancer that has spread to the bone, increasing levels of Prostate Specific Antigen (PSA), and currently receiving treatment with surgical or medical castration. The exclusion criteria include previous treatment with certain chemotherapy drugs, heart failure or recent myocardial infarction, and a history of epilepsy or seizures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The diseases being studied include peripheral nervous system diseases, pain, neuralgia, herpes zoster (shingles). The corresponding ICDCodes for these diseases are also provided. The drug being tested is ngx-4010. The eligibility criteria for this trial include having a diagnosis of post-herpetic neuralgia (PHN) with at least 6 months of pain since shingles vesicle crusting, specific pain scores, intact skin over the painful area, stable chronic pain medication regimen, negative pregnancy test for female subjects, willingness to use birth control, and compliance with study requirements. The exclusion criteria include certain medication use, substance abuse history, recent use of pain medications, previous participation in a trial involving NGX-4010, use of investigational agents or specific anti-arrhythmic drugs, uncontrolled diabetes or hypertension, significant pain from other causes, certain locations of PHN areas, presence of certain medical devices, hypersensitivity to certain substances, ongoing or untreated abnormalities or conditions, recent significant medical-surgical interventions, and evidence of cognitive impairment.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 3.\n- Diseases: The trial is focused on chronic hepatitis C.\n- ICD Codes: The ICD-10 codes associated with the disease are ['B18.2', 'B18.0', 'B18.1', 'B18.8', 'B18.9', 'K71.3', 'K71.4'].\n- Drugs: The drugs being tested in the trial are ribavirin and placebo.\n- Criteria: The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". \n\nThe \"Inclusion Criteria\" include requirements such as signed written informed consent, age 18 or older, presence of HCV RNA (measured by quantitative PCR), non-responder to previous therapy, liver biopsy consistent with chronic hepatitis C, and a wash-out period from previous therapy. \n\nThe \"Exclusion Criteria\" list factors that would disqualify a patient from participating in the trial, such as the use of systemic corticosteroids within 6 months, previous courses of therapy with PEGinterferon alpha plus ribavirin, other liver diseases, decompensated liver disease, HIV infection, insulin-dependent diabetes mellitus, severe haemoglobinopathy, positive liver and kidney microsomal auto antibodies, positive anti-thyroid antibodies, pregnancy, alcohol or intravenous drug abuse within the previous year, poor medical or psychiatric conditions, non-compliance with the study protocol, previous treatment with thymosin alpha 1, known hypersensitivity to PEGinterferon and/or ribavirin, history of severe depression, simultaneous participation in another investigational drug study or clinical trial involving investigational drugs within 3 months, and presence of serious pulmonary or cardiovascular disorders.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is type 2 diabetes mellitus. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are sitagliptin phosphate, glimepiride, placebo to sitagliptin, and placebo to glimepiride. The eligibility criteria for this trial include a diagnosis of type 2 diabetes mellitus as an inclusion criteria, while exclusion criteria include a history of type 1 diabetes mellitus, recent surgical procedures, participation in other studies with investigational devices or compounds, hypersensitivity or contraindication to sulfonylurea medication, previous use of dipeptidyl peptidase-4 (DPP-4) inhibitors, presence of HIV, current participation in a weight loss program or use of weight loss medication, history of certain blood disorders, cancers, heart, liver or kidney disease, and current or past use of recreational or illicit drugs, or a history of drug abuse or dependence, or increased alcohol consumption.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 3 and focuses on the disease \"b-cell lymphoma.\" The corresponding ICD-10 codes for this disease are listed as \"S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S.\" The drugs being studied in this trial are \"bevacizumab, rituximab, chop, placebo.\" The eligibility criteria for this trial include various inclusion and exclusion criteria, such as age restrictions, specific type of lymphoma, tumor size, performance status, and prior treatment history.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is phase 3. The disease being studied is allergic rhinitis. The corresponding ICD-10 codes for the disease are 'J30.89', 'J30.9', 'J30.2', 'J30.1', 'J30.5', and 'J30.81'. The drugs being tested are bdp nasal aerosol and placebo. The sample also includes the eligibility criteria for the trial. The inclusion criteria include being 4 to 11 years old, having a documented history of perennial allergic rhinitis, demonstrating sensitivity to at least one allergen through a skin prick test, and meeting other criteria. The exclusion criteria include having nasal pathology, recent respiratory infection or disorder, active asthma requiring treatment, and having other clinically significant conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease being studied is benign prostatic hyperplasia. The ICDCodes associated with this disease are 'N40.0' and 'N40.1'. The drugs being tested in this trial are tadalafil and placebo. The eligibility criteria for this trial include being diagnosed with benign prostatic hyperplasia, providing signed informed consent, and agreeing not to use other treatments for benign prostatic hyperplasia, erectile dysfunction, or overactive bladder during the study. The exclusion criteria include having prostatic cancer or being treated for cancer, having any condition that may negatively influence the transrectal ultrasound, being treated for heart disease with nitrate drugs, having moderate to severe cardiac disease, experiencing chest pain or heart-related procedures in the past 90 days, having very high or very low blood pressure, having uncontrolled diabetes, or having certain problems with the kidneys, liver, or nervous system.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being used in the trial are bicalutamide, buserelin, flutamide, goserelin, leuprolide acetate, and nilutamide. \n\nThe eligibility criteria for this trial include the following disease characteristics: histologically proven locally advanced adenocarcinoma of the prostate, diagnosed within the past 6 months, with specific criteria related to tumor stage, PSA levels, and Gleason score. Pelvic lymph nodes must be clinically negative, and there should be no small cell or transitional cell carcinoma by biopsy. Bony metastases should also be absent according to a bone scan.\n\nPatient characteristics include age under 80, performance status of ECOG 0-2, and a life expectancy of at least 5 years excluding malignancy. Hematopoietic, hepatic, renal, and other health parameters are also specified. Prior concurrent therapies are mentioned, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other treatments.\n\nIt is important to note that this description is based on the provided sample and may not represent the complete information in the table.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial is testing the effectiveness of the drug mannitol compared to a placebo. The eligibility criteria for participants include having a confirmed diagnosis of cystic fibrosis, being over 6 years old, having a FEV1 (forced expiratory volume in 1 second) between 30% and 90% predicted, and being able to perform lung function tests. Exclusion criteria include being terminally ill or listed for lung transplantation, having had a lung transplant, using nebulized hypertonic saline, experiencing a significant episode of haemoptysis (coughing up blood) in the three months prior to enrollment, having had a recent heart attack or stroke, being pregnant or breastfeeding, participating in another drug study within 4 weeks of study entry, having an allergy or intolerance to mannitol, using beta blockers, or having any condition or situation that may put the participant at significant risk or interfere with their participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The disease being studied is schizophrenia. The corresponding ICD-10 codes for schizophrenia are F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, and F20.9. The drug being tested is quetiapine fumarate. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include the patient's ability to provide written informed consent, a documented clinical diagnosis of schizophrenia, and the ability to understand and comply with the study requirements. Exclusion criteria include a history of non-compliance, lack of response to previous treatment with quetiapine, participation in another drug study within 4 weeks prior to enrollment, and previous participation in this specific study.",
    "The sample from the table represents a phase 3 clinical trial for breast cancer. The trial is specifically for patients with histologically confirmed breast cancer that has been completely resected. The eligibility criteria include having no clinically detectable residual loco-regional axillary disease and having undergone surgery for primary breast cancer, either a total mastectomy or a breast-conserving procedure with planned radiotherapy. The tumor must be confined to the breast and axillary nodes, and axillary lymph node dissection or a negative axillary sentinel node biopsy is required. Patients with negative or microscopically positive axillary sentinel nodes are eligible, and positive sentinel nodes must be treated with either axillary dissection or radiation. The trial excludes patients with distant metastases or locally advanced inoperable breast cancer. Bilateral synchronous invasive breast cancer is allowed if all other eligibility criteria are met. Hormone receptor status is also a requirement, with the tumor needing to be estrogen and/or progesterone receptor positive. The patient characteristics include being premenopausal, female, and having a premenopausal range of estradiol levels or meeting specific criteria for menstruation. Other patient characteristics such as performance status, life expectancy, and various medical conditions are not specified. The prior concurrent therapy section outlines the exclusion of certain treatments such as prior neoadjuvant or adjuvant chemotherapy, tamoxifen, and other hormonal therapies. The sample does allow for prior or concurrent neoadjuvant or adjuvant trastuzumab (biologic therapy). The use of bisphosphonates is generally not allowed, except in specific cases. The sample does not mention the duration or specific objectives of the trial.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial is focused on patients with locally advanced or relapsing prostate cancer. The eligibility criteria include being a male aged between 18 and 80 years old, having a Gleason score of at least 6, and an ECOG performance status of 0-2. The patients should also have a life expectancy of at least 5 years. At randomization, the patients should have two successive decreasing serum PSA levels of 1 ng/ml or less. \n\nThere are also exclusion criteria, such as having any suspected second primary tumors, evidence of metastatic disease, or any other malignancy within the last 5 years. Other exclusion criteria include acute spinal cord compression, ureteric obstruction, concurrent biological response modifier therapy, chemotherapy, or hormonal therapy. Patients who have had neoadjuvant or adjuvant hormonal therapy within the last year or 5-alpha reductase inhibitor treatment within the last 6 months are also excluded. Additionally, patients with concurrent hormonal therapy, radiotherapy, clinically significant elevation of serum creatinine or liver enzymes, hypersensitivity to GnRH or other GnRH analogues, or leuprorelin acetate are not eligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the disease \"bacterial pneumonia\". The ICD-10 codes associated with this disease are \"J15.9\" and \"P23.6\". The drugs being studied in this trial are \"ceftaroline fosamil for injection\", \"iv ceftriaxone\", \"placebo\", and \"clarithromycin\". The eligibility criteria for participants in this trial are listed, including inclusion criteria such as having community-acquired pneumonia and requiring initial treatment with IV antimicrobials, and exclusion criteria such as having a CAP suitable for outpatient therapy with an oral antimicrobial agent or a history of hypersensitivity or allergic reaction to certain medications.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and is focused on non-small cell lung cancer. The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in this trial are vandetanib and erlotinib. The eligibility criteria for participants include having confirmed locally advanced or metastatic NSCLC and having failed one or two prior chemotherapy regimens. The exclusion criteria include prior treatment with erlotinib, gefitinib, sunitinib, or sorafenib, as well as receiving chemotherapy or other anti-cancer therapy within 4 weeks of the study start.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3. The disease being studied is seizures. The icd-10 codes associated with this disease are 'G40.89', 'R56.1', 'F44.5', 'G40.501', 'G40.509', 'G40.111', and 'G40.119'. The drugs being tested in this trial are retigabine and placebo. The eligibility criteria for participants are listed under inclusion and exclusion criteria. Inclusion criteria include a diagnosis of refractory epilepsy with simple or complex partial onset seizures, a certain frequency of partial seizures, and being currently treated with up to three established AEDs. Exclusion criteria include existing medical or psychiatric conditions that could affect the patient's health, abnormal physical exam results, impaired renal function, evidence of progressive central nervous disease, history of primary generalized seizures, and history of clustering or status epilepticus within 12 months of study entry.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is described as \"phase 2/phase 3\". The diseases being studied are \"pulmonary disease, chronic obstructive\", \"COPD\", and \"lung diseases, obstructive\". The corresponding ICDCodes for these diseases are \"['J44.9', 'J44.1', 'J44.0']\" and \"['G91.1', 'I42.1', 'N11.1', 'J05.0', 'G47.33', 'J44.9', 'N13.8']\" respectively.\n\nThe drugs being investigated in this trial are \"indacaterol\", \"formoterol (12 \u00b5g b.i.d.)\", \"tiotropium (18 \u00b5g o.d.)\", \"placebo to indacaterol\", and \"placebo to formoterol\".\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a male or female adult aged 40 years or older, having a diagnosis of COPD, a smoking history of at least 20 pack years, specific lung function measurements, and other requirements. Exclusion criteria include being pregnant or lactating, recent hospitalization for a COPD exacerbation, requiring long-term oxygen therapy, having certain respiratory conditions or diseases, having a history of asthma or diabetes, and various other factors.\n\nIt is important to note that there may be additional protocol-defined inclusion/exclusion criteria that apply, but they are not specified in this sample.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is non-Hodgkin's lymphoma. The ICDCodes associated with this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being used in the trial are rituximab, chop (cyclophosphamide, hydroxydaunorubicin [doxorubicin], oncovin [vincristine], prednisone), cvp (cyclophosphamide, vincristine, prednisone), and analgesic/antipyretic and antihistamine drugs. The eligibility criteria for this trial include written informed consent, age of 18 years or older, previously untreated diffuse large B-cell lymphoma (DLBCL) or previously untreated follicular non-Hodgkin lymphoma (NHL), Eastern Cooperative Oncology Group (ECOG) performance status 0-2. There are also exclusion criteria, such as clinically significant cardiovascular disease, certain adverse events during Cycle 1, and prior premedication with additional corticosteroids.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The diseases being studied are acute coronary disease and unstable angina. The corresponding ICD-10 codes for these diseases are I24.0 and a list of codes including I20.0, I25.110, I25.750, I25.700, I25.790, I25.710, and I25.720. The drugs being investigated in this trial are clopidogrel and acetylsalicyclic acid (ASA). The eligibility criteria for this trial are listed, including inclusion and exclusion criteria. Inclusion criteria include being diagnosed with acute coronary disease with clinical symptoms and specific diagnostic indicators. Exclusion criteria include factors such as recent use of anticoagulants, previous administration of clopidogrel, contraindications to clopidogrel or aspirin, and active bleeding or a significant risk of bleeding.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 3 and is focused on diabetes. The diseases associated with the trial are \"diabetes\" and \"diabetes mellitus, type 2\". The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied in the trial are \"liraglutide\", \"sitagliptin\", and \"metformin\". The sample also includes the eligibility criteria for participants in the trial, including requirements such as having type 2 diabetes, being on metformin treatment for at least three months, having a specific range of HbA1c levels, and having a BMI less than or equal to 45.0. The exclusion criteria are also listed, which include factors such as previous treatment with certain medications, recent use of anti-diabetic drugs other than metformin, having any serious medical condition, and being pregnant or intending to become pregnant for female participants.",
    "The sample from the table represents a phase 3 clinical trial for metastatic colorectal cancer. The trial is testing the effectiveness of several drugs, including cediranib, folfox (5-fluorouracil, leucovorin, oxaliplatin), xelox (capecitabine and oxaliplatin), and a cediranib placebo. The eligibility criteria for participants include providing written informed consent, having carcinoma of the colon or rectum, and having one or more measurable lesions. Some exclusion criteria include receiving adjuvant/neoadjuvant therapy within 6-12 months prior to study entry, having untreated unstable brain or meningeal metastases, specific laboratory ranges, specific cardiovascular problems, and participating in other trials within 30 days.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 3. The disease being studied is prostate cancer. The ICDCodes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drugs being used in the trial are enzalutamide and placebo. The eligibility criteria for this trial include specific requirements for patients to be included or excluded. For example, patients must have histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features, ongoing androgen deprivation therapy, progressive disease despite androgen deprivation therapy, and no prior treatment with cytotoxic chemotherapy. There are also exclusion criteria, such as severe concurrent disease, infection, or co-morbidity that would make the patient inappropriate for enrollment, known or suspected brain metastasis or active leptomeningeal disease, and a history of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer. The sample also mentions an open-label treatment period and provides additional inclusion and exclusion criteria for patients receiving enzalutamide or placebo during the double-blind treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is atrial fibrillation. The ICDCodes associated with this disease are I48.0, I48.21, I48.91, I48.11, I48.19, and I48.20. The drugs being investigated in this trial are vernakalant injection and amiodarone injection. \n\nThe eligibility criteria for this trial are listed under \"Key Inclusion Criteria\" and \"Key Exclusion Criteria\". The key inclusion criteria include having symptomatic AF of 3 to 48 hours duration at baseline, being eligible for cardioversion, having adequate anticoagulation therapy for cardioversion, and being hemodynamically stable with specific blood pressure ranges. \n\nThe key exclusion criteria include having known or suspected prolonged QT interval, familial long QT syndrome, or previous ventricular arrhythmias, having symptomatic bradycardia or a low ventricular rate, having certain cardiac conditions or previous episodes of AV block, having recent myocardial infarction or cardiac surgery, and having uncorrected electrolyte imbalances.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and the disease being studied is pancreatic ductal carcinoma. The ICD-10 codes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial are ag-013736, gemcitabine, and a placebo. The eligibility criteria for participants in this trial include having histologically or cytologically confirmed metastatic or locally advanced pancreatic adenocarcinoma that cannot be surgically removed, having adequate renal, hepatic, and bone marrow function, and having a performance status of 0 or 1. The exclusion criteria include prior treatment with any systemic chemotherapy for metastatic disease, prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors, current or recent bleeding or thromboembolic events, and inability to take oral medication.",
    "The sample is a phase 3 trial for the treatment of type 2 diabetes mellitus. The trial is testing the effectiveness of the drug saxagliptin compared to a placebo. The inclusion criteria for the trial include having type 2 diabetes, being between the ages of 18 and 75, and being able to perform blood glucose measurements. Female participants must have a negative pregnancy test and use contraception. The exclusion criteria include having any other form of diabetes, being on multiple blood glucose lowering medications or insulin therapy, having certain health conditions such as high blood pressure or high triglyceride levels, and being pregnant or breastfeeding. Participants must also not have been treated with certain medications or have certain medical conditions. The sample provides a detailed list of the inclusion and exclusion criteria for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease being studied is overactive bladder. The ICDCodes associated with this disease are 'N32.81'. The drugs being used in the trial are propiverine hydrochloride and tolterodine extended-release tablet. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must be aged 18 to 65.\n- The patient must have a diagnosis of overactive bladder and experience symptoms for more than 3 months, including urinary frequency (more than 8 times within 24 hours), urgency, and/or urge incontinence.\n- The mean volume of a single urination should be less than 200ml.\n- The patient must be willing and able to accurately complete a micturition diary card.\n- The patient's urine routine test should show no urinary tract infection.\n- The patient must sign an informed consent form.\n\nExclusion Criteria:\n- The investigator confirms that the patient has severe stress incontinence.\n- The patient has a serious heart disease or arrhythmia that, in the investigator's opinion, makes them unsuitable for enrollment.\n- The patient has contraindications for anticholinergic therapy, such as urinary retention, gastric retention, and uncontrollable angle closure glaucoma.\n- The patient has a symptomatic acute urinary tract infection.\n- The patient has a recurrent urinary tract infection.\n- The patient has interstitial cystitis.\n- The patient has agnogenic hematuria.\n- The patient has a clinically significant bladder outlet obstruction.\n- The patient requires retention catheterization or intermittent catheterization.\n- The patient has a malignant tumor.\n- The patient has received anticholinergic drugs or other drugs for treating overactive bladder within the washout period or will receive these drugs during the study.\n- The patient is pregnant or lactating, or plans to become pregnant. \n- The patient has received other clinical study drugs or is participating in another clinical trial within 30 days.\n- Women of childbearing age who have not taken sufficient contraception measures within 3 months before random number distribution or intend to stop contraception measures during the trial or within one month after the treatment is over.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The disease being studied is hypertension. The ICDCodes associated with this disease are \"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", and \"I10\". The drugs being used in the trial are carvedilol and valsartan. The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria state that subjects must have residual (uncontrolled) hypertension on lisinopril monotherapy, defined as 24-hour ambulatory diastolic BP >85 mmHg. Exclusion criteria include a history of serious adverse effects with ACE inhibitor, Coreg, or valsartan, known or suspected causes of secondary hypertension, known ischemic heart disease requiring beta-blocker therapy, heart failure, obstructive valvular heart disease or obstructive hypertrophic cardiomyopathy, presence of clinically significant arrhythmias or conduction defects, chronic kidney disease, uncontrolled diabetes mellitus, history of alcohol or drug abuse, concomitant treatment with prohibited medications, any other medical condition that would interfere with participation in the study or pose a significant risk to the subject, persistent systolic BP elevations above 179 mmHg, positive pregnancy test or failure to practice adequate contraception in women of child-bearing potential, bronchospastic asthma requiring chronic steroid or inhaler therapy, and any women with child-bearing potential.",
    "The sample provided is for a phase 3 clinical trial. The disease being studied is asthma, and the corresponding ICD-10 codes for asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested in the trial are 'budesonide/formoterol (symbicort)' and 'budesonide'. The eligibility criteria for inclusion in the trial include being between 6 and 15 years of age, having a diagnosis of asthma with baseline lung function tests, and having received treatment with inhaled corticosteroids as specified in the protocol. The exclusion criteria include having severe asthma, recent treatment with non-inhaled corticosteroids, sensitivity to drugs specified in the protocol, or requiring treatment with beta-blockers.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3 and focuses on two diseases: Parkinson's disease and dyskinesia. The corresponding ICD-10 codes for these diseases are \"G20\" and \"K22.4\" and \"G24.01\" respectively. The trial involves two drugs, sarizotan and placebo. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The subject must be an outpatient.\n- The subject must have a diagnosis of idiopathic Parkinson's disease.\n- Prior therapy with all registered Parkinsonian medication is allowed.\n\nExclusion Criteria:\n- For female subjects, they must not be pregnant or lactating.\n- The subject must not be participating in another clinical study or have done so within the past 30 days.\n- The subject must not have received neurosurgical intervention related to PD.\n- The subject must not have relevant renal impairment.\n- The subject must not have relevant hepatic impairment.\n- The subject must not be suffering from any dementia or psychiatric illness.\n- The subject must not have a history of allergic asthma.",
    "The sample from the table is for a phase 3 clinical trial. The disease being studied is pulmonary disease, chronic obstructive (COPD). The ICD-10 codes associated with this disease are J44.9, J44.1, and J44.0. The drugs being tested in the trial are umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg. \n\nThe eligibility criteria for the trial include being an outpatient, providing written informed consent, being 40 years of age or older, and being male or female. Female participants must either be of non-childbearing potential (post-menopausal or surgically sterile) or use an acceptable contraceptive method. \n\nOther inclusion criteria include having an established clinical history of COPD, being a current or former cigarette smoker with a history of at least 10 pack-years, having a pre and post-albuterol/salbutamol FEV1/FVC ratio of <0.70, and having a pre and post-albuterol/salbutamol FEV1 of <=70% of predicted normal values. Participants must also have a score of \u22652 on the Modified Medical Research Council Dyspnea Scale (mMRC).\n\nExclusion criteria for the trial include being pregnant or lactating, having a current diagnosis of asthma, having other respiratory disorders such as alpha 1 antitrypsin deficiency, active lung infections, or lung cancer. Other exclusion criteria include having significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities, having contraindications to the study drugs, recent hospitalization for COPD or pneumonia, recent lung volume reduction surgery, abnormal and significant ECG findings, inability to withhold albuterol/salbutamol prior to spirometry testing, use of certain medications within defined time intervals, use of long-term oxygen therapy, regular use of nebulized bronchodilators, recent participation in a pulmonary rehabilitation program, history of alcohol or drug abuse, affiliation with the investigator site, or previous participation in related studies.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"type 2 diabetes mellitus\". The associated ICD-10 codes for this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The trial involves two drugs, \"hoe901-u300 (new formulation of insulin glargine)\" and \"lantus (insulin glargine)\". \n\nThe eligibility criteria for this trial are as follows:\nInclusion criteria:\n- Adult participants with type 2 diabetes mellitus inadequately controlled with non-insulin antihyperglycemic drug(s).\n- Signed written informed consent.\n\nExclusion criteria:\n- HbA1c less than (<) 7.0% (< 53 millimole per mole [mmol/mol]) or greater than (>) 11% (> 97 mmol/mol).\n- History of type 2 diabetes mellitus for less than 1 year before screening.\n- Less than 6 months before screening with non-insulin antihyperglycemic treatment.\n- Change in dose of non-insulin antihyperglycemic treatment in the last 3 months before screening.\n- Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit and/or initiation of Glucagon-like peptide-1 (GLP-1) receptor agonist in the last 6 months before screening visit.\n- Participants receiving only non-insulin antihyperglycemic drugs not approved for combination with insulin according to local labeling/local treatment guidelines and/or sulfonylurea or glinide (Note: non-insulin antihyperglycemic drugs not approved for combination with insulin, sulfonylurea and glinide are to be discontinued at baseline).\n- Current or previous insulin use except for a maximum of 8 consecutive days (for example, acute illness, surgery) during the last year prior to screening.\n- Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (for example, laser, surgical treatment or injectable drugs) during the study period.\n\nPlease note that the provided information may not include all the relevant considerations for potential participants in the clinical trial.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 3 and is focused on the disease \"acute myeloid leukemia\". The ICD-10 codes associated with this disease are \"C92.A1\", \"C92.A2\", \"C92.61\", \"C92.62\", \"C92.A0\", and \"C92.60\". The drugs being studied in this trial are \"cytarabine or supportive care\" and \"dacogen (decitabine) only\". The eligibility criteria for participants are listed, including both inclusion and exclusion criteria. Inclusion criteria include having a diagnosis of acute myeloid leukemia, a life expectancy of at least 12 weeks, and signing informed consent. Exclusion criteria include not having acute promyelocytic leukemia, not having any other active systemic malignancies, not having inaspirable bone marrow, not having received previous chemotherapy (except hydroxyurea) for any myeloid disorder, not having chronic respiratory disease that requires continuous oxygen use, not having received any experimental drug within 4 weeks before randomization, not being a candidate for a bone marrow or stem cell transplant within 12 weeks after randomization, and not having known HIV.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.\n\nIn this particular sample, the trial is focused on two diseases: endometrial hyperplasia and osteoporosis. The ICD-10 codes associated with these diseases are provided as well. The drugs being tested in the trial are bazedoxifene/conjugate estrogens (ce), raloxifene, and a placebo.\n\nThe eligibility criteria for participants are also listed. Inclusion criteria include being generally healthy, postmenopausal women aged 40-75 years with an intact uterus, and having completed their last natural menstrual cycle without hormone therapy at least 12 months prior to screening. Exclusion criteria include a history or active presence of thrombophlebitis, thrombosis, thromboembolic disorders, cerebrovascular accident, stroke, transient ischemic attack, malignancy, or treatment for malignancy within the previous 10 years.\n\nThe sample provided is just a portion of the complete record, as indicated by the mention of \"Additional criteria applies.\"",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 3 and focuses on the diseases glaucoma and ocular hypertension. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves two drugs, namely \"travoprost 40 mcg/ml + timolol 5 mg/ml eye drops, solution (duotrav)\" and \"dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops, solution (cosopt)\". The eligibility criteria for participants are also included, with the inclusion criteria stating that participants must be 18 years or older and have a diagnosis of glaucoma or ocular hypertension. The exclusion criteria state that participants must be under 18 years old. Additional protocol-defined inclusion and exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in phase 3.\n- Diseases: The trial is focused on colorectal cancer.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'].\n- Drugs: The drugs being tested in the trial are 'oxaliplatin based chemotherapy', 'panitumumab', 'irinotecan based chemotherapy', and 'bevacizumab'.\n- Criteria: The eligibility criteria for participants in the trial are listed, including requirements such as having adenocarcinoma of the colon or rectum, having metastatic colorectal cancer, having measurable disease according to specific criteria, having a certain performance status, and having adequate hematologic, renal, and hepatic function. There are also exclusion criteria listed, such as prior chemotherapy or biologic treatment for mCRC disease, recent major surgery, central nervous system metastases, and various medical conditions that may increase risks or interfere with the study.\n\nOverall, this sample provides information about a phase 3 clinical trial focused on colorectal cancer, including the specific diseases, drugs, and eligibility criteria involved.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on the treatment of chronic hepatitis C. The trial includes patients with specific HCV genotypes and cirrhosis determination, as well as those who have previously failed treatment. The sample also includes a list of ICDCodes associated with the disease. The drugs being tested in the trial are sof, rbv, placebo to match sof, and placebo to match rbv. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include specific HCV genotypes, cirrhosis determination, prior treatment failure, and certain laboratory values. Exclusion criteria include prior exposure to a specific antiviral drug, pregnancy or nursing, history of hepatic decompensation, significant medical disorders, excessive alcohol ingestion, and drug abuse.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and focuses on the disease \"depressive disorder, major.\" The ICD-10 codes associated with this disease are ['F33.0', 'F33.1', 'F33.9', 'F32.0', 'F32.1', 'F32.9', 'F33.40']. The drugs being studied in this trial are \"vortioxetine\" and \"placebo.\" \n\nThe record also includes eligibility criteria for participants. Inclusion criteria include having a major depressive episode recurrent as the primary diagnosis according to the DSM-IV-TR criteria, having a Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits, and having a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits.\n\nExclusion criteria include having previously participated in a Lu AA21004 clinical study, having any current psychiatric disorder other than Major Depressive Disorder, having a history of manic or hypomanic episode, schizophrenia, or any other psychotic disorder, having a diagnosis of alcohol or substance disorder that has not been in sustained full remission for at least years prior to screening, having a clinically significant neurological disorder or neurodegenerative disorder, having any Axis II disorder that might compromise the study, having abnormal thyroid stimulating hormone value, abnormal vital signs, abnormal Electrocardiogram, abnormal liver function tests, having a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication, having a disease or taking medication that could interfere with the assessments of safety, tolerability, or efficacy, having a known history of or currently having increased intraocular pressure or being at risk of acute narrow-angle glaucoma, having a clinically significant unstable illness, and having a significant risk of suicide according to the investigator's opinion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is hepatitis B. The icd-10 codes associated with this disease are B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, and B16.1. The drug being tested in this trial is clevudine. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being between the ages of 18 and 60, having HBV DNA levels at screening of at least 3 x 1,000,000 copies/mL, being HBsAg positive for more than 6 months and HBeAg positive, having AST and ALT levels within a certain range, and meeting certain bilirubin level requirements. Other criteria include being able to give informed consent and comply with the study requirements.\n\nExclusion criteria include currently receiving certain therapies, previous treatment with specific drugs, history of certain conditions, co-infection with HCV or HIV, pregnancy or breastfeeding, unwillingness to use contraception, history of alcohol or drug abuse, and presence of certain diseases or conditions. Additionally, being currently participating in another investigational study or taking traditional Chinese medication within a certain timeframe are also exclusion criteria.\n\nOverall, this sample provides information about the phase, disease, icd-10 codes, drug, and eligibility criteria for a specific clinical trial related to hepatitis B.",
    "The sample provided is for a phase 3 clinical trial. The trial focuses on two diseases, namely cystic fibrosis and pancreatic exocrine insufficiency. The diseases are identified by their respective ICD-10 codes. The trial involves two drugs, namely pancrelipase delayed release and a placebo comparator. The eligibility criteria for participants are listed, including requirements such as a confirmed diagnosis of cystic fibrosis and pancreatic exocrine insufficiency, stable body weight, and the absence of acute respiratory disease or any other acute condition. There are also exclusion criteria, such as a history of certain medical conditions or the use of immunosuppressive drugs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3, and the disease being studied is renal transplantation. The ICDCodes associated with this disease are N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, and Q60.1. The drug being investigated is fty720. \n\nThe eligibility criteria for this trial include:\n- Patients of any race between 18 to 65 years old (inclusive)\n- Patients scheduled to undergo a primary cadaveric or primary non-HLA identical living donor kidney transplantation\n- Patients who have provided written informed consent to participate in the study\n\nThe exclusion criteria for this trial include:\n- Recipients of multi-organ transplantation or those expected to receive a non-renal allograft during the study period\n- Graft cold ischemia time greater than 40 hours\n- Patients with a pulse rate less than 50 beats per minute (bpm) at screening\n\nIt is also mentioned that there may be other protocol-defined exclusion criteria that could apply.",
    "The sample provided is for a phase 3 clinical trial. The trial focuses on patients with rheumatoid arthritis. The ICD-10 codes associated with the disease are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drugs being studied in the trial are methotrexate, ocrelizumab, and a placebo. The eligibility criteria for inclusion in the trial include being an adult patient aged 18 or older, having active rheumatoid arthritis, and having inadequate treatment with any DMARD other than methotrexate. The exclusion criteria include having any other rheumatic autoimmune disease or inflammatory joint disease, currently receiving any DMARD other than methotrexate, previous treatment with any cell-depleting therapies, and having had any surgical procedure in the past 12 weeks or planning to have one within 48 weeks after the baseline.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 3, and the disease being studied is asthma. The ICDCodes associated with asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drug being used in the trial is levocetirizine. The sample also includes the eligibility criteria for the trial, which states that participants must have completed the previous 18-month treatment period of the EPAAC trial (NCT00152464) to be included, and there are no specific exclusion criteria mentioned.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 3. The disease being studied is colorectal cancer, and the corresponding ICD-10 codes for this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. \n\nThe eligibility criteria for the trial are listed under \"DISEASE CHARACTERISTICS\" and \"PATIENT CHARACTERISTICS.\" For disease characteristics, the criteria include histologically confirmed colorectal cancer, unresectable metastatic disease, measurable disease according to RECIST criteria, no prior chemotherapy for metastatic disease, and no untreated brain metastases, spinal cord compression, or primary brain tumors. \n\nFor patient characteristics, the inclusion criteria include an ECOG performance status of 0-2 (\u2264 70 years of age) or ECOG PS 0 (71-75 years of age), a life expectancy of at least 12 weeks, specific blood counts and liver function within certain ranges, and other factors such as not being pregnant or nursing, negative pregnancy test, and use of effective contraception for fertile patients. \n\nThe exclusion criteria include various factors such as serious nonhealing wounds, bleeding diathesis or coagulopathy, uncontrolled hypertension, cardiovascular diseases, allergy to certain proteins, presence of other malignancies, symptomatic peripheral neuropathy, lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, inability to take oral medication, and recent significant traumatic injury. \n\nThe prior concurrent therapy section mentions the time since previous treatments, radiotherapy, anticoagulants, major surgical procedures, open biopsy, and investigational agents. It also states that chronic daily high-dose acetylsalicylic acid should not be taken concurrently.",
    "The sample is a phase 3 trial for patients with chronic heart failure. The trial aims to test the effectiveness of two different drug combinations: olmesartan medoxomil + candesartan cilexetil placebo and olmesartan medoxomil placebo + candesartan cilexetil. The eligibility criteria for the trial include being an adult outpatient between the ages of 18 and 85, having a documented hospital admission for heart failure within the previous 3 months, having a functional NYHA class II-IV with a left ventricular ejection fraction (LVEF) of less than 40%, and having blood B-type (or brain) natriuretic peptide (BNP) levels greater than 400 pg/ml or NT-ProBNP levels greater than 1500 pg/ml. Patients with heart failure due to ischemic heart disease, idiopathic dilated cardiomyopathy (IDC), mitral or aortic insufficiency, or hypertension are eligible, as long as they have been on stable conventional treatment with diuretics, ACEI and/or beta-blockers, and/or aldosterone antagonists for at least 2 months prior to randomization, unless there is a documented contraindication or intolerance. The exclusion criteria include pregnant or nursing females, patients currently hospitalized for heart failure, patients with recent stroke or transient ischemic attack (TIA), patients with recent acute coronary syndrome, myocardial infarction, coronary artery bypass, or angioplasty, patients with planned cardiac surgery, revascularization, or resynchronization during the study period, patients with operable valvular disease or significant obstructive cardiomyopathy, patients with bradycardia (heart rate < 50 bpm), patients with hypotension (systolic blood pressure < 90 mmHg), patients with obstructive pneumopathy, and patients with clinically significant renal failure (creatininemia > 200 micromol/l).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 3. The diseases being studied are chronic kidney disease, renal dialysis, and renal insufficiency. The corresponding ICDCodes for these diseases are provided as well. The drugs being investigated in this trial are asp1585 and sevelamer hydrochloride. The eligibility criteria for this trial include specific requirements for patients with chronic kidney disease on hemodialysis, hyperphosphatemia, and patients who have been on a phosphate binder or phosphate lowering drug for 28 days or longer without a change in dosage. Inclusion and exclusion criteria are also listed, specifying certain conditions or medical history that would exclude patients from participating in the trial.",
    "The sample is a phase 3 trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have had type 2 diabetes for 3 months to 5 years and are either treatment-na\u00efve or not optimally controlled with diet and exercise alone or with one oral antihyperglycemic medication. The patients must be willing to take metformin and have a glycosylated hemoglobin (HbA1c) level between 6.5% and 9.5%. Females of childbearing potential must test negative for pregnancy and agree to use birth control during the study. The patients must have a stable weight, a body mass index (BMI) between 23 and 45 kg/m^2, and be motivated to perform self-monitored blood glucose testing and maintain a study diary.\n\nExclusion criteria include having type 1 diabetes, being treated with certain medications, having uncontrolled diabetes requiring hospitalization in the past 6 months, having stomach problems or gastric bypass surgery, experiencing heart or brain problems in the past 2 months, having certain abnormal test results, having a family history of certain conditions, having cancer within the past 5 years, having had an organ transplant or recent unapproved treatment, and having any condition that would interfere with the study medications or procedures.\n\nOverall, the sample is looking for patients with type 2 diabetes who meet specific criteria and are willing to participate in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 3, focusing on the disease \"fibromyalgia.\" The corresponding ICD-10 code for fibromyalgia is \"M79.7.\" The trial involves the drugs \"placebo\" and \"xyrem\u00ae.\" The eligibility criteria for this trial include being 18 years or older and meeting the diagnostic criteria for fibromyalgia according to the American College of Rheumatology (ACR). Subjects with a history of rheumatic disease or other disorders that may affect the accurate representation of subjective symptoms will be excluded. Additionally, any other condition that poses a risk to the subjects' participation in the trial will also be a reason for exclusion.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 3 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drug being tested, and the eligibility criteria for participants.\n\nIn this particular sample, the trial is focused on cytomegalovirus infections and inflammatory bowel diseases. The ICD-10 codes associated with these diseases are \"P35.1\" for cytomegalovirus infections and a list of codes including \"M06.4\", \"G61.89\", \"G61.9\", \"M35.81\", \"G61.81\", \"K75.9\", and \"M27.2\" for inflammatory bowel diseases.\n\nThe drug being tested in this trial is valganciclovir. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include patients suffering from Crohn's disease, ulcerative colitis, unclassifiable colitis, or pouchitis, and requiring treatment with corticoids and/or immunosuppressive drugs. Additionally, patients must have an infection by cytomegalovirus and have experienced a new attack within the previous three months. Exclusion criteria include patients with serious or complicated attacks requiring surgery, patients with psychiatric diseases or uncooperative behavior, patients with other serious diseases, and patients already participating in another clinical trial."
]